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Abstract 
 The adipose tissue has an important role in maintaining the energy homeostasis 
balance. Understanding its physiology is important for the development of treatments 
against diseases where this equilibrium is compromised, such as obesity and associated 
metabolic disorders. MicroRNAs (miRNAs) are important gene regulators and an 
increasing body of evidence suggests their involvement in adipogenesis and adipose 
metabolism. MiRNAs can also be secreted into the extracellular environment and be 
taken up by distal cells, mediating cell-to-cell communication. However, very little is 
known about adipose tissue-derived circulating miRNAs. Through miRNA PCR array 
analysis we identified several miRNAs that are differentially secreted among mouse 
undifferentiated and differentiated brown and white adipocytes, among which, miR-196a 
and miR-378a-3p showed a conservative pattern of secretion in different adipocyte 
models.  MiR-138-5p was identified as the unique miRNA differentially secreted between 
human brown and white adipocytes. Bioinformatics target prediction revealed that these 
miRNAs are potentially involved in important processes regulating the functioning of 
adipose tissue and its cross-talk with distal cells. By ultracentrifugation of adipose 
conditioned media and Nanosight technology, we investigated vesicle and vesicle-free 
miRNA carriers and characterized adipose derived vesicles. Finally, through microRNA 
array and mRNA sequencing we identified genes, miRNAs and pathways differentially 
enriched in human brown and white adipocytes contributing to improve the knowledge 
on the nature of human adipocytes, hampered by the scarce availability of human brown 
adipose samples. Through integration of the two analyses, we identify poorly known or 
novel miRNAs, potentially involved in the pathways associated with the genes 
differentially expressed between human brown and white adipocytes. Among the 
significantly downregulated miRNAs in brown versus white adipocytes we highlighted 
miR-513a-3p, miR-4511 and miR-4328. While, among the significantly upregulated 
miRNAs in brown versus white we highlighted miR-4698, miR-4516, miR-4531, miR-
29a-3p and miR-3915.  
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1.1   The adipose tissue  
 Adipose tissue is the main site for storing energy and in healthy conditions it 
constitutes 20% of the body weight [1]. Different types of adipose tissue exist and can be 
subdivided into two main categories, brown adipose tissue (BAT) and white adipose 
tissue (WAT). WAT and BAT cooperate in maintaining a delicate equilibrium between 
fat accumulation and energy dissipation, thus they present different structure, functions 
and location. However, both consist of a heterogeneous population of cells including 
endothelial cells, immune cells and pre-adipocytes. The pre-adipocytes, under 
differentiation stimuli, develop into mature brown or white, adipocytes that constitute the 
major cellular component of the tissue. Both tissues are innervated by the sympathetic 
nervous system (SNS) [2] even though at a different grade, with BAT being more highly 
innervated and vascularized than WAT.  
 Depending on its location, WAT is classified either as subcutaneous (SAT, under 
the skin) or visceral (mesenteric, gonadal, perirenal and omental). White adipocytes 
present a diameter comprised between 30-200 µm. Larger adipocytes are generally more 
highly metabolic and release more factors attracting immune cells [3]. WAT functions as 
an endocrine organ [4, 5] and a store of energy by accumulating triglycerides into a single 
large lipid droplet that occupies a central position in the mature adipocytes. The periphery 
includes the nucleus and few mitochondria.  
 In contrast, brown adipocytes are much smaller (15-60 µm in diameter) [6], their 
nucleus occupies a central position and triglycerides are stored in small multilocular lipid 
droplets. This increases the surface exposed to lipases to allowing easy access to the lipids 
that can be rapidly catabolised [7]. Brown adipocytes also contain a large number of 
mitochondria expressing high levels of uncoupling protein 1 (UCP1) in the inner 
membrane. This protein is responsible for non-shivering heat production in the brown 
adipocytes thus playing an important role in body temperature regulation [8]. BAT is 
present in mammals, in mice and human newborns it is principally located in the 
interscapular area. In humans its amount strongly decreases with the growth [9]. However 
recent PET/CT-scans (Positron Emission Tomography associated with Computed 
Tomography) demonstrated the presence of BAT in the supraclavicular, suprarenal, 
paravertebral areas and in the neck of healthy men exposed to cold temperature [10-12]. 
These data were then confirmed with the safer magnetic resonance imaging (MRI) 
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technique. [13] Moreover, cells with high thermogenic activity were found within white 
depots [14]. In murine experiments, Petrovic et al., induced epididymal fat cells to express 
high level of UCP1 enabling these cells to dissipate energy and present a brown-like 
phenotype, though, still keeping some classical white fat gene expression [15]. This 
introduced the concept of brite/beige adipocytes, which means brown in white. Lately 
beige adipocytes have been demonstrated to be distinct from classic brown adipocytes 
[16] and to arise from white adipocyte transdifferentiation [17]. 
   Fat tissue development 
 WAT develops soon after birth, while, BAT starts to form during the prenatal 
stage, in order to provide an immediate protection from the extrauterine colder 
temperature [18]. Both BAT and WAT derive from the mesoderm, which originates from 
mesenchymal (MSC) stem-cells, where the microenvironment contributes to the 
generation of mature adipocytes. MSCs are multipotent stem-cells which can self-renew 
and originate myocytes, chondrocytes, osteocytes, neurons, besides adipocytes [19]. 
White adipocytes derive from the Myf5-negative lineage, while classical brown 
adipocytes come from the Myf5-positive precursor, which is in common with myocytes. 
In these common precursors, PR-domain zinc-finger protein 16 (PRDM16) and 
CCAAT/enancher binding protein ß (C/EBPß) are the major players for suppression of 
muscle phenotype in favour of the brown phenotype [20]. However, in a recent study, 
white adipocytes in the interscapular and retroperitoneal area were found to be descended 
from Myf5-positive progenitors as well [13].  
   Adipogenesis: determination and differentiation 
 Although they have opposing functions and morphologic differences, the 
processes underling BAT and WAT development is regulated by an initial common 
cascade of events that takes different directions in the later stages of differentiation. 
Adipogenesis can be divided in two main phases: determination and differentiation. The 
first stage, determination, ends with the irreversible conversion of the pluripotent stem-
cells into committed pre-adipocytes that have partially lost the differentiation potential 
[21]. In vivo, the events occurring between these two stages are still unknown. However, 
in vitro, committed pre-adipocyte proliferation is strongly reduced due to contact 
inhibition, as long as no stimuli occur to induce the final differentiation [22]. These cells 
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express the pre-adipocyte factor-1 (Pref-1) that, in its soluble active form, prevents 
adipocyte differentiation [23]. The re-entry in the cell cycle is then induced by hormonal 
stimuli and differentiation is reached upon activation of a cascade of transcriptional 
factors where, the most important protagonists are peroxisome proliferator-activated 
receptor γ (PPARγ) and CCAAT/enhancer binding proteins (C/EBPs) [22]. Some 
proteins responsible for cell-cycle regulation have been found to also control adipocyte 
differentiation. In particular, E2F transcription factor is inhibited by C/EBPα and also 
indirectly by PPARγ [24]. E2F inhibition leads to a second growth arrest that allows cells 
to undergo the final stages of differentiation. E2F is also inhibited by the retinoblastoma 
proteins Rb, Rb-like proteins 1 and 2 (RBL1 and RBL2) also known as p107 and p130 
respectively [22] . More interesting, Rb and p107 have been proposed to be involved in 
the switch of white versus brown adipogenesis [25].  
   PPARγ and C/EBPs 
 PPARγ is a nuclear receptor and ligand-activated transcription factor and it is 
activated by thiazolidinedione (TZD) drugs, oxidized and unsaturated fatty acids, 
prostaglandins and eicosanoids. However, no endogenous ligands have been identified to 
induce PPARγ activation with comparable or higher efficiency than TZDs [26]. In 
addition to its crucial role in activation of adipogenesis, PPARγ expression is also 
fundamental for the maintenance of mature adipocytes [15]. Three different isoforms of 
PPARγ exist: PPARγ1, 2 and 3. The most expressed isoform in adipocytes is PPARγ2, 
which heterodimerizes with the retinoid X receptor (RXR), recruits cofactor proteins and 
in concert with these, unfolds the DNA structure in determined regions. This enable gene 
transcription and adipocyte differentiation [15].  
 C/EBPs are members of the C/EBP basic-leucine zipper protein family. C/EBPβ 
and C/EBPδ are induced at the early stage of adipocyte differentiation and in turn, 
increase the expression of C/EBPα. C/EBPβ is induced by the phosphorylated form of 
cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) [27] 
and is activated by mitogen-activated protein kinase (MAPK) and glycogen synthase 
kinase-3 β (GSK3β) [28]. Phosphorylated C/EBPβ dimerizes with another C/EBPβ 
monomer forming a DNA binding domain which promotes the expression of other genes 
including C/EBPα and PPARγ. C/EBPα expression leads to cell proliferation arrest and 
transcription of several adipocyte genes such as adipocyte protein 2 (aP2) and glucose 
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transporter 4 (GLUT4) [29]. Most important, C/EBPα maintains PPARγ expression and 
vice versa. C/EBPβ and C/EBPδ action is likely to be redundant since adipocyte 
differentiation is strongly affected only upon concurrent deletion of the two genes [30]. 
Moreover, C/EBPβ may compensate C/EBPα absence in brown adipocytes development. 
Indeed, C/EBPα ablation in mice prevented WAT development but did not impair BAT 
adipogenesis [22]. 
   Brown adipose tissue and beige adipocyte differentiation 
 BAT has been proposed as a potential alternative strategy to fight obesity since 
its activation would increase lipolysis preventing fat deposition in peripheral tissues non 
specialized in fat storage [31]. Indeed, mice with high brown/beige fat depots present 
elevated insulin sensitivity, glucose tolerance and obesity resistance [32]. Interestingly, 
beige adipocytes activated upon cold exposure or β-adrenergic stimuli, have been  shown 
to play a more consistent role in this process than pre-existing interscapular brown 
adipocytes [33]. Among the different types of white adipose tissues, subcutaneous depots 
are more predisposed for acquisition of thermogenic characteristics [34]. Beige cells show 
molecular signatures distinct from both white and brown adipocytes. Among beige-
selective genes, there are the developmental transcription factor 15 (Tbx15) and plasma 
membrane proteins such as transmembrane protein 26 (TMEM26) and CD137 [16, 35]. 
In addition, platelet-derived growth factor receptor-α (Pdgfr-α) has been found to be a 
marker for white precursor with potential ability of differentiation into beige adipocytes 
[36]. However, one of the most evident differences between constitutive brown and 
inducible beige adipocytes is that the former express UCP1 at high extent even in absence 
of stimuli, while beige adipocytes activate UCP1 and the thermogenic program only after 
cold exposure or β-adrenergic stimulation [15, 37]. Several proposals regarding beige 
cells origins have been suggested, such as derivation from resident stem cells in WAT 
depot [36], recruitment of stem cells in WAT from other tissues [38] or trans-
differentiation of mature white adipocytes [39]. However, one hypothesis does not 
necessary exclude the other ones. Despite descending from two different lineages, 
thermogenic activity in brown and beige adipocytes is apparently promoted by the same 
cascade of events that leads to UCP1 expression. In vivo, activation of the thermogenic 
program in fat cells is predominantly under the control of the SNS. SNS activated by cold 
temperatures, through norepinephrine release, triggers activation of specific genes 
24 
 
reputed to promote the program for heat production. This signalling pathway is mediated 
by ß-adrenergic receptors, described more in details below. One of the pathways involved 
in recruiting beige cells upon β3-adrenergic stimulation is represented by 
Cyclooxygenase-2 (COX-2) activation. Up-regulation of this enzyme induces the 
synthesis of Prostaglandins (PGs), which are able to promote the browning effect in WAT 
[40].  
 Another protein downstream of β-adrenergic signalling and involved in the 
thermogenic program is the Fibroblast growth factor 21 (FGF-21). It positively regulates 
glucose uptake in adipocytes and is generally produced and secreted by the liver [41]. 
However, activation of protein kinase A (PKA) and p38 MAPK, following β-adrenergic 
stimulation, induces brown adipocytes to became a source of FGF-21 as well [42]. FGF-
21 importance in non-shivering heat production is demonstrated by the fact that FGF-21 
Knock Out (KO) mice fail to activate an appropriate thermogenic program when exposed 
to cold temperatures [43].  
 A combination of all the pathways discussed above leads to a molecular cascade 
of numerous transcription factors that induce fat cells to acquire the specific 
characteristics for cold adaptation [44]. 
 The presence of PPARγ and C/EBPs is a prerequisite for brown and beige 
adipogenesis and their sustained expression plays a key role in maintaining the 
characteristics of mature adipocytes. Though, PPARγ and C/EBPα co-expression leads 
mesenchymal stem cells to only develop into white adipocytes [45]. Hence, PPARγ and 
C/EBPs, even if necessary, are not brown/beige-specific determinant factors. Indeed, 
brown/beige cell fate is subject to PRDM16 and PPARγ activator 1α (PGC-1α). However, 
while PGC-1α plays an important role in thermogenesis but is not decisive in phenotype 
determination, PRDM16 is strictly necessary for both the phenomena. In fact, in the 
absence of PGC-1α, several classical-brown genes are normally expressed, even though, 
thermogenesis activity is strongly impaired [46, 47]. On the contrary, in mice, lack of 
PRDM16 leads to the expression of a myocyte phenotype in BAT and negatively affects 
thermogenic activity [48]. 
 PGC-1α is induced under cold exposure through activation of the PKA-CREB 
(cAMP response element binding protein)   pathway [49, 50] and by FGF-21 [43] and 
regulates mitochondria biogenesis [43]. Its expression in white adipocytes, triggers the 
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transcription of genes involved in thermogenic activity, in particular UCP1 [51]. On the 
other hand, a factor responsible for PGC-1α inhibition through direct interaction is the 
corepressor RIP140 [52]. Another level of PGC-1α regulation is represented by several 
steroid receptor coactivators (SRC) such as SRC-1 and SRC-2, which respectively, 
promotes and inhibits PGC-1α- PPARγ interactions [53]. Interestingly, as discovered 
recently, PGC-1α in muscle cells regulates the expression of Irisin, a membrane protein 
that is secreted in the plasma, especially upon physical exercise. In mice, released Irisin, 
induced high thermogenic activity and beige cell formation in WAT depots [54].  
 PRDM16 is a protein with seven zinc-finger domains through which it binds 
specific DNA regions [55]. However, Seale et al., demonstrated that its predominant 
mechanism of action in adipocytes is by direct interaction with proteins such as PGC-1α, 
PGC-1β, PPARα and PPARγ [56]. PRDM16, besides directly promoting the classical-
brown fat genes, such as PGC-1α, UCP1 and cell death-inducing DFFA-like effector A 
(CIDEA) [48, 56, 57], inhibits specific white fat and muscle gene expression [57]. 
PRDM16 gene ablation resulted in primary brown pre-adipocyte differentiation into 
skeletal muscle [57]. Signaling stimulated by bone morphogenetic protein BMPs inhibit 
myogenesis [58]. Tseng et al, demonstrated that PRDM16 expression is positively 
regulated by BMP7 in brown precursor derived from mice [59].  
   Fatty acid biosynthesis lipolysis and beta oxidation  
 The ability to accumulate lipids can be considered as an evolutionary strategy to 
store energy in order to encounter relatively long periods of food scarcity. Animals such 
as C. elegans, Drosophila and sharks store lipids in gut cells, fat body and liver 
respectively [60-62]. The development of specialised fat depots in mammals implicates a 
high level of coordination among these tissues and other organs to regulate food intake, 
lipid absorption and transport, fatty acid biosynthesis and oxidation in order to maintain 
the homeostatic balance. Adipose tissue secretes a large number of hormones and 
cytokines, grouped under the name of adipokines [63] that contribute to the cross-talk 
among fat depots and distal tissues/organs. For example, leptin, also known as satiety 
hormone, is released in response to food intake by the adipose tissue and stimulates the 
hypothalamus to suppress appetite [64-66]. Mice with leptin mutation ob/ob or leptin 
receptor mutation db/db are phenotypically indistinguishable from wild type littermates 
at birth, but become obese because of uncontrolled appetite and consequent excess food 
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intake [67, 68]. Paradoxically, obese subjects present high concentrations of this hormone 
in the circulation. However, in obesity, hypothalamic resistance to leptin abolishes the 
beneficial effect of the satiety hormone [66].  
 Another important adipokine released by adipocytes in the blood stream is 
adiponectin [69]. This protein, encoded by the ADIPOQ gene, has anti-inflammatory 
functions and promotes lipid oxidation. Therefore, it promotes insulin sensitivity and 
protects against obesity [70-72], indeed, levels of circulating adiponectin is reduced in 
obese subjects and increase after weight loss [73]. 
 Several other factors control fatty acid oxidation, that takes place mainly in brown 
adipocytes and is accelerated in the thermogenic process activated by ß-adrenergic stimuli 
or promoted by diet [10]. The two main sources of fuel for brown adipocytes consist of 
lipids taken from the circulation and lipids synthesised de novo by the lipogenesis process. 
   Fatty acid uptake 
After absorption in the intestine, lipids are transported into the blood stream via the 
lymphatic system, packed into lipoproteins such as chylomicrons to reduce 
hydrophobicity. In the blood streams the Lipoprotein Lipase (LPL) catalyses the 
hydrolysis of the triglycerides from the chylomicrons into monoacylglycerol and free 
fatty acids that can be internalized by the brown adipocytes by different fatty acid 
transporter proteins (FATPs) and cluster of differentiation (CD) 36 (CD36) expressed on 
the cytoplasmic membrane [74]. In the cytoplasm, fatty acid binding proteins (FABP) 
such as FABP3, FABP5 and FABP4, also known as aP2, bind to the internalized fatty 
acids to prevent their lipotoxicity on cellular structures [75, 76]. Fatty acids (FAs) can 
then be oxidised or alternatively stored (figure 1). 
   Lipogenesis  
 De novo fatty acid synthesis is initiated by acetyl coenzyme A (acetyl-CoA) 
carboxylase (ACC), which, from Acetyl-CoA, forms Malonyl-CoA, that, in turn, is 
converted into palmitate, a 16 carbon saturated fatty acid, by the fatty acid synthase 
(FAS). Fatty acid chains of palmitate molecules are elongated by elongase enzymes such 
as elongation of very long chain fatty acids protein 3 (ELOVL3), which are located on 
the membrane of the endoplasmic reticulum. Fatty acids are then desaturated through the 
introduction of double bonds in determined positions of the chain by desaturase enzymes 
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such as stearoyl-CoA desaturase (SCD). At this stage, fatty acids are esterified and either 
stored into lipid droplets in the form of triacylglycerides or oxidised [77]. 
   Lipid storage 
 Triacylglycerides are packaged into lipid droplets surrounded by a phospholipidic 
layer where specific proteins, such as CIDEA and adipose triglyceride lipase (ATGL), 
control lipid droplet enlargement and lipolysis, respectively. As mentioned before, 
CIDEA mRNA is upregulated during adipogenesis and is considered as a brown marker. 
However its expression is downregulated after cold stimuli [78] and mice lacking the 
CIDEA gene are resistant to diet induced obesity [79]. 
   Lipolysis and fatty acid oxidation 
 Release of lipids from the lipid droplets is permitted by the lipolysis process that 
can be catalysed either by acid lysosomal lipases or by enzymes that work at neutral pH 
(neutral lipolysis). The most important lipases involved in neutral lipolysis are the adipose 
triglyceride lipase (ATGL), the hormone sensitive lipase (HSL) and the 
monoacylglycerol lipase (MGL) which control three different steps of the process and 
catalyse the formation of three different types of free fatty acids (FFAs): diacylglycerol 
(DG), monoacylglycerol (MG) and deglycerinated FFA respectively (reviewed in [77]). 
Long chain fatty acids (LCFA) can then be oxidized in the mitochondria and the very 
long chain fatty acid (VLCFA) in the peroxisome. However, the major contribution for 
thermogenesis is given by the mitochondrial fatty acid oxidation. This process is mediated 
by the acyl-CoA synthase 1 (ACSL1) and the carnitine palmitoyltransferase (CPT) 
system. Briefly, ACSL converts LCFAs into LCFAs-CoA which are in turn converted 
into LCFAs-carnitine by CPT-1ß through a trans-esterification reaction of the fatty acyl 
group. The carnitine/acylcarnitine translocase (CACT) transports the acylcarnitines into 
the mitochondrial matrix. Here, CPT-2 reconverts the LCFA-acylcarnitine into LCFA-
CoA which are then transferred into the mitochondrial inner membrane space and ß-
oxidized. This results in nicotinamide adenine dinucleotide (NAD) + hydrogen (H) 
(NADH) and flavin adenine dinucleotide + H (FADH) generation which transfer the 
electrons to the electron transport chain allowing the proton pumps to create the proton 
gradient for  adenosine triphosphate  (ATP) production or thermogenesis.  
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Figure 1 Lipid metabolism in adipocytes.  
Figure modified from [77]. A) Fatty acid uptake in brown adipocytes. LPL catalyses the release of free 
fatty acids (FFAs) from lipoproteins. FFAs are taken up by proteins such as cluster of differentiation 36 
(CD63), FA transport proteins transport FFAs. Once in the cytoplasm, FFAs are transported by fatty acid 
binding proteins (FABPs) into lipid droplets (LD). B) Lipogenesis. Alternatively to FFAs uptake, the cell 
can synthesise lipids by lipogenesis, which occurs in the cytoplasm. Product/substrate are indicated in 
black, while enzymes catalysing the transformation of substrates into the following products are in red. 
Fatty acid synthase (FAS) catalyses multiple reactions, resulting in the final product of palmitate (dashed 
arrow). Synthetized FFAs can be esterified for fatty acid oxidation or stored into lipid droplets.  
Enhancement of processes or protein expression upon ß-adrenergic stimuli are indicated by blue arrows. 
C) Fatty acid mobilization (neutral lipolysis) for oxidation, upon cold stimuli. With neutral lipolysis the 
hydrolysis of triglycerides triggers to release of glycerol and 3 FFAs that are used for thermogenesis. The 
enzymes involved in this proces are: adipose triglyceride lipase (ATGL), the hormone sensitive lipase 
(HSL) and the monoacylglycerol lipase (MGL). In basal conditions, G0/G1 switch gene 2 (G0S2) inhibits 
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ATGL and ATGL-coactivator comparative gene identification-58 (CG-I58) is sequestered by perilipin. 
Upon ß-adrenergic stimuli, activated PKA phosphorylates HSL, that translocates onto the membrane of 
LDs. Perilipin, phosphorylated by PKA releases CG-I58, which, in turn fully activates ATGL. D) Mobilized 
long chain fatty acids (LCFA) are then oxidised for heat production in mitochondria, while very long chain 
fatty acids are oxidised in the peroxisome.  
   Thermogenesis 
 Thermogenesis is the process of heat generation by burning calories and can be 
obligatory or adaptive. In the obligatory thermogenesis, heat is the result of the metabolic 
activity necessary for the basic functioning of the organism [80]. Adaptive thermogenesis 
is a regulated process for active heat production in response to external temperature and 
it can be classified as shivering and non-shivering [81]. The first one takes place in 
muscles, while, the latter one occurs in BAT and/or in WAT upon acquisition of brown-
like features. Non-shivering thermogenesis can be induced either by temperature or diet 
[82, 83]. As mentioned before, the key factor for non-shivering heat production is UCP1, 
also known as Slc25a7 and thermogenin, located in the inner membrane of mitochondria 
principally in BAT and beige adipocytes. UCP1 belongs to the UCP family which 
comprises 5 members of anionic carrier transporters with similar structure but different 
tissue distribution. UCP2 is ubiquitous, UCP3 is mainly expressed in muscles, while 
UCP4 and 5 are in the brain. Whereas ATP is the final product of coupled respiration, 
energy dissipation can be facilitated by the uncoupling of respiration by UCP1 and other 
inner membrane proteins, which creates a gap in the oxidative respiratory chain so that 
the protons pumped in the intermembrane area return in the mitochondrial matrix. 
Therefore the proton flux cannot reach the ATP synthase machinery resulting in heat 
generation instead of ATP synthesis [84]. This mechanism and therefore lipid 
consumption can be protracted at higher rate and independently of ATP saturating 
concentration [85]. UCP1 activity is under the control of ß-adrenergic receptors (ß-ARs). 
 The β-adrenergic receptors, which are classified as β1, β2 and β3 are expressed 
on the cell membrane, coupled with Gαs-proteins. β1-adrenergic receptor stimulation 
triggers constitutive BAT precursor proliferation, while, β3-adrenergic signalling is 
responsible for beige adipocyte differentiation and activation in WAT depots [86]. The 
β3-adrenergic receptors are expressed on fat cells rather than other type of cells, but their 
stimulation in humans did not lead to a significant recruitment of beige cells in white 
tissues [8]. The ß2-adrenergic receptors are mainly expressed in the vasculature of the 
adipose tissue but not on the adipocytes [87].  
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 Under stimuli, such as cold temperature exposure, norepinephrine is released by 
the SNS, and binds to the ß-AR. This causes a conformational change in the receptor and 
consequent activation of the coupled G protein. The Gαs subunit of the coupled G protein 
can exchange guanosine diphosphate (GDP) with guanosine triphosphate (GTP) and 
dissociate from the Gßɣ subunits, activating the adenylate cyclase, which triggers an 
increase in cAMP and PKA activation. PKA phosphorylates the Hormone-Sensitive 
Lipase, which in turn converts triacylglycerol into free fatty acids activating UCP1 and 
thermogenesis. This process also increases LPL activity in order to provide further fuel 
[88], indeed lipids absorbed via LPL were demonstrated to be is the major source of fatty 
acids in BAT [89]. However, ß-adrenergic stimulation also enhances de novo lipogenesis 
[90] 
 The coordination of BAT and WAT functions is a prerogative for the balance 
between energy storage and consumption of excessive fatty acids. The major factor 
compromising this equilibrium, nowadays, is represented by excessive food intake which 
leads to obesity and associated metabolic disorders such as insulin resistance, type 2 
diabetes (T2D) [91] and atherosclerosis [92].  The brown adipose tissue plays an 
important function in controlling fatty acid metabolism and counteracting obesity and it 
was shown that it is reduced in obese patients [10] 
   Obesity and adipose tissue dysfunction 
 Obesity is among the pathologies with the highest incidence in developed 
countries, mostly due to factors such a large availability of food, unhealthy diet rich in fat 
and carbohydrate and sedentary life style. Upon high fat intake WAT mass increases as 
adipocytes store excessive lipid. The two existing mechanism for adipose tissue 
expansion consist of increasing adipocytes size, defined as hypertrophy and increasing 
adipocytes number or hyperplasia. Studies on mice suggested that increased adipogenesis 
and therefore increased number of adipocytes occurs after achievement of the maximal 
size expansion of the pre-existing adipocytes [93, 94]. The coexistence of adipocyte 
hypertrophy and adipocyte hyperplasia is mainly observed in obese children [95, 96] . In 
contrast, as lean and obese human adults present a similar adipocyte turnover, adipocyte 
hypertrophy is thought to be the main mechanism occurring in adulthood for WAT mass 
growth, as well as the one causing adipose tissue dysfunction and related disorders [97, 
98].  
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During AT development or gain/loss of weight, different component of the adipose tissue 
contribute to the correct remodelling of the adipose depots. The major players involved 
in providing the conditions necessary for adipocyte growth and de novo adipogenesis are 
the extracellular matrix, endothelial cells and the immune cells, which functions are 
compromised in obesity. 
   Angiogenesis in the adipose tissue 
 Compared to other tissues, which size remain almost unvaried after completing 
the development, the adipose tissue has a striking ability to expand and regress through 
the whole course of the life, depending on the caloric availability. This plasticity requires 
a dynamic vascularization support ensuring the appropriated oxygen and nutrient supply 
as well as the clearance of toxic waste products. This mechanism has to be accompanied 
by re-modelling of the extracellular matrix (ECM) and requires communication between 
adipocytes and endothelial cells. Angiogenesis occurs during tissue development/repair 
by formation of new vessels that sprout form pre-existing ones. Briefly: the process starts 
with endothelial cell (EC) proliferation triggered by pro-angiogenic stimuli and followed 
by EC migration through the ECM to the site of new vessel formation where the capillary 
wall is degraded by extracellular proteinases. The cells establish intercellular junctions 
and organise themselves to form the lumen and connect to other new forming tubes 
(anastomosis). Each step requires a high degree of regulation that may be different from 
tissue to tissue. Vascular Endothelial Growth Factor A (VEGFA) is considered the master 
regulator of angiogenesis in adipose tissue and hypoxia is a potent stimulus that triggers 
its transcription. In normoxic conditions, oxygen-dependent enzymes, such as oxygen-
dependent prolyl hydroxylases induce degradation of hypoxia-inducible factor 1- alpha 
(HIF1α) preventing dimerization with HIF1ß. Hypoxia inactivates the oxygen-dependent 
enzymes and HIF1α dimerizes with HIF1ß forming the complex HIF1, which induces the 
transcription of vascular endothelial growth factor (VEGF). Studies on rodents have 
reported that high fat diet (HFD) is associated with hypoxia in adipose tissues [99, 100]. 
However, as reviewed in [101], studies in humans have shown that the differences in 
oxygen tension between adipose tissue in lean and obese subjects is not as prominent and 
consistent as in mice [102, 103]. The additional finding that blood flow in obese subjects 
was not increased proportionally to fat mass expansion [104] suggests that hypoxia in 
humans fails to induce sufficiently adequate angiogenesis. It has been demonstrated that 
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overexpression of active HIF1α elicits fibrosis and inflammation rather than an 
appropriate angiogenic response [105]. Beneficial effects of VEGF in adipose tissue were 
observed as its forced overexpression reduced inflammation and insulin-resistance 
associated with HFD besides increasing vascularization [106-110]. However, contrasting 
results have been reported regarding VEGF levels in obese, as its expression was found 
to be lower in adipose tissue (contra lateral abdomen) from obese compared to lean, while 
another study showed that VEGFA expression was greater in adipose tissues (omental 
and subcutaneous) from insulin-sensitive obese versus lean and insulin-resistant subjects 
[109]. All together, these results suggest that increased levels of VEGF in obese subjects 
may be a consequence of the activation of a mechanism for VEGF production 
independent from hypoxia or at least from HIF-1α [111, 112]. For example, PGC-1α 
activation by adrenergic stimuli is known to induce VEGFA [110, 113]. Therefore, obese 
subjects whose white adipose tissues have not lost the ability to acquire brown-like 
features might be able to induce VEGF expression in the adipose depots more efficiently 
than obese individual with white fat unresponsive to ß-adrenergic stimuli. However, this 
has to be proven. A relevant mechanism regulating VEGF expression is represented by 
activation of PPARɣ. Interestingly, expression of PPARɣ in endothelial cells results in 
the block of proliferation of these cells, while activation of PPARɣ in adipocytes 
stimulates adipogenesis in parallel with pro-angiogenic factor expression VEGFA [114]. 
   Extracellular matrix and its role in adipose tissue plasticity 
 The extracellular matrix provides the structural support to adipocytes and 
mediates many actions essential for the correct functioning, development and remodelling 
of the adipose tissue, such as cell adhesion and migration, interaction of ligands with 
cellular receptors, tissue repair after injury etc. There exist a large variety of ECM 
components, however, only the most relevant for the purpose of this study will be 
discussed. 
 Collagen is the major component of the ECM and the different types of this 
fibrotic protein are involved in a large number of functions [115]. Abnormalities in the 
expression of the different types of collagen compromise the functionality of the tissue. 
Obesity is characterized by an excessive presence of collagens in the adipose tissue [116] 
and collagen VI has been recognized as one of the most important collagen types involved 
in the development of fibrosis [117]. ]. Its ablation in mouse obese models improves AT 
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expansion and shows a protective effect against the development of diabetic phenotype 
[118]. Also collagenase V is increased in human obesity and it seems to exert an 
antiangiogenic function [119]. Additionally, adipose tissue fibrosis was found to be 
associated with increased insulin-resistance [120] 
 Another component of the ECM which expression is altered in obesity is 
Osteopontin (OPN) or secreted phosphoprotein 1. In obesity, macrophages display high 
expression of this glycoprotein, which mediates their infiltration in the adipose tissue in 
combination with integrins and CD44 [121, 122]. CD44 is a cell membrane receptor that 
interacts with different components of the ECM besides OPN [123]. It is widely expressed 
in many types of tissue and has different isoforms [124]. Its involvement in inflammation 
and insulin-resistance [125] is attracting scientists’ interest. 
 Integrins anchor cells to the extracellular matrix interacting with the cytoskeleton 
and ECM components and together with other focal adhesion proteins control cellular 
motility. There exist two families of integrins, α and ß which comprise eighteen and eight 
subunits respectively that form different combinations of integrin heterodimers [126]. 
Alteration of the integrin pattern of expression can result in insulin-resistance and 
impaired vascularization [122]. For example, mutation of ß2 integrin in mice was 
associated with insulin-resistance and recruitment of neutrophils in adipose tissue [127], 
while deletion of α2ß1 integrin enhanced vascularization in the muscles of obese mice 
[128].  
 Proteoglycans are proteins that are highly glycosylated and abundant in the ECM 
and are involved in a large number of processes. Among the different types, Heparan 
Sulphate (HS) proteoglycans (HSPG), containing mono or pluri HS chains, play an 
important role in creating chemokine gradients for cell attraction and contribute to the 
binding of ligands and their specific receptors expressed on the cell surface [129]. HSPG 
were found to play an important role in fatty acid transport across the plasma membrane 
of adipocytes [130]. HSPG structure is under the control of specific enzymes such as 
heparanases and sulfatases, secreted by resident cells, that modify the HP chains allowing 
or inhibiting the transport of vesicles and ligands through the extracellular matrix to the 
receptor targets [131, 132]. 
 Remodelling of the EMC is permitted by the action of different enzymes that 
degrade and regulate modifications of the ECM components [133]. These include matrix 
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metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). MMPs 
are classified based on their ECM component substrate, and therefore categorized as 
collagenase, gelatinase, elastase etc. [134]. TIMPs and MMPs involvement in the 
pathogenesis of obesity was suggested by the differential pattern of expression of MMPs 
and TIMPs in two different mouse models of obesity [135]. Moreover, Adam 
metalloproteinase domain 10 (ADAM10), a disintegrin metalloprotease known to inhibit 
angiogenesis by modulating Notch signalling [136] was found to be upregulated in obese 
mice and its silencing ameliorated insulin sensitivity [137] 
 In summary it is believed that in obesity, plasmatic membrane rupture of 
hypertrophic adipocytes and accumulation of ECM components cause necrotic adipocyte 
death. This results in lipid leakage and release of molecules, that recall macrophages, 
which, in turn sustain inflammation and promote insulin-resistance [122, 138]. 
   Obesity and insulin resistance 
 The precise mechanism that leads in obesity to the development of insulin 
resistance and T2D is still poorly understood. Insulin resistance in skeletal muscle and 
the inability of pancreatic ß-cells to release adequate levels of insulin into the circulation 
to regulate glycaemia, are the two prerequisites for the establishment of the diabetic status 
[139-141]. However not all obese individuals develop T2D, highlighting the great 
contribution of genetic/environmental predisposition to the disease.  
 The link between the development of insulin resistance and obesity resides in the 
high level of circulating fatty acids and the consequential low grade inflammation 
observable in hypertrophic adipose depots. Adipocytes are responsible for storing, 
synthesizing and releasing lipids to maintain appropriate circulating levels of fatty acids 
that can be up-taken and oxidized by distal tissues, principally skeletal muscles during 
fasting. In prolonged hyperphagia, adipocytes enlarge proportionally to the caloric intake. 
Initially, adipocytes respond to high food intake by increasing expression of enzymes 
involved in lipid storage processes and muscle still show normal sensitivity to insulin 
despite the slight increase of circulating fatty acids [142, 143]. With perpetuation of this 
condition adipocytes become hypertrophic and their endocrine activity is progressively 
impaired resulting in secretion of pro-inflammatory adipokines such as C-C Motif 
Chemokine Ligand 2 (CCL2), tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-
6) [144] that recruit and activate immune cells which sustain the inflammatory state 
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contributing to insulin resistance. Activated macrophages in turn start secreting cytokines 
[145] among which, TNFα plays a pivotal role in the process. TNFα transcription is 
activated through the IKKβ–NF-κB (inhibitor of nuclear factor (NF)-κB (IκB) kinase-β–
NF-κB) and the JNK–AP1 (Jun N‑ terminal kinase–activator protein-1) signalling 
pathways and has been found to inhibit PPARɣ activity via MAP4K4 or other kinases 
[146, 147], repressing the expression of adipogenic genes such as C/EBPs. This results in 
further impaired equilibrium between fatty acid storage and release in the circulation. 
Additionally TNFα induces PPARɣ degradation by activating caspases [148]. 
Consequently, free fatty acids circulating in high levels accumulate in peripheral tissues 
such as liver, arteries and muscles causing secondary diseases such as atherosclerosis, 
non-alcoholic-fatty liver disease (NAFLD) and muscle insulin resistance which sustain 
and further enhance the pathological condition. However, many other cytokines and 
mechanisms have now been found to contribute to the development of insulin resistance 
associated to obesity (reviewed in [149]). 
 Cytokine production and release is the downstream effect of activation of different 
signalling pathways that are mainly activated by free fatty acids [150], reactive oxygen 
species (ROS) [151], and cytokines themselves [152]. One mechanism responsible for 
cytokine production that takes part in inflammation and impairing the insulin signalling 
pathway is represented by activation of Toll-like receptors (TLR) among which TLR4 
has been found to play an important role in this process (reviewed in [152]) . TLR4 is 
expressed on the surface of the cellular component of different organs and tissues such as 
brain [153], liver [154], endometrial cells [155], vasculature [156], pancreatic ß-cells 
[157], thyroid [158], skeletal muscles [159], immune cells, and adipose tissue [160]. 
Lipopolysaccharide (LPS) is one of the strongest TLR4 agonist among the TLR4 ligands 
[161-163] and is expressed on the membrane of gram-negative bacteria [164]. HFD is 
associated with altered gut flora growth and permeability leading to excessive release of 
LPS in the blood stream [165-167]. As summarized in figure 2, LPS binds to TLR4, 
helped by accessory proteins such as LPS Binding Protein (LBP), CD14 and MD2 
(differentiation factor 2), activating two pathways initialized by MID88/TIRAP (myeloid 
differentiation primary response gene 88/Toll-IL-1 receptor (TIR) domain-containing 
adapter protein) and TRAM/TRIF (translocating chain-associated membrane protein/  
TIR domain containing adaptor inducing Interferon-ß). In the former, downstream factor 
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such as NF-KB, CREB, activator protein 1 (AP-1) induce transcription of pro-
inflammatory molecules among which, TNFα and IL-6, that in turn activate further 
pathways sustaining the pro-inflammatory cascade. On the other side the TRAM/TRIF 
triggers activation of interferon 1 (INF-1) genes and via IkB inhibits NF-kB activity in a 
negative feedback loop. Mediators of these cascades such as suppressor of cytokine 3 
(SOCS3), P38, IKKαß and JNK are involved in insulin receptor substrate (IRS) 
phosphorylation, impairing the insulin signalling cascade. 
 
 
 
 
 
Figure 2 TLR4 signalling cascades and insulin resistance 
TLR4 stimulated by LPS and aided by CD14 and MD2 accessory proteins triggers signalling cascades of 
TRAM/TRIF and MyD88/TIRAP pathways resulting in the final activation of NF-kB and other factors. 
This leads to pro-inflammatory regulator production such as IL-6 and TNFα, which in turn further sustain 
insulin resistance. Molecules and mediators of these cascades interfering with insulin pathway transduction 
through IRS-serine phosphorylation are indicated with a red star (*). 
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   NOD-Like Receptors 
 Another mechanism mediating inflammation and involved in insulin resistance 
development is represented by activation of the Nucleotide-binding Oligomerization 
Domain (NOD)-Like Receptors. NLRs consist of three domains: a C-terminal Leucine-
Rich Repeat (LRR) responsible for recognition of damage and pathogen associated 
molecular patterns (PAMPs and DAMPs), a central NACHT domain that mediates ATP-
dependent self-oligomerization, fundamental for NLR activation and an N-terminal 
domain which includes a caspase recruitment domain (CARD) and a pyrin domain (PYD) 
that mediates homotypic protein-protein interactions [168, 169]. NLRs are involved in 
the formation of inflammasomes, which are multiprotein complexes, located in the 
cytoplasm, that process pro-inflammatory cytokines triggering their maturation [170]. 
Different types of inflammasome have been identified and generally their structure 
consists of a sensor NLR protein, a protease caspase 1 and an ASC protein containing PYD 
and CARD domains that function as adaptor between the NLR protein and the protease 
caspase 1 [171].  Depending on the type, NLRs recognize molecules derived from gram-
positive and/or gram-negative bacteria as well as endogenous ligands such as saturated FFAs 
[172, 173] and lead to NF-kB pathway activation or maturation of the pro-inflammatory 
cytokine via the inflammasome machinery.  Similar to the toll-like receptors, activated 
mediators of this process impair the insulin signalling pathway (figure 3) [174, 175]. 
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Figure 3 NOD-like receptors and insulin resistance 
The figure shows a schematic representation of nucleotide-binding domain (NOD1/2) and NOD-like 
receptors family, pyrin domain containing protein 3 (NLRP3) inflammasome. NOD1/2 oligomerization 
upon activation by FFAs occurs by recruitment of receptor-interacting protein2 (RIP2) and triggers 
activation of NF-kB and MAPK. NF-kB is also activated by stimulated TLR4 and leads to expression of 
NLRP3 and precursors of IL-1β. NLRP3 oligomerizes upon recognition of DAMPs and triggers activation 
of procaspase-1 which catalyses maturation of IL-1ß. Secreted IL-1ß and mediators of the NOD signalling 
cascade impair insulin pathway by IRS1/2 inhibition (indicated by red star *). 
 
1.2   MicroRNAs 
 MicroRNAs (miRNAs) are small non-coding single stranded RNAs (ssRNAs), of 
about 18-25 nucleotides in length, that regulate gene expression at a post-transcriptional 
level. In particular they recognise specific sequences in the messenger RNA (mRNA) 
targets and inhibit them through two mechanisms: perfect pairing, which elicits direct 
mRNA cleavage and imperfect pairing, that blocks mRNA translation [177].  
   MicroRNA nomenclature 
 MicroRNA nomenclature consists of a prefix that specifies the species of origin, 
such as ‘mmu-’ for Mus musculus, ‘hsa-’ for Homo sapiens etc., followed by the three 
letters ‘miR-’ or ‘mir-’ and a number assigned sequentially. MicroRNAs of different 
species but with identical sequence have the same numbering but different prefix. ‘miR-
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’ refers to the mature miRNA whereas ‘mir-’ refers to the miRNA gene. MiRNAs can be 
grouped into families when closely related to each other, so that they have the same 
numbering but different suffixes. Lettered suffixes indicate miRNAs with very similar 
sequences that generate from distinct genes, such as hsa-miR-121a and hsa-miR-121b. 
MiRNA genes on different genomic locations generating identical mature miRNA 
sequence but distinct precursor sequences are distinguished by the addition of a numerical 
suffix such as mir-121-1 and mir-121-2. Mature miRNAs originating from opposite arms 
of the same precursor hairpin structure are referred as lead and passenger strand, where 
the lead is the most abundant strand and the passenger strand is indicated with the star 
symbol (e.g. miR-56*). When there is no clear evidence that one strand is more abundant 
than the other one the two miRNAs are distinguished by specifying 5p for the 5’ arm or 
3p for the 3’ arm (example: miR-142-5p and miR-142-3p). There are some miRNAs that 
do not fit into these conventions, either for historical reasons such as Let-7 and Lin-4 or 
because they are named by adopting a slightly different scheme, such as in the case of 
plants and viral miRNAs.  
   miRNA Biogenesis 
MiRNA genes have been found in every chromosome, Y included [178], which was 
previously thought not to have any miRNA. In 50% of cases the miRNA and mRNA loci 
are side by side, organised in clusters, which are concurrently transcribed in a unique 
primary polycistonic transcript and usually functionally correlated. MiRNA genes can 
also be located in intergenic regions. Their transcription is generally under the control of 
the host gene promoter, but sometimes they have their own independent promoters [179]. 
In mammals, miRNA transcription is mediated by the RNA polymerase II (RNA pol II) 
[180] (in most of the cases), or the RNA polymerase III (RNA pol III) when miRNAs 
genes are located in the proximity of Alu repeat sequences [181] . Transcription generates 
a pri-microRNA of variable sizes, generally several thousands of bases in length with a 
7-methylguanosine cap on the 5’ termini and a poly (A) (poly-adenosine) tail at the 3’ 
end. In the transcript, the central core relative to each miRNA folds up forming a hairpin 
structure presenting one or two loops. In the nucleus, pri-miRNAs are recognised and 
processed by the endonucleases Drosha and Pasha, which, in association with other 
proteins, such as DEAD box, p27, p68 and some ribonuclease proteins form the 
Microprocessor complex. Pasha, also known as DiGeorge syndrome critical region 8 
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(DGCR8), and Drosha present specific RNase III catalytic domains (RIIIDa, RRIIDb). 
Pasha ties the hairpin structure through its two double stranded RNA binding domains 
(dsRBDs). This allows Drosha to cleave the 5’ and 3’ strands of the miRNA at about 11 
bases after the junction between the double strand and the single strands of the hairpin 
structure. The pre-miRNA so formed is of about 70 nucleotides in length and presents a 
5’ phosphate group and a 2 nucleotide 3’ overhanging end [182, 183]. MiRNAs do not 
always need to be processed by the microprocessor complex. When miRNA genes are 
situated in short introns, with the termini in the splice donor and acceptor sequences, the 
pre-miRNA is directly obtained through the splicing process and transferred into the 
cytoplasm. These particular miRNAs are called “mirtrons”. Pre-miRNA transport across 
the nuclear pores is mediated by the nuclear receptor protein Exportin 5 (EXPO5) (figure 
4) which selectively recognizes dsRNA structures containing a number of base pairs over 
14 and a 3’overhang [184]. EXPO5 binds to the pre-miRNA in a GTP-dependent way 
inside the nucleus and releases it in the cytoplasm consequently to GTP hydrolysis [185].  
 In the cytoplasm, pre-miRNA is processed by the RNase III Dicer1 that presents 
several domains: an N-terminal DEXH-box helicase domain, a DUF283 domain which 
function is unknown, a Pwi Argonaute Zwille (PAZ) domain, two RNase III domain and 
finally a double stranded RNA binding domain (dsRBD) [186]. The 3’ of the pre-miRNA 
is recognized by the PAZ domain, while the RNase III domain facilitates a cleavage event 
that generates a ~ 22 bp dsRNA with a 2 nucleotides 3’ overhanging end [187]. 
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Figure 4 The biogenesis of miRNAs. 
The RNA polymerase generates a pri-miRNA. The pri-miRNA is cleaved into a 70–100 nt pre-miRNA 
with a hairpin structure and 2–3 nt 3’overhang by Drosha and DGCR8/Pasha complex. Then exportin5 
exports the pre-miRNA to the cytoplasm via the nucleus core. A) Dicer, with its partner TRBP2, binds to 
the pre-miRNA and shears it to form a dsRNA. Ago2 is ready to load a mature miRNA after the 
conformational change of Dicer and TRBP2 complex. B) Another pathway for miRNA maturation is 
dependent on Ago2 instead of Dicer complex. Ago2 loading a mature miRNA binds to GW182 to form the 
core components of RISC. The RISC binds to the mRNA . The target mRNA can undergo two different 
fates: C) degradation into the P-body by an exonuclease Xran1 following mRNA decapping and 
deadenylation; D) inhibition of protein translation based on the imperfect complementarity. 
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Trans-activator RNA-binding protein (TRBP) is phosphorylated by MAPK extracellular 
signal-regulated protein kinase (ERK) upon stimuli such as cell growth and confers 
stability to the DICER complex, relating the miRNA maturation process to the MAPK 
pathway [189].   
 In mammals, DICER interacts with argonaute proteins (Ago) that load the mature 
miRNA and in association with TRBP and other proteins, such as the accessory heat 
shock proteins 70 and 90 (HSP70 and HSP90), to form the miRNA Induced Silencing 
Complex RISC [190]. These proteins facilitate and permit the ATP-dependent process of 
miRNA loading onto Argonaute (Ago) proteins [191]. Ago proteins are present in all 
eukaryotic organisms and 4 isoforms exist: Ago1-4. All of them show similar efficiency 
in miRNAs recognition, but only Ago2 also presents endonuclease activity [186]. Only 
one strand of the mature miRNA is incorporated in the RISC complex, generally the one 
with a lower thermodynamic stability at the 5’ extremity. The other one, called passenger 
strand (miRNA*) is generally degraded [192, 193] If both the strands present a similar 
stability either strand can be selected for incorporation with the same probability. MiRNA 
incorporation in the Dicer complex was previously thought to be necessary for miRNA 
maturation, but an alternative way has been observed for miR-451 [194]. Once processed 
by Drosha, the pre-miR-451 consists of a small hairpin where the stem is made of 18 bp. 
Since Dicer is unable to process such short structures, miR-451 maturation is completed 
by Ago2, skipping the Dicer step [194]. A similar mechanism is likely to be adopted by 
brown adipocytes for miRNA maturation. In fact, a study showed that Dicer KO in Dicer-
conditional aP2-Cre transgenic mice did not affect BAT development in vivo, even 
though it impaired the expression of several genes [195]. Moreover, a study suggested 
that some miRNAs could be accumulated in inactive form and activated when needed 
[196]. The level of expression of these miRNAs might show only a little variation upon 
DICER1 ablation via Cre-recombinase induction. MiRNA loading onto Ago protein is 
widely considered to occur during miRNA biogenesis [197, 198]. However, in a recent 
study a pool of inactive mature miR-34, lacking a 5’ phosphate and not loaded on Ago2, 
was found in four human cell lines in the absence of DNA damage insult. MiR-34 is 
known to be induced by p53 and functions as a tumor suppressor. The miRNA pool was 
activated by 5’ end phosphorylation and loaded onto Ago2 only after exposure to ionizing 
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radiation. This mechanism could provide a miRNA response to specific stimuli more 
rapidly than the classic de novo miRNA biogenesis as observed in this study [196].  
   MicroRNAs and mechanism of action 
 The 5’ end of the miRNA sequence is referred to as the seed region and it is 
essential in the silencing process, as also supported by the fact that it is the most conserved 
sequence in miRNAs of multicellular organisms [199]. The seed sequence is generally 6-
8 nucleotides in length starting from the second nucleotide at the 5’end. The typical 
miRNA-target interactions are shown in figure 5. The first nucleotide is not a determinant 
for the pairing and thus is not necessarily complementary to the 3’ untranslated region 
(UTR) of the target. In the mRNA sequence, the presence of an adenosine not 
complementary to the correspondent first nucleotide in the 5’ end of the miRNA can 
increase miRNA activity [200]. The 3’ end of the miRNA, albeit not perfectly 
complementary to the target, can compensate mismatches in the seed region [186]. In 
some cases, the pairing of miRNA with the 5’ UTR of the mRNA targets can promote 
translation into protein instead of inhibiting it [201]. Several other types of 
miRNA:mRNA interactions different from the canonical ones have been recently 
reported to occur (figure 5). Based on the complementarity of miRNA sequences to the 
3’ UTR sequence of mRNAs, several algorithms have been developed to calculate 
miRNA-mRNA affinity and predict miRNA potential targets. These algorithms are 
designed to reduce the possibility of obtaining false results and take into account 
conservation of the sequences across species, free energy and accessibility to the target 
sequence. The most commonly used algorithms are miRANDA, PicTar, DIANA, miRdb 
and Target Scan. MiRanda algorithm [202] searches for complementarity between 
miRNAs and the mRNA 3’ UTRs without considering cross-species conservation of 
binding sites. Scores are assigned considering thermodynamic stability of the 
miRNA:mRNA duplex and grade of complementarity. One wobble pairing in the seed 
region compensated by matches in the 3’ region is allowed. Targetscan 
(http://www.targetscan.org/) searches for sites that are fully complementary to the seed 
region (nucleotides 2-7). Scores are calculated based on the length of perfect matching 
regions and the presence of adenosine nucleotide in the first position of the mRNA target 
sequence. It considers conservation of targets and miRNA families [200]. Pictar 
(http://pictar.mdc-berlin.de/) [203, 204] is similar to targetscan with the difference that it 
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searches for nearly perfect matches with regions of conservative 3’ UTRs. It calculates 
the free energy of the duplexes and considers multiple 3’ UTR binding sites. Diana 
(http://diana.imis.athena-innovation.gr/DianaTools/index.php) is a website that offers 
several types of bioinformatics tools. For miRNA target predictions it uses the Diana-
microT algorithm [205] which searches for MREs on 3’ UTRs of human mRNAs 
deposited in the RefSeq database. In a frame of 38 nt in the mRNA sequence, it calculates 
the minimum binding energy between the miRNAs and mRNA sequence for every shift 
on the mRNA sequence consisting of six nucleotides each. 
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Figure 5 Types of miRNA:mRNA interactions.  
On the left panel are shown canonical miRNA:mRNA interactions having the highest efficacy, with 8mer 
>>> 7mer-8m >> 7mer-A1 > 6mer. Less effective sites, such as 6mer or lower, can sometimes be 
compensated by interactions between the 3’ region of the miRNA and the mRNA as shown on the right 
panel (Alternative miRNA:mRNA interactions). ORF: open reading frame. 
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   The silencing process 
 Argonaute proteins present three conserved domains: PAZ, MID and PIWI [206]. 
The PAZ domain interacts with the 3’ end of the miRNA while the PIWI and the MID 
domains with the 5’ end of the miRNA (figure 6) in which nucleotides are positioned in 
a way to favour interaction with the mRNA target. An RNase-like fold in the PIWI 
domain confers the catalytic ability of Ago2 to cleave the mRNA target. However, mRNA 
cleavage by Ago2 occurs predominantly in mRNA inhibition mediated by siRNAs, which 
share the same machinery for gene silencing. Indeed, numerous mismatches in 
miRNA:mRNA interactions impede Ago2 to cleave the mRNA [207]. The silencing 
process requires the participation of additional proteins, including GW182 which 
interacts with the PIWI domain of Ago2. Several proteins belong to GW182 protein 
family, such as TNRC6A/B/C. These proteins present Glycine (G) and Tryptophan (W) 
repeats through which they play an important role in the silencing process. Inhibition of 
mRNA translation into protein can occur either at the initiation of protein production or 
during the elongation stages, as a consequence of mRNA degradation, dropping off the 
ribosome or proteolytic degradation of the forming polypeptide (figure 7) [208, 209]. 
There is evidence that reduced expression of protein is not necessarily accompanied by 
reduced expression of mRNA [210, 211].  
 mRNA degradation in this process is triggered by decapping and deadenylation 
events. mRNA stability and translation into protein in eukaryotes is permitted by several 
factors that induce its circularization and hence protection from degradation [212, 213]. 
Specifically, the complex eukaryotic translation initiation factor 4E (eIF4F) includes two 
proteins: eIF4E and eIF4G, with the former interacting with the 5’ cap and the latter 
binding to poly A binding protein (PABP), which, as suggested by the name, interacts 
with the poly A tail. Subsequently, CAF1-CCR4-NOT, recruited by GW182, catalyses 
the adenosine residues removal [214] impeding mRNA circularization and translation 
initiation [215]. The DCP1-DCP2 (decapping protein1-2) in association with  enhancer of 
mRNA decapping 4 (EDC4) and DEAD-Box Helicase 6 (DDX6) catalyses 5’ decapping 
exposing mRNA to the 3’ and 5’ RNase activity of the exoribonuclease 1 (XRN1) [186].  
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Figure 6 Argonaute protein structure and miRNA:mRNA interaction 
The figure shows PAZ, PIWI Mid and N-terminal domains of argonaute protein. The 3’end of the miRNA 
interacts with the PAZ domain, while the 5’ end is held by MID and PIWI domains favouring 
miRNA:mRNA interaction. 
 
 Decapping, deadenylation and mRNA degradation occur in P-bodies [216, 217], 
also known as GW-bodies. These compartments contain a high amount of vesicles 
(MLVs) on which membrane dissociation of GW182 and RISC takes place. GW182 is 
embedded in intraluminal vesicles (ILV) and degraded after ILV fusion with lysosomes 
[218]. Ago2 is then delivered back into the cytoplasm by binding HSP90 that acts as a 
carrier. The whole mechanism of RISC dissociation and miRNA release are still to be 
clearly elucidated. However, Simons et al., demonstrated that miRNAs [219] during this 
process can be included into MLVB and then secreted in association with proteins or 
inside exosomes [220, 221]. Ago2 has been found in association with several circulating 
miRNAs and GW182 inhibition resulted in impaired exosome production. This suggests 
an involvement of Ago2 and GW182 in miRNA secretion. Investigation of their role in 
this process would be of great interest for elucidating the mechanisms through which 
miRNAs are released in the extracellular environment and mediate cell-to-cell 
communication. 
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Figure 7 The silencing mechanism mediated by miRNAs in animals 
mRNA circularization, for polysomes loading and translation, is mediated by the proteins PABP, eIF4G 
and eIF4E containing miRNA. The RISC complex containing GW182, AGO2 and the miRNA interacting 
with the 3’ UTR of the mRNA prevents mRNA translation into protein in different possible ways: B) post 
initiation block by promoting proteolytic degradation of the nascent polypeptide or ribosome drop-off;  A) 
disruption of the cap complex (initiation block). mRNA degradation occurs upon deadenylation, and 
decapping. In sequence, GW182 recruits CAF1-CCR4-NOT complex, which removes the poly A tail. The 
5’ cap of the deadenylated mRNA is then removed by the DCP1-DCP2 complex in cooperation with EDC4 
and DDX6 also recruited by GW182 (decapping).  The exonuclease XRN1 degrades the unstable mRNA 
(5’ to 3’ decay). 
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   Mechanism of gene regulation 
 An increasing body of evidences suggests that gene regulation mediated by 
miRNAs is not a simple mechanism but rather the result of a complex network where 
miRNAs, coding and non-coding genes “talk” to each other through the language of 
miRNA response elements (MREs). MREs are those sequences on mRNAs responsible 
for miRNA-mRNA interactions. The principle of this mechanism, hypothesized by 
Salmena and colleagues, resumes previous observations and is based on the existence of 
pseudogenes and long non-coding genes, that possess the same MREs of coding genes 
and can potentially compete for the same set of miRNAs influencing protein translation 
[222]. Pseudogenes are genomic DNA sequences similar to the ones of real genes but that 
are not functional, as they generally do not code for proteins, have premature stop codons 
or present some sort of mutations [223]. With their expression level differing among 
diverse types of tissue or altered in certain pathologies [224], pseudogenes may influence 
miRNA activity on a real gene in a tissue-specific way. Long non-coding genes (lncRNA) 
do not code for proteins and their transcription results in RNAs with a length of over 200 
nucleotides. As demonstrated, lncRNAs can interact with miRNAs [225, 226]. The 
presence of competitors for miRNAs, results in decreased miRNA detection and activity 
[227-229]. Therefore, at a post-transcriptional level, miRNAs regulate RNAs and vice 
versa. An example of miRNA regulated Post-transcriptionally by RNA molecules is 
represented by a non-coding RNA of herpesvirus saimiri which sequesters human miR-
27 and induces its degradation [227]. This new logic of gene expression regulation 
resembles in a certain way the dynamics of competition observed in proteins, where the 
concentration of competitors and degree of affinity are determinant factors. The high 
number of combinatorial events, reflect the complexity of the regulatory mechanism of 
gene expression. Affinity between miRNAs and RNA competitors or RNAs and miRNA 
competitors relies in the existence of different modalities for miRNA-mRNA interaction 
and the resulting bound efficacy (figure 5). Recent studies have shown that also miRNA-
miRNA interactions occur [230, 231], remarking the complexity in the post-
transcriptional gene regulation network.  
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   MicroRNA secretion 
 The complexity of multicellular organisms requires every cellular member to 
work harmoniously in synchrony with all other cells in order to ensure the correct 
functioning of the organism. Communication between organs, tissues and cells is 
fundamental to accomplish this aim. Several molecules can be delivered in different ways 
from one cell to another where they transmit signals and modify the program in the 
acceptor cell. This regulates numerous processes like apoptosis, cell growth, 
proliferation, and differentiation [232]. Many messenger molecules are well known and 
only relatively few have been discovered recently [232]. Among these, circulating 
miRNAs have attracted interest in the last few years.  
RNA molecules are very susceptible to degradation since the extracellular environment 
is enriched in RNase enzymes that work as a defence against exogenous nucleic acids, 
such as viruses genes [233]. Even so, miRNA presence has been detected in many body 
fluids [232]. They also show strong resistance to non-physiological conditions like drastic 
pHs and temperature variations [234, 235]. This necessarily implicates the existence of 
protection systems. So far, three different ways by which miRNAs are released in the 
extracellular environment have been identified. These include: spontaneous spill out as a 
consequence of cellular damage, active incorporation into delivery systems consisting of 
membranes (exosomes, micovesicles), and through protein/lipoprotein association [188]. 
The principle mechanisms for miRNAs secretion are represented in figure 8. 
   MicroRNA vesicles-mediated secretion 
Incorporation of molecules into messenger systems allows exchange of information 
between cells. The process can be divided into three main stages: incorporation/release, 
travelling toward the acceptor cell and finally cellular uptake. During each phase, 
molecules have to overcome numerous obstacles to successfully reach the target [236]. 
Lipid membranes constitute an efficient system for this purpose since they can easily fuse 
cellular membranes and reach different organelles or cellular compartments [236]. The 
release of membranous particles through fusion with the plasma membrane is known as 
exocytosis and can be constitutive or inducible [237]. In the first instance, release occurs 
soon after the vesicle has formed, while, the second one requires particular stimuli that 
increases Ca2+ concentration. One mechanisms underlying this process is mediated by the 
51 
 
adenosine triphosphate (ATP)-gated ion channel P2X7 receptor which is activated by 
extracellular ATP and is involved in inflammatory processes [238]. 
 Circulating membranous microparticles can be divided into exosomes and 
microvesicles. Both of them, as demonstrated in many studies, facilitate extracellular 
miRNA transport [188]. For some miRNAs identified as circulating through vesicles, the 
distinction between the two systems is not always specified. In fact, Microvesicles (MVs) 
are derived from direct blebbing of the plasma membrane with heterogeneous size (1nm 
to 1000 um) [239, 240]. Exosome dimensions vary between 30-150 nm [241, 242], but 
they differ in composition, biogenesis and way of secretion. However, the two are mixed 
in the extracellular environment, and without specific marker analysis, it is not possible 
to discriminate one from the other [243].  
 Exosomes originate by subsequential intralumen invaginations (ILV) of the multi-
vesicular bodies (MVBs) membrane [244], which in turn originate in the GW-bodies . 
The GW-bodies are cellular compartments similar to the P-bodies in terms of structure 
and function [245]. MVBs are intracellular compartments that mediate transfer of 
molecules between early-endosomes and late-endosomes, which together regulate the 
fate of incoming and/or outgoing molecules [244]. Exosome release into the extracellular 
environment follows the fusion of the MVBs membrane with the plasma membrane 
[246]. MiRNA incorporation into exosomes can occur during RISC complex dissociation 
in the MVBs [219, 243]. Many markers have been identified, among these, there are the 
heat shock proteins involved in miRNA maturation HSP70 and HSP90 which might 
constitute a link between miRNA biogenesis and their release through exosomes [246].  
 Another mechanism underlying exosome and miRNA secretion may be 
represented by the ceramide-dependent secretory machinery as reported by Kosaka in 
2010 [247] and confirmed by Mittelbrunn et al. [248]. In their work, inhibition of the 
regulator for ceramide biogenesis, sphingomyelinase 2 (nSMase2), negatively affected 
exosome formation and miRNA secretion from T cells. 
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Figure 8 Different transporters for miRNA transport.  
The RISC in the GW-body is dissociated from the membrane of MVBs by the ESCRT, and the GW182 is 
eliminated from the RISC and sorted into the ILVs for degradation by entering the lysosome. MiRNAs are 
transported in exosomes by the fusion between MVB sand plasma membrane or in microvesicles through 
budding of plasma membrane. Protein complexes and apoptotic bodies could also carry miRNA in 
extracellular environment. 
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   MicroRNA-protein secretion 
The first protein proposed as carrier for miRNA was nucleophosmin I (NPMI). This 
nucleolar phosphoprotein is responsible for RNA and ribosomal protein transfer from 
nucleolus to cytoplasm. Its incubation with a synthetic miR-122 prevented miRNA 
degradation by RNaseA [188]. In human plasma, High Density Proteins (HDL) have been 
found in association with several miRNAs [249].  
 One of the most intriguing proteins involved in extracellular miRNA transport is 
represented by Ago2, which is fundamental in miRNA maturation and mRNA silencing. 
It was found associated with several miRNAs in human plasma [188]. However, it is still 
not clear if the association occurs inside the cells or after secretion. It was also 
demonstrated that most of the miRNAs detected in the extracellular environment were 
bound to proteins rather than included in vesicles [250]. The contrary was showed by 
Gallo et al., where miRNA were principally inside exosomes [251]. However, there is 
evidence that miRNA-proteins complexes can be incorporated into and released as 
circulating vesicles. Li et al., could in fact detect Ago2-miRNA presence into 
microvesicles [252]. They also proposed that miRNA included in vesicles but not 
associated with Ago2 might be degraded once absorbed by the acceptor cells. Different 
cells might have different mechanisms for secretion of the same molecules [188]. This 
could justify the presence of both miRNA-Ago2 complexes inside vesicles and alone in 
extracellular fluids [188, 252]. 
   miRNA delivery  
 The discovery of exosomes containing miRNAs has aroused great excitement in 
the scientific community for the implication of this novel potential mechanism of miRNA 
delivery in the cross talk between cells. However, a quantitative and stoichiometric 
analysis of miRNA content in exosomes from human blood samples has revealed that a 
single exosome contains on average, less than one molecule of a specific miRNA [253] 
for which functionality is therefore biologically insignificant. However, this conclusion 
was made on the assumption that miRNAs are equally distributed in the exosome 
population of human blood. In contrast, in vitro studies show that different types of 
cells/tissues present differential expression of exosomal miRNAs demonstrating that 
miRNAs are not equally distributed in the exosome population. Therefore, more 
significant concentrations of a specific miRNA could be contained in a single exosome 
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as well as no copies at all of that miRNA might be present in exosomes derived from a 
different type of cell. The ability of exosomes to deliver their cargo to selective target 
cells would further improve the achievement of a substantial concentration of a given 
miRNA in a specific cell/tissue type. Whether exosomes can selectively target specific 
cells is still unclear. Some studies show that exosomes can virtually target any type of 
cells [254], while others suggest that expression of specific molecules on the cellular and 
exosomal surfaces are required for exosome uptake [131]. An example of specific 
interaction is given by monocyte-derived dendritic cells that were showed to selectively 
internalised exosomes from breast milk expressing MUC1 (Cell Surface Associated 
Mucin 1) via DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin) and MUC1 interaction [255]. Derivation from other sources or 
absence of MUC1 resulted in failed exosome uptake by these cells. Another study 
revealed that more than one mechanism for exosome internalization, are likely to exist. 
Indeed, treatment with a blocker of integrin-mediator receptor internalization resulted in 
decreased exosome uptake by macrophages and dendritic cells but not microglia [255]. 
In vitro studies also suggest that miRNAs delivered into distal cells are functional and 
can effectively modulate acceptor cell pathways. Initial evidence was reported by 
Zernecke et al., who demonstrated that miR-126, delivered by apoptotic bodies, reduced 
expression of RGS16 in recipient HUVEC cells [256]. Successively, the results of many 
other in vitro studies supported the functionality of delivered miRNAs into recipient cells 
[257-260]. A study conducted recently, exhaustively addressed the question whether this 
process actually occurs in vivo. Thomou T. and colleagues discovered that BAT-derived 
exosomes containing miR-92b suppress FGF-21 in liver and also reduce its circulating 
levels [261]. This effect was observed selectively for exosomes released by BAT, 
although other fat depots contribute to miR-92-exosome release, supporting the fact that 
exosome uptake can be tissue specific. Moreover, this demonstrates that miRNAs 
packaged into exosomes can travel long distances and their function is not limited to 
autocrine and paracrine actions. In contrast, this is still not clear for miRNAs associated 
to vesicle-free system. However, evidence show that also these carriers are able to deliver 
functional miRNAs into recipient cells [262]. Neuropilin-1 (NRP-1) is a cell surface 
receptor expressed on different type of cells and involved in the internalization of several 
types of ligand [263]. It was demonstrated to efficiently mediate uptake of miRNAs 
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complexed with Ago2. NRP1 was found to have high affinity for miRNAs either in 
association with Ago2 or Ago2-free. Vice versa, NRP1 bound with high affinity to Ago2 
either associated to miRNAs or alone. Internalised miRNAs promoted migration and 
proliferation in human ACHN cells (kidney adenocarcinoma cell line). As NRP-1 is 
widely expressed in different cell types, it would be logic to assume that miRNA 
internalization is not a selective process. However, a population of ACHN cells was found 
to be naturally NRP1-negative [262] and did not internalise the miRNA tested. Moreover, 
even though circulating vesicle-free miRNAs are mainly associated with Ago2, other 
types of proteins carrying miRNAs could exist. Finally, components of the ECM that are 
not present in in vitro studies, should be considered in this process, as they are known to 
favour or inhibit ligand-receptor binding [264] and their expression could be tissue-
specific. 
   MicroRNAs in adipocyte differentiation and metabolic disorders 
 An increasing body of studies has revealed that miRNAs play important roles in 
the different steps of adipogenesis. Some miRNAs have been identified as regulators of 
the commitment of MSC to the adipocyte lineage while others have been found to play a 
major role in the later stage of the pre-adipocyte differentiation into mature adipocytes. 
Additionally, some of these miRNAs are specific promoters of the brown, white or beige 
phenotype. An example of miRNA regulating early stages of adipogenesis is mmu-miR-
204, which has a homologue in humans, namely hsa-miR-211. This miRNA targets runt-
related transcription factor 1 (RUNX1) in MSCs inhibiting the osteogenic lineage in 
favour of the adipogenic program [265]. Another miRNA with similar function is miR-
103a-3p as its overexpression in human adipose derived stem cells (hADSCs) inhibited 
osteogenic proliferation and differentiation. Cyclin Dependent Kinase 6  CDK6 and 
DICER1 were identified as miR-103a-3p targets [266] .  
 MiRNAs such as miR-10b, miR-15, miR-26a, miR-34c, miR-101 miR-185 miR-
224 and others were found to be upregulated in the late stages of differentiation 
suggesting their potential involvement, not only in adipogenesis but also in the metabolic 
activities pertinent of mature adipocytes [267].  
 Among the miRNAs that were found to promote adipogenesis there are: miR-371, 
the cluster miR-17-92, miR-21 miR-103 miR-143 and miR-378. The former was reported 
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to induce the expression of FABP4 and adiponectin, the cluster miR-17-92 downregulates 
Rb2/p130 and miR-21 modulates the anti-adipogenic pathway mediated by Transforming 
growth factor beta (TGF-ß) [268]. MiR-143 showed opposing functions depending on 
the stage of differentiation. In fact, ADSCs differentiation was inhibited by 
overexpression of miR-143 during clonal proliferation stage and promoted it in the 
terminal phase, during growth arrest. In this study MAP2K5 was identified as a miR-143 
target [268]. MiR-103 promotes 3T3-L1 adipogenesis by inhibiting myocyte enhancer 
eactor 2D (MEF2D), a suppressor of differentiation [269], besides targeting CDK6 and 
DICER in hADSC, as mentioned previously. 
 MiR-378, besides promoting adipocytes differentiation, was found to be involved 
in a large number of functions, not only restricted to the adipocytes, such as metabolism, 
lipid storage, cell differentiation/proliferation [270] and angiogenesis [271], many of 
which have been reviewed by Bart Krist et al., [272]. Mir-378a is located in the intron of 
the Ppargc1b gene [273], and it was reported to be co-expressed with PGC-1 during cell 
differentiation, suggesting their involvement in similar processes [270]. From mir-378a 
the mature miR-378a-3p and miR-378a-5p are generated, situated in the opposite arms 
forming the pre-miR378a stem loop. These miRNAs were previously identified under 
different names: miR-422b, miR-378 and miR-378-3p for miR-378a-3p and miR-378 and 
miR-378* for miR-378a-5p, both in human and mouse. MiRNAs with very similar 
sequences to miR-378a have been identified in different locations of the genome and have 
been named as: miR-378b, c, d1, d2, e, f, g, h, i and j in mouse and human [274-278]. 
However, a large body of study has mainly focussed on miR-378a-3p and its opposite 
strand miR-378a-5p. The sequence of miR-378a-5p is identical in mouse and human, 
while, mmu-miR-378a-3p and hsa-miR-378a-3p differ by one nucleotide [278, 279]. 
MiR-378a-3p and miR-378a-5p generally take part in similar processes [270] despite 
showing in certain cases opposite functions. For instance, in the cardiac cells H9c2, the 
enzyme lactate dehydrogenase A (LDHA), a direct target of miR-378a, was 
downregulated by miR-378a-3p but upregulated by miR-378a-5p [280]. The existence of 
different names for these miRNAs can generate confusion and sometimes the precise 
strand of miR-378a is not specified [281]. In mice, removal of the intron region containing 
mir-378a leads to HFD-induced obesity resistance and high mitochondrial activity and 
oxygen consumption [279]. MiR-378a has been demonstrated to promote adipogenesis 
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by positively regulating the activity of CEBPα and CEBPß which in turn results in 
enhanced transactivation of GLUT4 [270]. Pan, D., et al., reported that ectopic 
expression of miR-378a-3p in mice promotes enlargement of interscapular BAT but not 
of WAT, [282] suggesting that determined functions of miR-378a are tissue specific. 
 Another miRNA that was found to be mainly involved in brown adipogenesis is 
miR-365 which is transcribed in cluster with miR-193 [283]. However, they have been 
proposed as necessary not only for the late brown differentiation but also for early brown 
and white adipogenesis. MiR-193/365 were found to directly target and negatively 
regulate RUNX1 Translocation Partner 1 (RUNX1T1), an inhibitor of adipogenesis 
[284]. MiR-193/365 inhibition in the stromal vascular fraction of interscapular BAT of 
C57BL/6 mice, affected lipid accumulation and the expression of genes such as aP2, 
C/EBPα and PPARγ [283] that are crucial for both white and brown adipogenesis. 
However, the most important evidence in this work was that miR-196/365 specifically 
promotes the brown phenotype by targeting genes that activate the myogenic program 
such as CDON [285] and the insulin-like growth factor-binding protein 5 (IGFBP5) 
[286]. This was confirmed by a significant decrease of classical-brown proteins like 
UCP1, PPARγ, PGC1α PRDM16, and CIDEA when miR-193/365 inhibition was 
induced by locked nucleic acid (LNA) technology. Indeed, UCP1 over-expression was 
obtained when miR-193/365 was ectopically expressed in vitro in C2C12 myoblasts. 
Interestingly, after forcing PRDM16 expression in these same cell lines, miR-193/365 
was up-regulated, probably, as a result of PPARα induction promoted by PRDM16. 
However, a later study showed contrasting results demonstrating that development and 
function of BAT in mice, was not affected by the absence of miR-193/365 cluster [287].  
 MiR-26a and miR-26b are up-regulated in the early phases of adipogenesis and 
miR-26a has been associated with promoting energy dissipation in brown adipocytes by 
targeting ADAM metallopeptidase domain 17 (ADAM17) also known as tumor necrosis 
factor-α-converting enzyme [288]. This protein is responsible for the cleavage of the 
membrane protein Pref-1 that generates soluble form of protein Pref-1 (50kD) previously 
discussed, which inhibits adipocyte differentiation [289]. In the same study, MiR-26a and 
miR-26b were found to upregulate UCP1 mRNA expression at the early and late stage of 
white and also at the late brite stages [288]. 
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 Also miR-133 has been associated with human and mouse BAT development 
versus myogenic differentiation. MiR-133, initially believed to be muscle specific was 
later found to be also expressed in BAT [290]. It directly targets PRDM16 and, at high 
levels, inhibits the brown phenotype [291]. In fact, all its variants present in the seed 
portion a complementary sequence to the 3’ UTR of PRDM16. MiR-133 transcription is 
positively regulated by myocyte specific enhancer factor 2 (MEF2C) expression of which 
is reduced after cold acclimatization or adrenergic stimulation as a consequence of 
increased cAMP levels [283]. However, miR-133 decrease in muscles or promotion of 
brown phenotype in muscle progenitors was only achieved when cold exposure was 
prolonged for more than one week [292]. 
 Also miR-155 is a negative regulator of brown adipogenesis. Its expression 
inhibits and is inhibited by C/EBPβ [293], while, its induction is promoted by TGF-β1 
[294]. This is further supported by chromatin immunoprecipitation assay data which 
revealed the presence of TGF-β1 on the enhancer sequence of miR-155. Moreover, miR-
155 expression strongly decreased when BAT pre-adipocytes were induced to 
differentiate, while, inhibition of C/EBPβ resulted in over-expression of miR-155 [295]. 
 MiR-33 is involved in the control of lipid metabolism gene expression [296, 297] 
and regulates fatty acid and cholesterol homeostasis by targeting receptor-interacting 
protein 140 (RIP140), a nuclear corepressor that inhibits the brown phenotype [298]. 
Thus, miR-33 might also be involved in promotion of brown adipogenesis. [296, 297].  
 Another miRNA, miR-27, has been described recently as negative regulator of 
brown adipogenesis by directly targeting PRDM16, PPARα, CREB [299] and PPARγ 
[300]. 
 MiR-455 is up-regulated during brown adipogenesis [290], and modulates 
thermogenesis. This miRNA promotes differentiation by suppressing anti-adipogenic 
genes such as RUNX1T1 and NECDIN. Moreover, it inhibits HIF1α activating MAPKα1 
and mitochondrial biogenesis [301]. 
 One of the most intriguing miRNAs in adipogenic differentiation is represented 
by miR-196a. This miRNA is involved in the acquisition of classic brown characteristics 
by white pre-adipocytes after β-adrenergic stimuli or cold exposure, the so called 
“browning” effect [302]. MiR-196a is encoded by two genes, mir-196a-1 and mir-196a-
2, both embedded in homeobox (HOX) gene clusters (HOXC) on chromosome 17 and 
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12, respectively and present a complimentary sequence to the HOXC8 transcript [302, 
303]. Thus, their strict correlation in adipogenesis regulation is not surprising. HOXC8 is 
a member of HOX family present at high levels in white progenitors and strongly 
decreases during brown differentiation. Indeed, it acts as a brown adipogenesis inhibitor 
and is directly repressed by miR-196a. In addition, HOXC8 regulates C/EBPβ expression 
by binding the C/EBPβ locus, as shown by chromatin immunoprecipitation assay (ChIP) 
in mouse. A role for miR-196a in promoting brown-like differentiation is supported by 
the in vivo experiments where transgenic mice for this miRNA demonstrate high energy 
consumption and resistance to obesity [302].  
 MiR-138 is encoded by mir-138-1 and mir-138-2 genes located on the 
chromosomes 3 and 16 respectively [304]. MiR-138 was reported to inhibit human 
adipose derived stem cell (ADMSC) differentiation and to target EP300 inhibitor of 
differentiation 1 (EID1) [305]. EID1 was reported to inhibit 3T3-L1 differentiation into 
white adipocytes by decreasing PPARɣ expression via pRb inhibition. EID1 was 
associated with decreased lipid droplet formation and increased expression of brown 
genes such as UCP1 and PGC-1α [306]. Similarly, other studies showed that treatment 
with EID1 leads to ADMSC differentiation into highly metabolic adipocytes expressing 
high levels of UCP1 and CITED1 (Cbp/P300 interacting transactivator with Glu/Asp rich 
Carboxy-terminal Domain 1) [307], while EID1 suppression inhibited ADMSC 
differentiation [305]. EID1 was proposed as a promoter of white adipocyte 
transdifferentiation into beige adipocytes [307]. According with these findings, at least 
partially, miR-138 was downregulated in differentiating ADMSC and its overexpression 
resulted in reduced fat accumulation and downregulation of CEBPα, PPARɣ2, FABP4 
and LPL [305]. Therefore, miR-138 is likely to inhibit brown/beige adipogenesis in 
favour of the white phenotype by repressing EID1. MiR-138 was found to be 
overexpressed in amniotic MSC (hAMSC) from obese mothers compared to lean controls 
[308] while it was overexpressed in serum from non-diabetic obese subjects compared to 
lean controls [309]. This suggests that the intracellular and extracellular role of miR-138 
in obesity may differ depending on the cell type in which it is synthesised or taken up. 
 Some other miRNAs have been identified as suppressor of adipose differentiation. 
MiR-448 inhibits adipogenesis by negatively regulating Kruppel-like factor 5 (KLF5) 
[310], miR-369-5p by targeting FABP4 and reducing levels of adiponectin [311], while 
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miR-130 by targeting PPARɣ [312]. MiR-29a/b/c was found to be downregulated during 
the contact inhibition stage and its overexpression inhibited adipogenesis by targeting 
DNA methyltransferase 3 (DNMT3A) [313] which is involved in the epigenetic 
modification of DNA during adipogenesis [314].  
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1.3   Hypothesis & Aims 
 The adipose tissue has an important role in maintaining the energy homeostasis 
balance. Understanding its physiology is important for the development of treatments 
against diseases where this equilibrium is compromised, such as obesity and associated 
metabolic disorders. MiRNAs are important gene regulators and an increasing body of 
evidence suggests their involvement in adipogenesis and adipose metabolism. MiRNAs 
can also be secreted in the extracellular environment and be taken up by distal cells, 
mediating cell-to-cell communication. Exosomes secreted by the adipose tissue were 
found to contain miRNAs capable of regulating gene expression in distal organs. 
However, a large part of the data derive from analysis of miRNAs in blood samples or 
miRNAs released by adipose tissues, where it is not possible to identify the specific 
cellular component secreting miRNAs. Circulating miRNAs are transported by different 
types of carriers, however, most of the studies have focussed either on total adipose 
miRNAs or specifically on adipose exosomal miRNAs, leaving the other typology of 
miRNA carriers largely unexplored. Therefore, we hypothesise that brown and white 
adipocytes secrete different miRNAs that can potentially mediate cell-to-cell 
communication and that also vesicle-free systems contribute to adipose-miRNA 
transport. Stimulation of ß-adrenergic receptors in adipocytes triggers a cascade that 
induces transcription of several factors and activation of the beta oxidative program; 
therefore, we hypothesise that it can also affect miRNA expression and secretion. 
The high degree of cell heterogeneity of human BAT and its scarce availability for 
scientific research, slow the progresses on comprehending the differences between human 
brown and white adipocytes. We hypothesise that as in the mouse, human brown and 
white adipocytes, besides having substantial differences in terms of gene and miRNA 
expression, secrete different miRNAs for cell-to-cell communication. For all these 
reasons we aimed: 
 
1) To identify microRNAs differentially secreted between undifferentiated and 
differentiated brown and white adipocytes in mouse. 
2) To test extracellular and intracellular level of expression of the selected miRNAs 
among the ones identified as differentially expressed among undifferentiated and mature 
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brown and white adipocytes, in different adipose models in order to verify 
consistency/inconsistency between mouse and human adipocytes. 
3) To identify microRNAs differentially secreted by mature brown and white adipocytes 
in human cells. 
4) To predict miRNA targets of the secreted microRNAs which display a pattern of 
expression that is consistent across the adipose models for further investigations on the 
role of miRNAs in the cross-talk between adipocytes and distal cells. 
5) To define whether the selected miRNAs are released by adipocytes in the extracellular 
environment preferentially through incorporation into vesicles or in association with 
vesicle-free systems. 
7) To assess whether ß-adrenergic stimulation affects miRNA release. 
6) To identify genes differentially expressed between human mature brown and white 
adipocytes. 
7) To identify pathways enriched in human brown versus white adipocytes. 
8) To identify miRNAs potentially involved in the pathways associated with the genes 
differentially expressed between human brown and white adipocytes. 
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2  Chapter 2 – Materials & Methods 
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2.1   Materials  
   Cell Culture Reagents 
DMEM/F12 (Gibco, Fisher Scientific, Loughborough, UK) 
Advanced DMEM (Gibco, Fisher Scientific, Loughborough, UK) 
Seahorse XF Base Media (Agilent Technologies, Stockport, UK) 
Heat Inactivated Foetal Bovine Serum (Fisher Scientific, Loughborough, UK) 
Penicillin/Streptomycin (100X) (Fisher Scientific, Loughborough, UK) 
L-Glutamine (100x) (Invitrogen, Fisher Scientific, Loughborough, UK)  
Bovine Serum Albumin (Sigma-Aldrich, Haverhill, UK) 
Krebs-Ringer Bicarbonate Buffer (Sigma-Aldrich, Haverhill, UK) 
Collagenase, Type 1 (Sigma-Aldrich, Haverhill, UK) 
Insulin (10 mg/ml) (Sigma-Aldrich, Haverhill, UK) 
Dexamethasone (Sigma-Aldrich, Haverhill, UK) 
3-Isobutyl-1-methylxanthine (Sigma-Aldrich, Haverhill, UK) 
Indomethacin (Sigma-Aldrich, Haverhill, UK) 
Rosiglitazone (Cayman Chemical, Cambridge, UK) 
Triiodo-L-thyronine (Sigma-Aldrich, Haverhill, UK), Haverhill, UK)  
0.05% Trypsin-EDTA (Invitrogen, Fisher Scientific, Loughborough, UK) 
   Europium-based like Elisa Reagents 
Primary antibodies 
CD9 (Monoclonal Mouse IgG2B) (R&D, Bio-Techne, Abingdon, UK)  
CD81 (Monoclonal Mouse IgG1) ( Bio-Rad AbD Serotec, Kidlington, UK) 
CD63 (Monoclonal Mouse IgG1) (Bio-Rad AbD Serotec, Kidlington, UK) 
Human Serum Albumin (Monoclonal Mouse IgG2A) (R&D, Bio-Techne, Abingdon, UK) 
IgG2b (eBioscience, Fisher Scientific, Loughborough, UK) 
IgG1 (eBioscience, Fisher Scientific, Loughborough, UK) 
 
Secondary antibodies 
Anti-mouse IgG (Goat) biotin labelled (Perkin Elmer, Shropshire, UK) 
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Reagents 
DELFIA Eu-N1 Streptavidin (Perkin Elmer, Shropshire, UK) 
DELFIA Wash Buffer (Perkin Elmer, Shropshire, UK) 
DELFIA Assay Buffer (Perkin Elmer, Shropshire, UK) 
Enhancement Solution (Perkin Elmer, Shropshire, UK) 
Reagent Diluent (R&D, Bio-Techne, Abingdon, UK) 
 
   Chemicals and reagents 
Ethanol (Sigma-Aldrich, Haverhill, UK) 
Chloroform (Sigma-Aldrich, Haverhill, UK) 
Random Hexamers (Invitrogen, Fisher Scientific, Loughborough, UK) 
JumpStart SYBR Green I Mix (Sigma-Aldrich, Haverhill, UK) 
MMLV Reverse Transcriptase (Sigma-Aldrich, Haverhill, UK) 
RNAse OUT Ribonuclease Inhibitor (Invitrogen, Fisher Scientific, Loughborough, UK) 
TRI reagent® (Sigma-Aldrich, Haverhill, UK) 
100x ROX reference dye (Sigma-Aldrich, Haverhill, UK) 
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Haverhill, UK) 
DNase I, amplification grade (Sigma-Aldrich, Haverhill, UK) 
10x MMLV buffer (Sigma-Aldrich, Haverhill, UK) 
Glucose powder (Sigma-Aldrich, Haverhill, UK) 
Sodium Pyruvate (100mM) (Fisher Scientific, Loughborough, UK) 
Oil Red O (Sigma-Aldrich, Haverhill, UK) 
10mM dNTP mix (Invitrogen, Fisher Scientific, Loughborough, UK) 
5x Reaction BF (Exiqon, Vedbaek, Denmark) 
Enzyme mix (Exiqon, Vedbaek, Denmark) 
Particle-free water (Fresenius Kabi, Runcorn, UK) 
RNase-free water (Invitrogen, Fisher Scientific, Loughborough, UK) 
   Kits 
miRCURYTM RNA Isolation Kit-Biofluids (Exiqon, Vedbaek, Denmark) 
miRCURY LNATM Universal RT microRNA PCR (Exiqon, Vedbaek, Denmark) 
Amplification grade DNase I kit (Sigma-Aldrich, Haverhill, UK) 
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DNA extraction REDExtract-N-Amp (Sigma-Aldrich, Haverhill, UK) 
miRNeasyR Mini Kit (Qiagen, Manchester, UK) 
miRCURY LNATM Hi-Power Labeling Kit Hy3TM/ Hy5TM (Exiqon, Vedbaek, Denmark) 
Illumina TruSeq Stranded mRNA Library Prep Kit (Exiqon, Vedbaek, Denmark) 
 
   Media formulations 
DMEM/10 Media (Fisher Scientific, Loughborough, UK) 
DMEM/F12 with phenol red supplemented with 10% v/v FBS and 1% (v/v) 
Penicillin/Streptomycin  
 
A-DMEM/3 Media (Fisher Scientific, Loughborough, UK) 
Advanced DMEM/F12 with phenol red supplemented with 3% (v/v) FBS, 1% (v/v) 
Penicillin/Streptomycin and 1% (v/v) L-Glutamine 
 
Seahorse Media for Oxygen Consumption assay (Agilent Technologies, Stockport, UK) 
Seahorse XF base media, Glucose (25mM), Sodium Pyruvate (1mM), pH 7.4 
 
   Buffers  
10x Dnase I Reaction buffer (Sigma-Aldrich, Haverhill, UK) 
200 mM Tris-HCl, pH 8.3, 20 mM MgCl2 
DNase Stop solution (Sigma-Aldrich, Haverhill, UK) 
50 mM EDTA 
MMLV 10x reaction buffer (Sigma-Aldrich, Haverhill, UK) 
500 mM Tris-HCl, pH 8.3, with 500 mM KCl, 30 mM MgCl2, 50 mM DTT 
Phosphate Buffered Saline (PBS) 
140mM NaCl, 2.5mM KCl, 1.5mM KH2PO4 pH7.2, 10mM Na2HPO4 ,pH7.2 
 
Kreb-Ringer bicarbonate buffer (Sigma-Aldrich, Haverhill, UK) 
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1.8 g/L D-Glucose, 0.0468 g/L Magnesium Chloride [Anhydrous], 0.34 g/L Potassium 
Chloride, 7 g/L Sodium Chloride, 0.1 g/L Sodium Phosphate Dibasic [Anhydrous], 0.18 
Sodium Phosphate Monobasic [Anhydrous], 1.26g/L Sodium Bicarbonate, pH 7.4. 
 
   Solutions 
Seahorse Calibrant Solution (Agilent Technologies, Stockport, UK) 
Paraformaldehyde 4% in PBS (1X) (Affymetrix,  Buckinghamshire, UK) 
Harris Haematoxylin Solution (Sigma-Aldrich, Haverhill, UK) 
Extracting Solution (Sigma-Aldrich, Haverhill, UK) 
Tissue Preparation Solution (Sigma-Aldrich, Haverhill, UK) 
Neutralization Solution (Sigma-Aldrich, Haverhill, UK) 
Lysis Solution BF (Exiqon, Vedbaek, Denmark) 
Protein Precipitation Solution BF (Exiqon, Vedbaek, Denmark) 
Wash Solution 1 BF 
Wash Solution 2 BF 
Acid Ethanol: 1 ml concentrated Hydrochloric Acid in 400 ml 70% ethanol 
Eosin (Sigma-Aldrich, Haverhill, UK) 
Eosin Yellowish (1g) in 100 ml of distilled water  
 
Stock Oro Solution (Sigma-Aldrich, Haverhill, UK) 
Stock Oil Red O powder (0.5g) in 100 ml of absolute isopropanol 
 
Working Oro Solution 
Stock Oro solution diluted in distilled water 3:2 
 
   Primers and oligonucleotides 
ʎ-Bacteriophage RNA (Sigma-Aldrich, Haverhill, UK) 
Unisp6 and all Spike-ins (Exiqon, Vedbaek, Denmark) 
LNA miRNA Primers (Exiqon, Vedbaek, Denmark) 
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Table 1 Primer sequences for human genes 
Gene Name Forward primer Reverse primer 
L19 GCGGAAGGGTACAGCCAA GCAGCCGGCGCAAAA 
UCP1 GTGTGCCCAACTGTGCAATG CCAGGATCCAAGTCGCAAGA 
FABP4 TGTTGCAGAAATGGGATGGAAA CAACGTTCCCTTGGCTTATGCT 
HOXC9 CCGGCAGCAAGCACAAAGAG AGCGGGCGTGAATCCAGTT 
CIDEA CATGTATGAGATGTACTCCGTGTC GAGTAGGACAGGAACCGCAG 
PGC1a TGAAGAGCGCCGTGTGATT CAGTTCTGTCCGTGTTGTGTCA 
FABP3 CTGGAAGCTAGTGGACAGCAA CACCTGCCTGGTAGCAAAAC 
AGO2 CCAGCTACACTCAGACCAACAGA GAAAACGGAGAATCTAATAAAATCATGAC 
DICER1 TTGCTTGAAATGGAACCAGAAA ACTCTGACCTTCCCGTCGTAAG 
GW182 TACTGTGCGGGAAGTTGAC CCAGGCACTAGTTGAAGGCA 
SLC27A2 AAGGCCCCGGTTTCTAAGAA TTAAAGCCCTCCTCCTCCACCAG 
CPT-1B AGGAGCCCTCTCATGGTGAA TGGCGTGGATGATGTTTCCC 
CYT-B ACAACCCCCTAGGAATCACC GAGGGCGTCTTTGATTGTGT 
RIP140 ACATTTGGAGGGAGGCTTCAT GCTTTCGTTTCTGCAGTAGGAAGTA 
 
Table 2 Primer sequences for mouse genes 
Gene Name Forward primer Reverse primer 
L19 GGAAAAAGAAGGTCTGGTTGGA TGATCTGCTGACGGGAGTTG 
Ucp1 TACCCAAGCGTACCAAGCTG ACCCGAGTCGCAGAAAAGAA 
aP2 ACACCGAGATTTCCTTCAAACTG CCATCTAGGGTTATGATGCTCTTCA 
Cidea CACGCATTTCATGATCTTGGA GTTGCTTGCAGACTGGGACAT 
Dicer1 TTTGCACGTACCCTGATGCT TTGCCAAGGCGATACAGGTT 
Ago2 CCATCTAGCTGTGAAGGCTCTGA TTCTTAGGGCCAGGCTTTAAAA 
Gw182 GACAATGTCATGCCCCACACT CAAGCCTATAGGAAAGTTGCTGAAA 
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   Miscellaneous 
Oil Red O (Sigma-Aldrich, Haverhill, UK) 
Cell strainer (40 µm) (Fisher) 
Syringe filters (0.22 µm) (MicroScience) 
Seahorse XF24 cell culture microplates and cartridges (Agilent, Technologies, Stockport, 
UK) 
Cell culture plates (Fisher Scientific) 
OptiSeal  32.4 ml tubes system (Beckman Coulter) 
RNase-free tubes (Sigma-Aldrich, Haverhill, UK) 
Elisa Strip Plate, F16, highbinding (Greiner Bio One) 
Permount (Invitrogen, Fisher Scientific, Loughborough, UK) 
Optically clear adhesive seals (Appleton Woods) 
miRCURY LNATM microRNA Array 7th Gean (Exiqon) 
RNeasyR Mini Spin Columns (Quiagen) 
MicroRNA Mini Spin Columns (Exiqon) 
100 nm Polystyrene Latex Beads (Sigma-Aldrich, Haverhill, UK) 
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2.2   Methods 
   Cell culture and differentiation 
  Adipose tissue consists of a heterogeneous population of cells including pre-
adipocytes and mature adipocytes. Even though the mature adipocytes represent the 
major component of the tissue, being differentiated cells they have lost mitotic 
properties and cannot proliferate. Therefore, to obtain a sufficient number of cells to 
perform experiments or create an immortalised cell line it is necessary to isolate pre-
adipocytes which can be grown and successively differentiated in vitro. 
   In vitro differentiation 
 Several protocols have been developed to induce in vitro adipocyte 
differentiation. Treatments generally consist of the same set of drugs with concentrations 
and length of treatment being adapted to the different cells of interest in order to optimise 
differentiation. The differentiation cocktail usually contains triiodothyronine (T3), 
dexamethasone, indomethacin (Indo), insulin, 3-isobutyl-1-methylxanthine (IBMX), 
hydrocortisone and a thiazolidinedione (TZD) drug, like rosiglitazone. TZDs are a group 
of drugs that are known to activate PPARγ, hence, stimulating adipogenesis and 
differentiation [26]. However, some brown adipocyte cell lines do not require 
rosiglitazone for differentiation, while, in white adipocytes rosiglitazone is normally 
included to induce differentiation. Insulin is a potent hormone able to induce adipogenesis 
by activating a signal transduction cascade that culminates with adipose-specific gene 
transcription, although the precise mechanism is still not fully clarified. However, insulin 
has been proposed to act through insulin receptor substrates 1 and 2 (IRS1 and IRS2) by 
promoting CREB and MAPK phosphorylation [316, 317]. Dexamethasone (Dex) is a 
synthetic glucocorticoid and has been demonstrated to synergistically act with insulin in 
adipose differentiation through glucocorticoid receptors [318]. IBMX, a non-specific 
inhibitor of phosphodiesterases [319], acts on differentiation by increasing intracellular 
cAMP levels that is a crucial event for differentiation as previously discussed in the 
introduction. T3 is a thyroid hormone that promotes adipose gene expression through 
nuclear T3 receptors [320]. T3 has also been demonstrated able to induce UCP1 
expression in primary adipocytes [321]. Indomethacin is a non-steroidal anti-
inflammatory drug able to inhibit cyclooxygenases (COX). However, as proposed by 
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Styner et al., indomethacin exerts a pro-adipogenic effect by increasing C/EBP and 
PPARγ expression in a prostaglandin-independent way [322]. 
   Mouse interscapular brown and subcutaneous white primary adipocytes 
 Primary adipocytes were obtained and differentiated as previously described 
[323]. Briefly, interscapular BAT and subcutaneous WAT were dissected from 4 to 10-
week old mice. The tissues were digested in a Krebs-Ringer bicarbonate buffer (KRB) 
solution containing 0.2% collagenase Type I and 2% BSA. After 45 minutes, 8 ml of 
KRB solution containing 2% BSA was added to every 3 ml of digested tissue to stop the 
enzymatic activity of collagenase. The tissues were centrifuged at 1000 rpm for 7 min at 
RT and the supernatant was discarded. The stromal fraction was resuspended in 
DMEM/F12, penicillin/streptomycin 1% and FBS 10% (DMEM10), filtered through a 40 
µm strainer and plated in tissue culture flasks. Media was replaced every other day and 
cells were allowed to grow until 80/90% confluent. Following trypsinization, 4 – 5 x 104 
cells per well were reseeded in a 12-well dish. At 100% confluence differentiation was 
started. Concentrations of components contained in induction and maintenance media for 
differentiation protocol are listed in table 4. Induction media was added and left for 96 
hours, at the end of which, it was replaced with maintenance media 1. After 48 hours cells 
were switched to maintenance 2 and kept for at least 48 hours prior to start experiments. 
Table 3 Media for mouse brown and white primary cells differentiation (in DMEM/10) 
Compound Induction  
Media (96 h) 
Maintenance 
media 1 (48 h) 
Maintenance 
media 2 
Insulin 1 µg/ml 1 µg/ml 1 µg/ml 
T3 1 nM  1 nM 1 nM 
Rosiglitazone 2 µM 2 µM - 
IBMX 250 µM - - 
Indomethacin  30 µM - - 
Dexamethasone 0.5 µM - - 
   Explants 
  Interscapular BAT and subcutaneous WAT explants were obtained from 
4 to 10-week old mice. The dissected tissues were cut into 2 mm pieces using scissors in 
order to increase the tissue surface in contact with the media for gaseous exchange, 
thereby minimising the necrosis process. The explants were placed into cell culture inserts 
in 6-well plates and incubated for 2 hours in DMEM10 at 37 °C, 5% CO2. After 5 washes 
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with DMEM/F12 to remove debris and serum traces, explants were left in serum-free 
media (2 ml) for 6 hours either in the presence of CL316,243 (CL) (10 µM) or DMSO for 
control wells. Media was collected for miRNA detection. Tissues were frozen in liquid 
nitrogen, weighed and homogenised in 1 ml of TRI reagent® for total RNA extraction. 
   Mouse immortalised adipocytes 
 Brown and white adipose tissue cell lines were generated previously [324]. 
Briefly, interscapular BAT and subcutaneous WAT of four 10-week old female 129Sv 
mice were digested and centrifuged. The cells collected from the stromal vascular fraction 
were cultured and immortalized with retroviral-mediated expression of temperature-
sensitive simian virus 40 (SV40) large T-antigen (H-2Kb-tsA58). Cells were grown at 33 
°C in DMEM10, and selected for 2 weeks in the presence of 100mg/ml Geneticin (G418) 
[324]. Afterwards, G418 concentration was decreased to 50 µg/ml [5]. Cells were 
passaged at 80% confluence and experiments were conducted between 12-26 passages. 
Cells were seeded in plates pre-coated with 0.1% gelatin and at 80% confluency 
differentiation was started. Two different protocols were used to differentiate brown and 
white adipocytes. Components and their concentration in induction and maintenance 
media for white and brown adipocytes are listed in table 5 and 6 respectively. Induction 
media and maintenance media were administered for 96 and 48 hours respectively to 
differentiate white adipocytes. Next, cells were kept in maintenance media 2 before 
starting experiments. For brown adipocytes, differentiation induction media was added 
and kept for 48 hours. Subsequently, cells were cultured in maintenance 1 until 
experiments were started. 
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Table 4 Media for mouse white adipose cell lines differentiation (in DMEM/10) 
Compound Induction  
Media (96 h) 
Maintenance 
media 1 (48 h) 
Maintenance media 
2 
Insulin 5 µg/ml 1 µg/ml 1 µg/ml 
T3 0.1 nM 0.1 nM 0.1 nM 
Rosiglitazone 5 µM 1 µM - 
Biotin 16 µM 16 µM - 
Pantothenic acid  1.8 µM 1.8 µM - 
Ascorbic acid 100 µM 100 µM - 
IBMX 500 µM - - 
Dexamethasone 0.25 µM - - 
 
Table 5 Media for mouse brown cell line differentiation (in DMEM/10) 
Compound Induction  
Media (48 h) 
Maintenance media  
Insulin 1 µg/ml 1 µg/ml 
T3 1 nM 1 nM 
Indomethacin 125 µM - 
IBMX 500 µM - 
Dexamethasone 0.25M - 
   Human immortalised brown and white adipocytes 
 Human brown and white adipose cell lines were a kind gift from Prof Fredrik 
Karpe (University of Oxford). Preadipocytes were obtained from abdominal 
subcutaneous adipose tissues of a lean and healthy male volunteer as reported by Collins 
at al., [325] and immortalized  by using the pLenti6.3/V5-DEST lentiviral expression 
system to coexpress human telomerase reverse transcriptase (hTERT) and human 
papillomavirus type-16 E7 oncoprotein (HPV16-E7) as described by Pinnick et al., [326]. 
The brown/beige cell line was generated from adipose tissue obtained from a neck 
dissection using the same methodology (data not published). 
 Cells were seeded in 12-well gelatin pre-coated plates and grown at 37 °C, 5% 
CO2 in DMEM10. At 80% confluency, differentiation was started. Induction and 
maintenance media were prepared in Advanced DMEM/F12, FBS 3%, 
penicillin/streptomycin and L-Glutamine 1% (A-DMEM3) as illustrated in table 7. 
Induction media was added to the cells and refreshed every 3 days. Starting from day 12, 
concentration of all the compounds was serially decreased by 2-fold every two days for 
brown adipocytes while, on day 12, white adipocytes were switched to maintenance 
media 1. In both cases media was refreshed every 2 days for the next 6 days to reach full 
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differentiation. Prior to any experiment, brown and white adipocytes were kept for 48 
hours in maintenance media 2. 
Table 6 Media for human brown and white adipocyte differentiation (in A-DMEM3)  
Compound Induction  
Media  
Maintenance 
media 1 
(white adipocytes 
only)  
Maintenance 
media 2 
Insulin 1 µg/ml 1 µg/ml 1 µg/ml 
T3 10 nM 0.1nM 0.1nM 
Rosiglitazone 5 µM 5 µM - 
IBMX 500 µM - - 
Dexamethasone 0.25 µM - - 
Indomethacin 125 µM - - 
 
   Haematoxylin-eosin stain for histology 
 Haematoxylin and eosin staining of brown and white adipose tissues was 
performed by Dr Sean James (University of Warwick). Briefly: dissected tissues, with a 
thickness of about 3 mm, were immediately placed into 4% paraformaldehyde for 
fixation. After a maximum of 48 hours, tissues were moved into 70% ethanol. Next, 
casseting and wax infiltration steps were performed prior to embedding into paraffin 
block. Tissue sections were cut, so that width was approximatively 4 µm, and collected 
onto glasses slides. Wax ribbons were transferred onto a warm water bath (43-45°C) and 
spread on the microscope glass slide before drying at least for one hour at 45°C. To 
perform haematoxylin stain, the slides were deparaffinised by bathing three times in 
Xylene, three times in ethanol (sequentially: 100%, 95% and 80%) for 3 minutes each 
and rinsed in deionized water for 5 minutes. Subsequently, the slides were stained with 
Haematoxylin for 3 to 10 minutes, and rinsed in tap water. Next, the slides were quickly 
dipped 12 times in acid ethanol for destaining, rinsed twice in tap water and once in 
deionized water, for 2 minutes each time. The slides were then stained with eosin for 30 
seconds and bathed 3 times in 95% ethanol, 3 times in 100% for 5 minutes each time and 
3 times in Xylene for 15 minutes. Tissue sections were covered with coverslip slides 
Permount and dried overnight under hood prior to histology analysis. 
75 
 
   Oil Red O staining 
  A stock solution of Oil Red O (ORO) was made by dissolving 0.5 g of ORO 
powder in 100 ml of absolute isopropanol and stirred overnight. Stock ORO solution 
was further diluted in distilled water 3:2, stirred for 10 minutes and passed through a 
0.22 µm filter. Medium was removed from adipocytes and cells were washed with PBS. 
Cells were fixed with 4% paraformaldehyde for 15 min. Paraformaldehyde was 
removed and cells were washed twice with PBS for 5 min. Working ORO solution 
(500µl) was added to each well and incubated for 1h. Afterwards, the ORO solution was 
discarded and cells were quickly washed with 60% isopropanol. Cells were further 
washed with PBS and examined by microscopy. All steps were performed at RT. 
Stained cells were stored at 4 °C in PBS. 
   DNA isolation 
 DNA from human adipocytes was isolated using the DNA extraction 
REDExtract-N-AmpTM Tissue PCR Kit protocol. A mix containing Extraction Solution 
and Tissue Preparation solution 4:1 was prepared for n+1 samples. To lyse the cells, 60 
µl of this mix was added into each well of a 12-well plate. After scraping and 
homogenising, the lysates were placed into fresh nuclease-free tubes and incubated at RT 
for 10 min and at 95 °C for 3 min. Neutralization Solution B (50 µl) was added to each 
tube. Samples were vortex mixed and diluted 1:4 in nuclease-free water. DNA 
concentration was measured using a NANOdrop. To perform relative mitochondrial DNA 
quantification, 10ng of DNA was amplified through Real Time qPCR. 
   Total RNA isolation from cells 
 Medium was removed and cells were washed with PBS, lysed in 1 ml of T RI 
reagent® and transferred into RNase-free tubes. Samples were incubated at room 
temperature (RT) for 5 minutes to allow the complete dissociation of the nucleoprotein 
complex. Chloroform (0.2 ml, TRI reagent®:Chloroform 5:1 v/v) was added and samples 
were vigorously shaken for 15 seconds, incubated at RT for 3 min and centrifuged at 
12,000 x g for 15 minutes at 4 °C. The lower red phenolchloroform phase and the 
interphase, resulting from phase separation, were discarded. The upper aqueous phase 
was transferred into a new RNase-free tube and 100% Isopropanol (0.5 ml, TRI reagent®: 
Isopropanol 2:1 v/v) was added. Samples were incubated for 10 minutes at RT to allow 
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RNA precipitation followed by centrifuging at 12,000xg for 15 minutes at 4 °C. The 
supernatant was removed; the pellet was washed with 75% Ethanol (1 ml) and centrifuged 
at 7,500xg for 5 minutes at 4 °C. The supernatant was discarded, the pellet was air-dried 
and resuspended in 10 µl of RNase-free water. RNA concentration was measured using 
a NANOdrop (lab-tech). 
   Medium sample collection and exosome precipitation  
 Medium was removed from cells or explants. Cells were washed five times with 
PBS and cultured in serum-free medium. Media samples were collected after 5/24/96 
hours or 5 days and transferred into 15 ml tubes. A series of centrifugation steps was then 
performed: to eliminate non-adherent cells, samples were centrifuged at 300xg for 10 min 
and the pellet was discarded; samples were than centrifuged at 16,000xg for 25 min, 
passed through 0.22 µm filters and either stored at -80 °C, directly processed for miRNA 
analysis or ultra-centrifuged at 120,000xg for 2 hours with OptimaL-100 XP 
ultracentrifuge (Beckman) rotor SW32Ti to isolate vesicles. The pellet was gently washed 
with PBS and resuspended in 2.5 ml of PBS or unconditioned serum-free media. Samples 
were analysed for vesicle characterization. 
   RNA isolation from media and serum samples 
 Total RNA was extracted from serum or media samples using the MIRCURYTM 
isolation kit-biofluids. An aliquot of 250 µl per sample was transferred to a new 
microcentrifuge tube. Lysis solution BF (60 µl) containing 16.67 µg/mL of RNA carrier 
(ʎ or MS2-bacteriophage RNA) and 1 µL of spike-in template mixture or Unisp6 spike-
in alone was added to each sample. After mixing, samples were incubated for 3 min at 
RT. Next, 20 µl of Protein Precipitation solution BF were added. After 1 minute of 
incubation at RT samples were centrifuged at 11,000 x g for 3 min. The clear supernatant 
was transferred to a new collection tube and 270 µl isopropanol was added to the spin 
column. The solutions were mixed and transferred to a binding column. The column was 
incubated for 2 min at RT and emptied using a vacuum-manifold or centrifuged for 30 
sec at 11,000xg followed by flow-through discard. Wash solution 1 BF (100 µl) was 
added to the spin column and emptied or centrifuged as before. The same operation was 
performed with 700 µl and successively 250 µl of wash solution 2 BF. To dry the column 
entirely the last vacuum or centrifugation was extended to 2 min. The dry spin columns 
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were transferred to a new collection tube and 50 µl of RNase free water was added directly 
on the membrane of the spin column. The column was incubated for 1 min at room 
temperature prior to centrifugation at 11,000xg. The RNA was stored at -80 °C or directly 
reverse transcribed into cDNA. 
   Reverse transcription  
Principle 
 In reverse transcription, total RNA is converted into cDNA by a reverse 
transcriptase enzyme (DNA polymerase RNA-dependent) in the presence of nucleotides 
and a primer. The primer can be non-specific or specific for the gene of interest. The 
reaction results in RNA-DNA hybrid products. The newly polymerized DNA will work 
as template in the next amplification through classic PCR or Quantitative Real-Time PCR 
reaction (q-PCR). The product amplified is proportional to the initial amount of RNA 
(Figure 9 panel A).  
 In this study the reagents for reverse transcription reaction were: Moloney Murine 
Leukemia Virus Reverse Transcriptase (M-MLV) and random hexamers for total RNA 
reverse transcription. To reverse transcribe microRNAs the miRCURY LNATM Universal 
RT Kit has been used. A poly (A) tail is ligated to the mature microRNA template. A poly 
thymine (T) primer with a 3’ degenerate anchor, consisting of bases that can bind to any 
base and a 5' universal tag is used to synthesize the cDNA. The latter can be successively 
amplified in the Q RT-PCR reaction (figure 9 panel B). 
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Figure 9 Representation of reverse transcription and Real-Time qPCR.  
A) Reverse transcription using random hexamer. 1) Random primers anneal to complementary mRNA 
sequences and total RNA is converted into cDNA. 2) The gene of interest is amplified by the use of forward 
and reverse primers specific for that gene. Sybr green molecules intercalate the double stranded cDNA and 
the signal increases with the amplification of the gene. B) Reverse transcription using Universal MIRCURY 
LNA RT. 1) Poly(A) tails are ligated to the mature miRNAs. 2)The primer for the reverse transcription 
consists of a 3’ degenerate anchor able to bind to any base, a poly(T) portion that anneals to the poly(A) 
tail of the mature miRNA and that is attached to a 5’ universal tag allowing miRNA reverse transcription 
into cDNA. 3) These regions in the cDNA synthesized will be complementary to the miR-specific reverse 
primer and will work as a template in the Real Time qPCR. The miR-specific reverse and forward primers 
anneal to the miRNA of interest and allow miRNA amplification, 4) which is the quantified by the Sybr 
Green signal. 
 
   DNase treatment  
 To remove DNA contamination, 200 ng of cellular RNA were dissolved into 4 µl 
of free-RNase water and treated with 0.5 µl of amplification grade DNase I and 0.5 µl of 
10x DNase I buffer. After 15 min of incubation at RT, the reaction was stopped by adding 
0.5 µl of stop solution and incubating at 65 °C for 10 min to inactivate the DNase I. 
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   Cellular total RNA RT 
 To reverse transcribe total cellular RNA, 1 µl of Random Hexamers and 1 µl of 
dNTPs were added to the DNase-treated samples. The reactions were made up to 12 µl 
with water, incubated at 70 °C for 10 min and cooled in ice for 2 min. Afterwards, a 
master mix for n+1 samples was prepared and added to the samples. It contained for each 
sample: M-MLV Buffer (2 µl), M-MLV (1 µl), RNase OUT (0.5 µl) and RNase-free 
water up to 20 µl final volume of reaction. Reverse transcription reaction conditions were 
25 °C for 10 min, 37 °C for 50 min and 80 °C for 10 min. The obtained cDNA was diluted 
by adding 150 µl of nuclease-free water and stored at -20 °C.  
   MicroRNA Reverse Transcription (miRCURY LNATM Universal RT) 
 The concentration of DNase treated-cellular RNA was adjusted to 5ng/µl in 
RNase-free water and 2 µl of this solution or total RNA from serum/media samples were 
reverse transcribed in a 10 µl final volume of total reaction, containing 5x Reaction Buffer 
(2 µl), nuclease-free water (5 µl) and enzyme mix (1 µl). For cellular RNA reverse 
transcription, 1 µl of water was substituted with 0.5 µl of Synthetic Unisp6 RNA spike-
in and 0.5 µl of random hexamers. To ensure the same concentration of all the reagents 
for each reaction, a mix for n+1 sample was prepared and 8 µl of this was added to each 
RNA sample. The reaction was gently vortexed and incubated for 60 min at 42 °C. The 
reverse transcriptase was heat-inactivated for 5 min at 95 °C. The newly formed cDNA 
was immediately cooled at 4 °C and directly amplified or stored at -20 °C. Before PCR, 
cDNA was diluted 1:80 in nuclease free water. 
   Real Time Quantitative PCR (qPCR) 
  Principle 
 Quantitative Real-Time PCR allows relative DNA amplification and its 
simultaneous quantification by the use of particular fluorescent systems. It is based on a 
classic PCR, where, during the exponential phase, the amount of amplified DNA copies 
is proportional to the initial cDNA quantity and to the fluorescence emitted by the 
fluorophore. Through this technique it is possible to measure the absolute or relative 
expression/amount of a particular gene using respectively cDNA or genomic DNA as 
input for the amplification reaction.  
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 In Real Time PCR systems, the user sets the thermal cycles specific for the 
optimal functioning of the enzyme. During the amplification a laser light, sent through 
optical fibres, excites the fluorophore’s light emission, collected back by the optical 
fibres, is directed to a spectrophotometer. The signal is detected by a charged coupled 
device (CCD) camera and analysed by the software. The output results consist of a 
graphic where the fluorescence signal, ΔRn, at each time point, is plotted versus the cycle 
number. The software calculates ΔRn by subtracting Rn- to Rn+ (ΔRn = Rn+- Rn-) where 
the normalized reporter value (Rn) is the ratio between the fluorescence intensity of the 
reporter dye and the passive reference dye. The Rn values, obtained during the first cycles, 
are used to determine the baseline Rn-, which represents the background. Indeed, initially, 
the amount of cDNA template is very low and only the background signal is detectable. 
Proceeding with the reaction, the DNA copies increase and so do the Rn+ values. The 
cycle at which the change of intensity exceeds the threshold of the baseline is referred as 
threshold cycle (Ct). Therefore, the higher the amount of amplified DNA the lower is the 
cycle. This reflects the level of expression of the gene and can be used for statistical 
comparisons, considering that a lower Ct corresponds to a higher amount of amplified 
DNA. 
  Primer design 
 Primers for mRNA were synthesised by Sigma Aldrich and 100 µM stocks were 
prepared by dissolving the dried nucleic acids in nucleic acid nuclease-free water and 
stored at -20 °C. Design was performed using Ensemble Genome Browser Primers tool 
(http://www.ensembl.org/index.html) or Primer 3 (http://simgene.com/Primer3). Primer 
characteristics were evaluated through USCS Genome In-silico PCR 
(http://genome.uscs.edu/cgi-bin/hgPcr). These include: size of product between 70-150 
nucleotides, melting temperature and GC content around 60 °C and 55% respectively. 
Primers for mRNAs of specific proteins were designed so that one was complementary 
to a sequence of an exon-exon junction, in order to exclude amplification of eventual 
contaminating genomic DNA.  
 For mature microRNAs, locked nucleic acid LNA primers were used. LNA 
primers are oligonucleotides containing one or more locked nucleic acids where the ribose 
ring is “locked” by a bridge connecting the 2' oxygen and the 4' carbon (figure 10). The 
presence of these modified nucleotides induces an increase in the melting temperature of 
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the primer from +2 to +10 °C per each LNA base [327] allowing higher specific 
complementarity and a shorter length of the sequence compared to unmodified primers. 
Primer mixes were purchased from Exiqon, dissolved into 400 µl of nuclease-free water, 
aliquoted and stored at -20 °C. 
 
Figure 10 Illustration of DNA and LNA nucleotides.  
Left panel shows the structure of a standard deoxyribonnucleotide. In the right panel is represented an LNA 
monomer which ribose ring present a bridge connecting the 2’ oxygen to the 4’ carbon.  
  SYBR Green I PCR 
 In this study, Real-Time PCR analysis has been performed by using SYBR Green 
I. This fluorophore is an asymmetrical cyanine dye able to bind the DNA. The DNA-dye-
complex absorbs blue light with a maximum wavelength (λ) of 497 nm and emits green 
light (λmax= 520 nm). SYBR Green molecules preferentially bind to double stranded DNA 
intercalating in its minor grooves, hence, fluorescence intensity increases with PCR 
product accumulation at every cycle.  
 For genomic or protein-encoding genes 2 µl of cellular DNA/cDNA sample or 
nuclease-free water non-template control were mixed in a 96 well plate with 18 µl of a 
master mix previously made and aliquoted in the wells. Master mixes were prepared in 
different tubes for every target and reference gene with a volume for n+1samples. Each 
one contained the following reagents at the following final concentrations in 20 µl final 
volume: 1X Jumpstart SYBR Green I mix, 300 nM forward and reverse primer, ROX 
reference dye 0.1X and nuclease free-water up to the 20 µl final volume.  
 Real Time PCRs for microRNA detection were performed similarly. In this case, 
4 µl of cDNA or non-template control was used as input. The master mix contained 1X 
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Jumpstart SYBR Green 1 mix, 0.5 µl of primer mix, ROX reference 0.1X and water up 
to 10 µl final volume reaction.  
 Every DNA/cDNA and non-template sample was tested in duplicate. The plates 
were centrifuged to avoid bubbles and sealed with clear optical seals. PCR reactions were 
run in the 7500 Real-Time PCR machine (Applied Biosystems). Thermocycler conditions 
consisted of an initial denaturation at 95 °C for 2 min followed by 40 cycles at 94 °C for 
34 s, 60 °C for 34 s and a final step at 72 °C for 30 seconds at which data were collected. 
A step for melting curves was added to evaluate the presence of single or multiple 
products. 
 
  MiRNA profiling in media from mouse and human adipocytes  
 Experiments were conducted at Exiqon Services, Denmark. MiRNA real-time 
qPCR mouse&rat panel was used for mouse samples and miRNA real-time qPCR human 
panel for human samples.  
 RNA isolation from mouse samples was performed as per MIRCURYTM isolation 
kit-biofluids instructions and as described in paragraph 2.2.8. 
 Total RNA was extracted from human samples using the Qiagen miRNeasyR 
Mini Kit. Media was lysed in 700 µl Qiazol lysis reagent in a Qiagen TissueLyzer with 
one 5mm stainless steel bead. The lysate was transferred into a fresh tube containing 140 
µl chloroform, mixed, incubated for 2 min at RT and centrifuged at 12.000xg for 15 min 
in a 4 °C microcentrifuge. The upper aqueous phase was transferred to a new 
microcentrifuge tube and 1.5 x volume of 100 % ethanol was added. After mixing gently, 
750 µl of the sample was transferred to a Qiagen RNeasyR Mini spin column in a 
collection tube and centrifuged at 8.000 x g for 15 sec at RT. The process was repeated 
until all remaining sample had been loaded. The Qiagen RNeasyR Mini spin column was 
rinsed with 700 µl Qiagen RWT buffer and centrifuged at 8.000xg for 15 sec at RT 
followed by another rinse with 500 µl Qiagen RPE buffer and centrifuged at 8.000xg for 
15 sec at RT. A rinse step (500 µl Qiagen RPE buffer) was repeated twice. The Qiagen 
RNeasyR Mini spin column was transferred to a new collection tube and centrifuged at 
15,000xg for 2 min at RT. The Qiagen RNeasyR Mini spin column was transferred to a 
new microcentrifuge tube and air dried for 1 min. Total RNA was eluted by adding 50 µl 
of RNase-free water to the membrane of the Qiagen RNeasyR mini spin column and 
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incubated for 1 min before centrifugation at 15,000xg for 1 min at room temperature. The 
RNA was stored in a -80 °C freezer. 
 The spike-ins used for quality control RNA isolation of both human and mouse 
samples were Unisp2, Unisp4 and Unisp5. 
  MiRNA real-time qPCR Panels 
 RNA (19 µl) was reverse transcribed in 95 µl reactions using the miRCURY 
LNA™ Universal RT microRNA PCR, Polyadenylation and cDNA synthesis kit 
(Exiqon). Each RT was performed in duplicate, including an artificial RNA spike-in 
(UniSp6). The obtained cDNA was diluted 50x and using a pipetting robot it was 
transferred together with Exilent SYBR Green mastermix to qPCR panels preloaded with 
primers in 10 µl PCR reactions, according to the protocol for miRCURY LNA™ 
Universal RT microRNA PCR; each microRNA was assayed once. For quality controls 
miR-23a, miR-30c, miR-103, miR-142-3p, miR-451 and the spike-ins were pre-assayed. 
Negative controls were performed excluding template from the reverse transcription 
reaction and profiled like the samples. The amplification was performed in a 
LightCycler® 480 Real-Time PCR System (Roche) in 384 well plates. The amplification 
curves were analysed using the Roche LC software, both for determination of Cq (by the 
2nd derivative method) and for melting curve analysis.  
  Data analysis  
 The raw data was extracted from the Lightcycler 480 software. PCR reactions that 
gave rise to multiple melting curve peaks or single peaks with melting temperature 
inconsistent with the specifications for the corresponding assay (in-house database) or 
with amplification efficiency below 1.6 were removed from the dataset. For Spike-ins 
and quality control miRNAs an average Cq (quantification cycle) was calculated for the 
duplicate RT’s, and evaluation of expression levels was performed based on raw Cq-
values. Only assays that detected 5 Cqs lower than the negative control were included in 
the data analysis. For assays that did not yield any signal on the negative control, the 
upper limit of detection was Cq equal to 37. Normalization of raw values after 
background filtration was performed based on the average of the assays detected in all 
samples as this is shown to be the best normalization for qPCR studies involving 
numerous assays [328]. Indeed, the stability value of the average Cq of the assays (143 
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in mouse and 34 in human) detected in all samples (n (mouse) = 16, n (human) = 8) calculated 
through the Normfinder algorithm was the lowest compared the ones of each single 
miRNA. Therefore ΔCq values were obtained as follows:  
Normalized Cq = average Cq – assay Cq (sample) 
 Principal Component Analysis was performed prior to differential expression 
analysis to evaluate variation among the assays. Briefly, PCA is a method used to reduce 
the dimension of large data sets by considering only those variables that inflict large 
variance to the data. The component accounting for the largest variation is plotted along 
the X-axis; the second largest is plotted on the Y-axis etc. If samples present pronounced 
differences in terms of one particular biological characteristic, for example level of 
differentiation or cell type, this will be a primary component of variance. Each sample 
will scatter in different areas of the PCA plot corresponding to their biology eventually 
clustering with samples presenting similarity for that characteristic. This method is 
particularly useful also to assess the quality of the samples and therefore the reliability of 
the results that can be obtained by their analysis for a specific experiment. For instance, 
if RNA quality inflicts further variation to the samples, these last will no longer cluster 
based on their biology and can be removed from the data analysis. PCA plot for mouse 
and human experiments was obtained by including the top 50 or 30 microRNAs, 
respectively, that had the largest variation across all samples. 
 Normalised Cqs (ΔCq) were used for differential expression analysis. T-test was 
performed for microRNAs detected in at least three samples per group, to identify 
differences in miRNA expression between two groups. Raw p-values were adjusted for 
multiple testing by the Benjamini-Hochberg procedure. The normal distribution of the 
data was assessed by a Shapiro-Wilk normality test.  
  MicroRNA array 
 RNA from human differentiated brown and white immortalised adipocytes was 
sent to Exiqon Services, Denmark, where all the experiments were performed. RNA 
quality was verified by an Agilent 2100 Bioanalyzer profile.  
The miRCURY LNA™ microRNA Hi-Power Labeling Kit, Hy3™/Hy5™ (Exiqon, 
Denmark) was used as per the manufacturer instructions. Total RNA (550 ng) from the 
samples was labelled with Hy3™ and reference with Hy5™ fluorescent label. The Hy3™ 
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labelled samples and a Hy5™-labelled reference RNA sample were mixed pair-wise and 
hybridized to the miRCURY LNA™ microRNA Array 7th Gen (Exiqon, Denmark), 
which contains capture probes targeting all microRNAs for human, mouse or rat 
registered in the miRBASE 18.0. The hybridization was performed according to the 
miRCURY LNA™ microRNA Array Instruction manual using a Tecan HS4800™ 
hybridization station (Tecan, Austria). Next, to avoid decolourization of the fluorescent 
dyes, microarray slides were scanned and stored in an ozone free environment (ozone 
level below 2.0 ppb). The scanning was performed using the Agilent G2565BA 
Microarray Scanner System (Agilent Technologies, Inc., USA) and the image analysis 
was carried out through the ImaGeneR 9 (miRCURY LNA™ microRNA Array Analysis 
Software, Exiqon, Denmark).  
 To evaluate the labelling reaction, hybridization 
, and the performance of the array experiment in general 52 different spike-in controls 
were added in concentrations covering the full signal range in both the Hy3™ and the 
Hy5™ labelling reactions. For correlation (R2) of the signal intensities across all slides 
>0.95 hybridization was considered successful. 
 The threshold of detection was calculated for each individual microarray slide 
multiplying by 1.2 the 25th percentile of the overall signal intensity of the slide. 
MicroRNAs with intensities above threshold in less than 20% (or 2) of the samples were 
removed from the final dataset used for the expression analysis. 
 The quantified signals were corrected to the background (Normexp with offset 
value 10, [329]) and normalized using the global LOWESS (LOcally WEighted 
Scatterplot Smoothing) regression algorithm. Normalized values were used to calculate 
the log median of the ratio for each of the four spots (M) on slide. The log2 (fold change), 
corresponding to the deltaLogMedianRatios, was calculated to analyse differential 
miRNA expression between brown and white adipocytes. Statistical analysis was 
performed using R/Bioconductor limma package as described in paragraph 2.2.10.9. 
  Next generation (mRNA) sequencing 
 Next generation sequencing methods include different high throughput 
technologies progressively improved from the first sequencing technique developed by 
Frederick Sanger in 1997 [330]. The advantages offered by the NGS compared to 
previous sequencing methods consists mainly in the possibility to sequence not only a 
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restricted number of selected genes of interest, but instead to provide a complete view of 
the coding transcriptome allowing identification of novel genes isoforms, besides being 
highly efficient and cost effective. All these techniques have in common three main steps: 
library preparation, sequencing and data analysis. In this study, mRNA sequencing 
technique was performed to sequence the transcriptome of human brown and white 
adipocytes using the Illumina TruSeq Stranded mRNA Library Prep Kit. This system 
targets all polyadenylated transcripts of the transcriptome with a size above or equal to 
170 nucleotides, which are selected using an Oligo-dT magnetic bead strategy and 
fragmented using divalent cations at high temperature. The fragments are then reverse 
transcribed into cDNA. In this phase, first strand cDNA is obtained using reverse 
transcriptase and random primers. The second cDNA strand is synthesized using DNA 
Polymerase I and RNase H. The second strand is converted into NGS cDNA libraries. 
The sequencing is then performed through the Illumina platform. A description of the 
process is schematized in figure 11. For this experiment 1x50bp cut fragments (single 
read) and Illumina TruSeq Stranded mRNA Library Prep Kit were used running 50 
million reads per sample. Read alignments and counts were performed using TopHat and 
HTseq-count packages in R. 
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Figure 11 mRNA sequencing (Illumina)  
The figure shows A) the steps of mRNA sequencing. 1) Total RNA is extracted and 2) poly-A tailed fragments are 
isolated using beads on which poly-T strands are anchored to the surface. 3) Isolated RNA is fragmented and 4-5) 
reverse transcribed into cDNA. 6-7) Adaptors are ligated to the cDNA. These contain indexes, sequencing primer 
regions and sequences designed for hybridization with the oligos attached on the cell flow surface of the slide. 8) The 
cDNA is thermally denatured and the single strands anneal to the oligos attached on the surface of the slide through the 
complementary sequence of the adaptor. 9) Complementary cDNA is polymerized and the original template is removed. 
11) The remaining filament bends over and the adaptor region hybridizes to the second type of oligo present on the 
flow cell forming a bridge structure. 12) The complementary strand is polymerized and 13) the bridge denatured. The 
process is then repeated over and over from step 10. The simultaneous amplification of all the fragments originally 
attached to different areas of the slides results in the formation of 14) millions of clusters. Afterwards, the reverse 
strands are cleaved and washed away. 16) Sequencing by synthesis of the forward strand starts by 15) adding the primer 
specific for the sequencing primer region 1 of the adaptors and 4 fluorescent labelled and blocked nucleotides. At each 
cycle, only one nucleotide is incorporated in the forming strand based on the complementarity to the template. The 
clusters are excited by a laser light and 16) the characteristic signal is emitted by the specific nucleotides incorporated. 
Signal is acquired and the lock removed from the nucleotide so that the next nucleotide can be incorporated. The process 
is repeated until the first read is completed. The number of cycles determines the length of the read. The base call is 
determined by the signal intensity and the wave length. For each cluster all identical strands are read simultaneously. 
Successively, the read product is removed and the index is read by adding the index primer. At the end of the entire 
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process, reads with similar length and base calls are clustered together, obtaining contiguous sequences which are then 
17)  aligned to a reference genome. B) Adapter structure for single and paired end reading. The function of the 
index is to associate the reads to the different samples. In single end-reading, strands are read only in one direction and 
only read primer 1 sequence are included in the adapters along with flow cell binding, index primer and primer regions. 
In paired end reading, strands are read in both directions. To do so, read primer2 sequence is added to the adapters. 
  Unsupervised and supervised analysis of mRNA sequencing and microRNA 
array data 
  Variation among samples was analysed by principal component analysis, 
performed on all samples and all sequencing read count data or miRNA data. The 
significance of differentially expressed genes and miRNAs between brown and white 
adipocytes was assigned using Student’s t-test and p values were adjusted with 
Benjamini-Hochberg correction. Gene targets of the differentially expressed miRNAs 
were predicted using Bioconductor (R) package miRNAtap which performs target 
prediction aggregation from the prediction algorithms: DIANA [331], Miranda [202], 
PicTar [204] and TargetScan [332]. We set a minimum of two sources through the 
command: getPredictedTargets(mir, species = 'hsa',method = 'geom', min_src = 2), so that 
targets were considered only when predicted by at least two out of the four 
aforementioned algorithms. Identification of the pathways (from Kyoto Encyclopedia of 
Genes and Genomes (KEGG) database) associated to differential expressed genes 
between brown and white adipocytes were identified using hypergeometric test (phyper 
function in R)  
   Vesicle characterization 
  Sample preparation and analysis were performed at the Velindre Cancer Centre, 
Division of Cancer & Genetics, and Cardiff University. 
  Nanoparticle tracking analysis (NanoSight™) 
  Vesicle characteristics were analysed by Nanoparticle tracking through the 
NanoSight NS300 system (NanoSight Ltd, UK) similarly to as described previously 
[333]. This technology enables the visualization in real time of nanoparticles (10-
1000nm) present in liquid suspensions and provides information on their size 
distribution and concentration analysing dynamic light scattering and Brownian motion 
characteristics. The system consists of a laser module inside a sealed housing on top of 
which an optical flat element is fixed. A flow-cell top-plate is assembled on the flat 
element, forming the sample chamber connected to a tubing system. The sample is 
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injected through a syringe connected to the inlet tube and a syringe pump dispositive 
allows its flow into the chamber at a constant controlled rate. When the sample reaches 
the chamber the laser beam illuminates the particles suspended in the fluid. By scattering 
the laser light, each particle and their motion can be visualised and monitored by a high 
sensitivity camera. The particles are seen as small points moving randomly upon 
collision with atoms or other molecules suspended in the fluid. This type of movement 
is referred as Brownian motion and is related to the viscosity of the liquid, the 
temperature and the size of particles but not to particle density or refractive index. The 
nanoparticle tracking analysis (NTA) software calculates each particle diameter using 
the Stokes-Einstein equation. Especially for those samples containing a largely 
heterogeneous population of particles, this particle-by-particle approach results in a 
more sensitive analysis compared to classical Light Scattering techniques such as 
Dynamic Light Scattering (DLS), which provide an average of particle size. The sample 
is let out from the chamber to a discharge container via another tube.   
  For this analysis, the instrument was configured with a 532 nm laser. For each 
sample, administrated under controlled flow, six replicate videos of 30s were taken at 
25 °C by the high sensitivity digital camera sCMOS system and the speed of the syringe 
pump was set to 80. For data collection the NTA-software was used with minimal 
expected particle size, minimum track length, and blur settings in automatic mode and 
detection threshold set to 5. Samples were diluted in particle-free water (Fresenius Kabi, 
Runcorn, UK) adjusting concentration to 2×108 - 9×108 particles/ml and run after 
calibration with 100 nm standard polystyrene latex beads. Data were analysed adjusting 
for the dilutions applied. 
  Europium-based ELISA-like assay for exosome marker detection 
  Europium is a lanthanide metal used in Time Resolved Fluorometry (TRF) as a 
chelate label for several types of assays, especially immunoassays. In standard 
fluorometry, excitation of the fluorophore and detection of the fluorescence emitted by 
the exited fluorophore occur simultaneously, generating a high autofluorescent 
background signal. The fluorescence lifespan of lanthanides is much longer than 
traditional fluorophores; therefore, fluorescence measurements can be taken in a 
delayed time after excitation, reducing the background signal. Lanthanides present some 
additional properties contributing to improved efficiency and sensitivity of the system, 
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such as: narrow emission peak and large difference between excitation and emission 
wavelengths, known as Stokes’ shift. In this study, for the detection of exosome 
markers, Delfia reagents have been used. The addition of the enhancement solution 
induces the dissociation of the Europium which is then incorporated into protective 
micelles. In this way, the fluorescence signal can be further amplified. 
  The assay was performed as following: isolated vesicles were resuspended in 2 
ml of PBS and immobilized on high-protein-binding ELISA plates by adding 100 µl of 
sample per well and incubating overnight at RT. The wells were washed 3 times with 
1x Delfia Wash Buffer using a plate washer. Non-specific sites were blocked with 300 
µl of 1% (w/v) BSA/PBS at RT for 2h. After washing as before, vesicles were incubated 
for 2h at RT with 100 µl of primary mouse monoclonal antibodies (IgG2b) anti-human 
CD9, CD81, CD63 in parallel with the controls for IgG2b and IgG1, all diluted in 0.1% 
(wt/v) BSA in PBS at the concentration 1 µg/ml. Wells were washed as previously and 
incubated for 1h at RT with secondary goat anti-mouse (IgG) biotinylated antibodies 
(PerkinElmer Life) at a working concentration of 0.2 µg/ml. Samples were washed as 
previously and incubated for 45 min at RT with 100 µl of Europium-Streptavidin 
conjugate in red assay buffer 1:1000 (v/v). After washing 6 times, 100 µl of 
Enhancement Solution was added to each well. Samples were incubated at RT for 5 min 
and readings through TRF were taken on a BMG Pherastar plate reader with excitation 
filter set on UV (TRF340) dug11 + wg320, filter emission at 615 nm, delay time and 
window of 200 and 500 µs, respectively. 
   Oxygen consumption  
  Cellular respiration can be either anaerobic or aerobic. In the first case ATP is 
generated via the glycolysis which produces lactic acid and protons. With aerobic 
respiration oxygen is used to oxidise fatty acids for ATP and /or heat generation through 
UCP1. The Seahorse XF Analyzer provides information on these metabolic events by 
monitoring the changes in oxygen and proton concentrations in the extracellular media. 
The system consists of a 24/96 cell culture plate where cells are seeded and a sensor 
cartridge that is placed on top of the plate. The cartridge, pre-incubated overnight or for 
a minimum of 4 hours with the calibrant solution at 37 °C without CO2, is inserted first 
in the instrument to allow the calibration of the probes. At the end of the calibration the 
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cell culture plate is inserted as well. The cartridge has an individual sensor for each well. 
Two different fluorophore probes are embedded in polymers at the bottom of each 
sensor, one quenchable by oxygen and the other one by protons (H+). Inside the 
instrument, the sensor is lowered to 200 µm above the cell monolayer (figure 12), 
creating a micro chamber, which allows the small changes in oxygen and proton 
concentrations to be detected almost immediately, instead of hours. The detection, based 
on the quenching chemistry, occurs upon stimulation of the fluorophores by a light 
diffused by optic fibres that insert themselves into each sensor sleeve during the 
measurements. The emission of the excited fluorophores is captured back via the optical 
fibres. When the sensor detects a 10% drop of oxygen or proton concentration the 
instrument lifts the sensor allowing the media to mix, restoring the cells baseline and 
avoiding cell damage. The measurements can be repeated several times and the oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) can be calculated. 
Surrounding the sensor probe sleeve, there are 4 ports in which different drugs can be 
preloaded and injected sequentially in the same experiment, in order to study their effect 
on cell metabolism. The protocol can be personalised, setting the desired times of drug 
injections and measurements.  
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Figure 12 Seahorse XF analyzer plate for OCR and ECAR measurments 
On the top left is shown a seahorse cell culture well plate covered by the green cartridge. In the 
magnification of a well of the seahorse plate are represented the resting and measuring phases. During the 
measuring phase the cartridge probe is lowered 200 µm above the cell monolayer, creating the 
microchamber environment, where the oxygen and proton concentration are measure by the oxygen and 
pH sensors. The sensor is surrounded by 4 ports that can be used for drug injection. 
 Base line OCR and ECAR were measured in Isoproterenol (ISO)-
treated/untreated human adipose cell lines as follows. Differentiated human brown and 
white adipocytes were trypsinised and 50,000 cells per well were reseeded into a 24-well 
seahorse plate. Cells were left in maintenance media containing insulin and T3 for 24 h 
to recover from trypsinization. Media was removed and cells were gently washed with 
seahorse media. Afterwards, 675 µl of pre-warmed seahorse media containing glucose 
(25mM) and Sodium Pyruvate (1mM) (pH 7.4) was added to each well. Cells were 
incubated at 37 °C in a non-CO2 incubator in the presence of either Isoproterenol (10 µM) 
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or dimethyl sulfoxide (DMSO) for control wells for 40 minutes, both to allow media 
temperature and pH to reach equilibrium before measurement and isoproterenol to induce 
UCP1 function. The plate was run in the Agilent Seahorse XF24 Analyzer to measure the 
base line OCR. The assay protocol was set so that in a 3 times loop, media was mixed for 
3 minutes and measurements were taken for 2 minutes after a delay time of 2 minutes, to 
allow the oxygen partial pressure to reach equilibrium. 
   Statistical methodology for hypothesis testing 
 To provide a comprehensive understanding of the choice of methodology 
undertaken the principles of the different statistical tests utilized in this study and 
specified in the results section, relative to each experiment, will be briefly described in 
this section. Indeed, there exist different types of statistical tests that can be used to 
analyze data in testing a determinate hypothesis. The choice should be taken accounting 
for different situations relative to the number of samples (one, two or more than two) 
involved and the assumption that the data come or do not come from a known distribution. 
Based on the last criterion, the test to perform could be parametric, in the cases that data 
(interval or ratio types) are known or assumed to follow a determined distribution, or non-
parametric when no a priori knowledge on data distribution is available or not applicable.  
  Student’s t-test 
 The t-test, also referred as Student’s t-test, is one of the most frequently used 
parametric tests in medical/biological science. It is performed to compare the means of 
two and no more than two groups, in order to verify whether they are different from each 
other. There exist different types of t-test depending on the groups to compare. For 
instance, the one- sample t-test is used to compare a single group sample mean with the 
mean of a known population, the paired t-test, which compares the mean of two groups 
dependent one to each other. The independent or unpaired t-test that is used to compare 
the mean of two independent groups. To give some examples, the one-sample t-test could 
be performed to compare the mean of intelligence quotient (IQ) of 30 subjects treated 
with a drug, with the average of the IQ of the population, which is known to be 100, in 
order to investigate whether the drug increases or decreases the IQ. Therefore, the mean 
IQ of this group is compared to 100, the mean of the population. If the IQ of 30 individuals 
was measured before and after the treatment in the same subjects and the comparison 
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were to be done between the mean IQ of pre-treatment and the mean IQ of post-treatment, 
the paired t-test would be more appropriated. In the case that the IQ is measured on a 
sample of untreated subjects and a sample of different subjects treated with the drug, an 
independent t-test should be performed. To perform a t-test the samples must satisfy the 
conditions of normality, random sampling and equal variances of populations. In the one-
sample case, where the mean c of the sample is compared to the mean µ of a known 
population, the null hypothesis (H0) and the relative alternative hypothesis (Hα), which 
can be anything but H0, could be stated in three different ways: 
H0 : µ = c, Ha : µ ≠ c 
H0 : µ > c, Ha : µ < c 
H0 : µ > c, Ha: µ > c 
Assuming that the sample follows the normal distribution, the formula of the t test 
formula can be extracted from the standardized normal distribution Z test by substituting 
the sample standard deviation s to the population standard deviation σ as shown below: 𝑍 = #$%&'                       t = #$%('  
Where 𝑋 is the mean of the sample, µ the mean of the population and n the number of the 
measurements. The t value is then used to calculate the p value, which represents the 
probability, under the null hypothesis, of obtaining the observed value of the statistic test 
(in this case t-test) or a “more extreme” one, depending on the hypothesis stated. It defines 
whether it is possible to reject the null hypothesis after establishing the critical value α, 
obtained by subtracting the level of confidence from 100. Commonly the level of 
confidence is established as 95%, therefore, in this case, α is 0.05. Depending on the 
hypothesis stated among the three reported above the test will be a two-tailed or one tailed 
t-test. In the first case, where there is no a priori knowledge, a two tailed (both tails of the 
t-distribution curve are considered) t-test must be performed. In the second and the third 
cases, the sample mean c is expected to be greater and lower than µ respectively, therefore 
a one-tail t-test (only right and left tail respectively considered) would be the correct test. 
According to this, the appropriate table of t distribution is consulted. Based on the critical 
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value determined and the degrees of freedom (n-1), the p value or the range of the area in 
which the p value falls is calculated.  
 In the independent t-test, under the assumption of equal variances and normal 
distribution of the two populations, as the comparison is between the two sample means, 
the formula becomes: 
t = 	  #+$#, $(%+$%,)/(+0,) +'+1 ,',  
 
Because the samples are assumed to come from an identical population with a normal 
distribution, the mean of the two populations are assumed to be 0 and the t formula 
becomes: 
t = 	  #+$#,/(+0,) +'+1 ,', 
where the pooled variance of the samples is used and calculated as follows, as the variance 
of the population is not known 
𝑠(314) = (𝑛3 − 1)𝑠34 + (𝑛4 − 1)𝑠44𝑛3 + 𝑛4 − 2  
and the degrees of freedom are: 𝑑𝑓 = 	  𝑛3 − 	  𝑛4 − 2 
In the case that the condition of equality of variances is violated, the t test formula remains 
the same but the degrees of freedom are calculated as: 
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𝑑𝑓 = 𝑠12𝑛1 + 𝑠22𝑛2𝑠12𝑛1 4	  	  𝑛1 − 1 + 𝑠22𝑛2 4𝑛2 − 1
 
The equality of variances can be assessed using the F test and the tables of the F 
distribution. The degrees of freedom are calculated for each group as	  	  𝑑𝑓 = 𝑛 − 1. 
𝐹 = 𝐿𝑎𝑟𝑔𝑒𝑟	  𝑠4𝑆𝑚𝑎𝑙𝑙𝑒𝑟	  𝑠4 
The paired t-test is very similar to the one sample t-test as the samples are dependent. 
The t value is calculated as: 
𝑡 = 𝑑𝑠F𝑛  
Where 𝑑 is the mean of all the differences between the two observations on each pair and 𝑠F is the standard deviation of the differences. Under the null hypothesis, the degrees of 
freedom are, also in this case, 𝑑𝑓 = 𝑛 − 1. 
 All the t-tests performed in this study were independent t-tests except when 
measuring miRNA content in media before and after ultracentrifugation as the samples 
were not independent. Indeed the miRNA content was measure in the same sample before 
and after vesicle precipitation. In this case, paired t-test was used. 
  The Shapiro-Wilk test 
 The Shapiro-Wilk test is a test used to assess whether a sample actually comes 
from normally distributed population. The statistical null and alternative hypotheses are 
stated as: 
H0 : the sample (of size n) is drawn from a normally distributed population 
           Hα : the sample is drawn from a not normally distributed population. 
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The formula of the Wilko-Shapiro test is: 𝑊 = 𝑎I 𝑥I 4𝑥I − 𝑥 4 
where, 𝑥I is the 𝑖LM smallest value of 𝑥 (single observation) and 𝑎 is the Shapiro-Wilk 
constant. Through the use of the Shapiro-Wilk tables the null hypothesis is rejected if W 
< Wα. Therefore, for p values smaller than the critical value α there is evidence that the 
data do not follow a normal distribution. In the opposite situation, a large p value does 
not mean that that the data are normally distributed, but rather that there is not enough 
evidence proving that the data are not normally distributed (failure to reject the null 
hypothesis). 
  The Benjamini-Hochberg correction for p-value adjustment 
 When performing a large number of statistical tests, some of these will give 
significant results purely by chance. For example, when performing one statistical test 
where the p-value threshold has been determined as 0.05, there is a chance of one in 
twenty times (5%) that result is a false positive. If a larger number of tests are performed, 
let us say 20000 tests, such as it happens in microRNA array where there are more than 
20000 of probe sets, the probability of obtaining false positives becomes 1000 
(20000*0.05), which is extremely high to be accepted. The Benjamini-Hochberg 
correction adjusts the p-values in order to reduce the false positive results under the 
condition that the individual tests are independent from each other. In other words, this is 
a method of error type I (false positives) controls. In this procedure, the p value obtained 
by the different tests performed are sorted from smallest to largest and ranked (the 
smallest rank will be rank 1, the second smallest rank 2 until the largest n rank). Then 
each p-value is multiplied by the total number tests (largest rank n) and divided by its 
rank number.  
  The ANOVA  
 In comparisons involving more than one sample, the analysis of variance ANOVA 
should be used, in order to control the error type I that is given by multiple testing [334]. 
The null hypothesis can be formulated as following: 
H0 : µ1 = µ2 =…=µk 
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If multiple t-tests are performed, their outcomes cannot be used to draw a single 
conclusion and, therefore, when verifying whether the aforementioned H0 is rejected or 
we fail to reject it. There exist different types of ANOVA. However here we will only 
consider the one-way and the two way ANOVA focussing on the last one as it was the 
only type performed in this study. The one-way ANOVA is designed for investigating 
data in which only one factor is considered, for example when verifying the effect of a 
drug on a number k of independent samples. The null hypothesis would be that all the 
groups present the same mean, and the alternative hypothesis, that at least one of the k 
population means differs from all of the others. If a second factor is introduced, for 
example a second drug, then two-ways ANOVA is more appropriate. The null hypothesis 
will be that there is no significant variability between the k groups, and the alternative 
hypothesis is that there is such variability. The variability of the sample is well 
represented by the variance of the sample (s2): 
𝑠4 = (𝑥 − µμ)4𝑛 − 1  
where x is a data point and µ is the population mean. The numerator of the variance is the 
sum of squares and is indicated as SS. The principle of the ANOVA is to partition the 
overall variance of a larger population from which the individual populations of the 
different conditions (for example observations of drug A in each of the sample groups) 
are drawn, into different parts, and one of these parts is always error/noise. Therefore, by 
partitioning the overall sum of squares, the total sum of squares in one-way ANOVA and 
the relative degrees of freedom will be: 
SSTotal = SScondition + SSerror 
                                      N - 1 =    (k - 1)    + (N – k) 
Subsequently, the error mean squares (MSerror) and the condition mean squares 
(MScondition) are calculated:  
𝑀𝑆PQQRQ = 𝑆𝑆PQQRQ𝑁 − 𝑘 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑀𝑆URVFILIRV = 𝑆𝑆URVFILIRV𝑘 − 1  
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The ratio of these two values is used to test the null hypothesis and follows an F 
distribution with v1 = k-1 and  
𝐹 = 𝑀𝑆URVFILIRV𝑀𝑆PQQRQ  
This is a one-tail test as the statistic value can either be equal to or larger than 1. In the 
first case the null hypothesis is true and in the second it is rejected. 
 The two-way ANOVA, allows us to also account for the variation of additional 
factors or grouping of the experimental units, which are defined as blocks. The two- way 
ANOVA without repetitions is also called randomized block experiment. The partitioning 
of the overall sum of squares and its degrees of freedom below will be in this case: 
SSTotal = SStreatment + SSblock +    SSerror 
                                bk – 1   =   (k -1)       +     (b – 1)   +    (b-1) (k – 1)  
where k is the number of the samples and b of the blocks. Then the MS of the partitions 
are calculated: 
𝑀𝑆LQPWLXPVL = 𝑆𝑆LQPWLXPVL𝑘 − 1 ; 	  	  𝑀𝑆Z[RU\ = 𝑆𝑆Z[RU\𝑏 − 1 ; 	  	  	  𝑀𝑆PQQRQ = 𝑆𝑆PQQRQb − 1 k	  – 	  1 	  	  	  	  	  	  	  	  	  	   
 
The F statistics of the treatment and the blocks will be: 
𝐹 = 𝑀𝑆LQPWLPVL𝑀𝑆PQQRQ 	  	  	  	  	  	  	  	  	  	  	  	  𝐹 = 𝑀𝑆Z[RU\𝑀𝑆PQQRQ	  	  	  	   
The null hypothesis is rejected if  F > 1.  
 The two-way ANOVA can also be with replications. In our study it was with 
replications as we had triple biological replicate for each group. In this case an additional 
type of measurement is introduced, that is the interaction between factors. The two-way 
ANOVA with replication is also referred as factorial experiment as it allows to 
investigating the effect of a factor A and simultaneously of a factor B on a dependent 
variable y (which could be the expression of a gene of interest), alongside with the 
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interactions between different levels of the factors on the dependent variable y. An 
interaction occurs when the effect of one factor varies for different levels of the other 
factors. An example could be the synergic or antagonistic effect of two drugs on the 
expression of a gene. The partitioning of the SSTotal is in this case: 
sscells 
                    SSTotal =    SSA    +  SSB  +    SSA×B    +  SSerror 
                            abn – 1  =   (a -1)   +   (b – 1) + (a-1) (b – 1)        + ab (n-1) 
                             N-1                                 ab-1 
When designing such a factorial experiment, the lay-out of the data can be imagined as a 
three-dimensional matrix, where, the first index/dimension represents the factor A, the 
second represents the factor B, and the third represents the position of the observation 
within the ij cell, where, αi is the i-th unit of factor A and ßj is the j-th unit of factor B. 
Each cell represents the set of observations under factor Ai and Bj. As before the MS of 
the partitions are calculated as the sum of square of the partition divided by the relative 
degrees of freedom. First, is tested the interaction between factors where the hypothesis 
are: 
H0 : (αß)ij = 0 for all i, j 
Ha : there is at least one pair i, j for which (αß)ij ≠ 0 
and the F statistics is: 
𝐹a×c = 𝑀𝑆A×B𝑀𝑆PQQRQ 
If 𝑀𝑆A×B is significantly larger than 𝑀𝑆PQQRQ, the null hypothesis is rejected. In this case 
pairwise t-tests are performed using multiple comparisons tests which correct for the error 
type I, such as the Bonferroni, Tukey’s tests etc. 
If we fail to reject the null hypothesis at this stage, the following hypothesis are tested: 
1)   H0 : α1 = α2 = … αa = 0 
 Ha : there is at least one pair of factors A presenting unequal means 
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and  
2)   H0 : ß1 = ß2 = … ßb = 0 
            Ha : there is at least one pair of factors B presenting unequal means. 
The F statistics for testing the null hypothesis are respectively: 
𝐹a = 𝑀𝑆A𝑀𝑆PQQRQ 
and  𝐹c = 𝑀𝑆B𝑀𝑆PQQRQ 
The assumptions in the factorial two way ANOVA are that the n samples in each cell are 
independent and drawn from a population with µij and normally distributed. Such 
populations are assumed to present the same variance. 
   Tukey’s test 
 As the ANOVA only allows to test whether the results are significant but does not 
provide information on among which group’s mean are the significant differences, 
additional post-hoc tests need to be used when performing multiple comparisons. The 
Tukey’s HSD (honest significant difference) test [335], compares every mean with every 
other mean. It was employed in this study to perform multiple comparisons after factorial 
two-way ANOVA. The HSD represents the least amount that means must vary from each 
other to be significantly different. The HSD is first calculated as: 
𝐻𝑆𝐷 = 𝑞 𝑀𝑆𝑒𝑟𝑟𝑜𝑟𝑛\  
where q is the constant that is determined from the studentized range q table by using and 𝑛\ is the sample size, which is assumed to be equal in each group. The HSD value 
obtained is then compared to each mean difference. If HSD is smaller than the difference 
between the means considered, such means are significantly different. The assumptions 
for the use of this test are the same of the t-test, such as the observations are independent 
among and within groups, such groups are normally distributed, the groups of the 
compared means present equal within variance. The sample size is assumed to be equal 
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for each groups, but if this assumption is violated, the Tukey-Kramer  test can be used 
instead [336]. 
  KEGG database and the hypergeometric test  
 The KEGG is a database (http://www.genome.jp/kegg/or http://www.kegg.jp/) in 
which genes are mapped into pathways, integrating systemic, chemical, genomic and 
functional information deriving from experimental knowledge [337]. In order to have an 
overview of the potential function of the genes differentially expressed between brown 
and white adipocytes, the hypergeometric test was performed to identify the KEGG 
pathways enrichment in brown and white adipocytes. The hypergeometric distribution is 
a discrete probability distribution and describes the probability that k objects (genes) and 
exactly k, have a determined property (are associated with the KEGG category) in a 
sample of n objects (differentially expressed genes) drawn from the given set. When a 
random variable x follows a hypergeometric distribution, the cumulative distribution 
function formula is given as follows: 
𝑃 = X\ k$XV$\kVl\m3  
where N is the number of objects and would represent the number of gene that have a 
KEGG annotation and m is the number of objects having a determined property and 
would correspond to the number of genes annotated to specific pathways. The 
assumptions made to perform the hypergeometric test, are that the population is discrete 
and defined with a known value and trials are done without replacement. 
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3  Chapter 3 – Results             
Intracellular and extracellular 
miRNAs in different adipocyte models 
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3.1   Introduction 
 MiRNAs are important gene regulators. Their presence in several biological fluids 
has recently raised the hypothesis that they could also mediate cell to cell communication, 
besides being used as biological markers. Several studies have investigated miRNA 
function in adipogenesis and the different profiles of miRNA expression presented by 
brown and white adipose tissues highlights their importance [338]. However, very little 
is known about the miRNAs secreted by adipocytes. In this study we have profiled the 
miRNAs secreted into media by mouse differentiated and undifferentiated brown and 
white adipocytes, seeking to identify differences in the miRNA secretome among these 
groups of cells. The differentially secreted miRNAs could have key local or distal actions 
intrinsic to the functions of white and brown adipocytes. Therefore, some of the most 
significantly differentially secreted miRNAs were selected and their intracellular and 
extracellular level of expression were analysed in different adipose models. In this chapter 
we also show the results obtained by profiling miRNA secreted by human mature brown 
and white adipocytes and the effect of ß-adrenergic stimulation on the intracellular and 
extracellular expression of the selected miRNAs in the different adipose models. Prior to 
analysis of miRNA expression, the adipose systems were characterized to evaluate their 
reliability as brown and white models. The immortalised human and mouse adipocytes 
will be referred for simplicity as human and mouse cell lines, even though they do not 
come from a monoclonal population. 
3.2   Mouse adipocyte cell lines differentiation  
 Mouse brown and white pre-adipocytes were seeded in 6-well plates and 
differentiated as described in the methods section. Pictures of differentiated adipocytes 
were taken with a Nikon DS-L3 camera. RNA was isolated and gene expression was 
analysed by Real-Time qPCR. Statistical analysis was performed using two-way 
ANOVA and significance assigned for p-value<0.05. Differentiation observed at the 
microscope, was confirmed by the increased mRNA level of aP2 in mature adipocytes 
compared to pre-adipocytes (figure 13). Indeed, aP2, also called FABP4, is known to 
increase during adipogenesis and is considered a marker of differentiation. The mRNA 
of UCP1, the most relevant marker of brown phenotype, was overexpressed in brown 
preadipocytes compared to the white preadipocytes and significantly increased (about 
100 fold) with the differentiation in both cell types. As expected, it was 10 fold higher in 
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mature brown compared to white adipocytes. Similarly, CIDEA, another brown marker 
gene, was upregulated during differentiation and 100-fold overexpressed in mature brown 
adipocytes compared to differentiated white adipocytes.   
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Figure 13 Gene expression and lipid droplets accumulation in mouse brown and white adipose cell 
lines.  
(A) mRNA expression of aP2, UCP1 and CIDEA of interscapular brown and subcutaneous white adipose 
cell lines before and after differentiation normalised to L19. Bars represent fold change means ±SEM of 
the biological triplicates and compared to differentiated brown adipocytes. * indicates p≤0.05, ** p≤0.01 
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and *** p≤0.001 according to multiple comparisons in two-way ANOVA test. Differentiated brown (B) 
and white (C) mouse adipose cell lines. 
 
   UCP1 mRNA induction upon CL treatment in differentiated brown and white 
adipose cell lines 
 To verify the ability of the cells to induce UCP1 transcription upon ß-adrenergic 
stimulation, differentiated brown and white adipocytes were treated for 6 hours with CL 
(10 µM), a highly selective ß3-AR agonist, or DMSO for controls. UCP1 mRNA levels 
were then compared between untreated and CL-treated adipocytes. As shown in figure 
14, both BAT and WAT responded to CL raising UCP1 expression. The mRNA levels 
were 12-fold increased in BAT and only three times higher in WAT. Functional studies 
on uncoupled respiration of this brown adipocyte cell line has been documented 
previously in Jaimiao Hu et al., [339]. 
 
 
Figure 14 UCP1 mRNA induction upon CL treatment in differentiated brown and white adipose cell 
lines 
Graphs show UCP1 mRNA level of expression in interscapular BAT (left panel) and subcutaneous WAT 
adipose cell lines (right panel) untreated I and treated with CL (CL) for 6 hours. Expression levels were 
normalised to L19 and bars represent the fold changes means of the triplicates ± SEM compared to brown 
or white adipocyte controls (BAT C and WAT C). ** indicates p≤0.01, according to t-test. 
 
 
   Regulation of genes involved in miRNA maturation during differentiation of 
mouse adipose cell lines  
 The transition from an undifferentiated stage towards a more differentiated one 
requires a profound change in gene expression that will define the fate of a cell. MiRNAs 
are known for their important contributions to gene regulation and an increased demand 
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for these small RNAs, consequently, would require a raised availability of the molecules 
responsible for their maturation. Therefore, we analysed the changes in mRNA 
expression of Dicer1, Ago2 and GW182 genes in brown and white undifferentiated and 
mature adipocytes. Differentiation of mature adipocytes was confirmed by the increased 
level of aP2 compared to preadipocytes (Figure 15). 
All the genes tested were upregulated in mature brown adipocytes even though the 
changes in mRNA expression were only significant for Dicer1 and Ago2. The latter 
showed a similar trend of expression in white adipocytes. On the contrary, Dicer1 and 
GW182 levels remained unvaried between undifferentiated and mature white adipocytes. 
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Figure 15 Regulation of genes involved in miRNA maturation during differentiation of mouse brown 
and white adipose cells  
The graphs show mRNA expression of aP2, Ago2, Dicer1 and GW182 in undifferentiated and 
differentiated brown and white adipocytes. The mRNA levels of each gene were normalised to L19. Bars 
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represent average fold changes of the biological triplicates ± SEM compared to preadipocytes (BAT D0 
and WAT D0). Significance was assessed according to Student’s T-test, p≤0.05 (*) and p≤0.01(**). 
   MiRNA PCR Array 
  To identify miRNAs differentially secreted among undifferentiated and 
differentiated brown and white adipocytes we profiled miRNA expression of media from 
undifferentiated and differentiated brown and white adipocytes using miRCURY LNATM 
Universal RT microRNA PCR Mouse&Rat panel I+II comprehensive for 752 miRNA 
assays. Because in media samples housekeeping genes cannot be used for normalisation, 
the same number (1.2 x106) of differentiated and undifferentiated brown and white 
adipocytes was seeded into each well of a 6-well plate. Because miRNA concentration in 
the media can be low, cells were left in serum-free media for 24 hours to allow miRNA 
accumulation and simultaneously avoiding cell sickness due to a long time in serum-free 
conditions. Media samples (4 biological replicates for each group) were collected, 
processed for serial centrifugations, filtered and stored at -80 °C. The next steps were 
performed at Exiqon Service. RNA was isolated and reverse transcribed. The cDNA 
obtained was run on the miRCURY LNATM Universal RT microRNA PCR Mouse&Rat 
panel I+II. Data were collected through Lightcycler Software. The controls performed 
(non-templates and RNA spike-ins) proved good technical performance of the profiling 
experiment and data were analysed. 
 Variation among the assays was analysed by unsupervised two-way hierarchical 
clustering (figure 17), Principal Component Analysis (PCA) (figure 16) and pairwise 
volcano plots (data not showed). 
 The PCA plot shows that samples clustered into the 4 expected groups. The 
biggest contributor to the observed variance appeared to be the differentiation status of 
the cells. The white vs brown adipocytes factor was robust but in this sample set a 
secondary contributor.  
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Figure 16 PCA plot (miRNA PCR array analysis on media from mouse adipocytes) 
The principal component analysis performed on all samples and on the top 50 miRNAs with highest 
standard deviation. 
 
 Figure 17 shows the heat map diagram obtained by the two-way hierarchical 
clustering performed on all samples and on the top 50 microRNAs with highest standard 
deviation. The shade of colours in the red-green scale of each spot represents the relative 
level of each miRNA (rows) expressed for the corresponding sample (columns). The 
differences in miRNA expression between media from undifferentiated and mature cells 
as largest contributor to variance previously observed in the PCA plot, is marked by the 
red and green squares. The diagram provides an alternative graphical visualization of the 
clear differences that exist among the 4 groups of cells. To identify miRNAs differentially 
secreted among the groups, data were analysed pairwise using t-test with cut-off of p-
value <0.05 and filtered for Benjamini-Hochberg correction to exclude false positives 
(cut-off value < 0.05). The results revealed that 45 miRNAs were differentially secreted 
between undifferentiated brown (UB) and undifferentiated white (UW), 118 in UW 
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versus differentiated white (DW), 123 in UB versus differentiated brown (DB) and 12 
between DB and DW (table 8) 
 
 
Figure 17 Heat map and unsupervised hierarchical clustering 
The clustering was performed on all samples, and on the top 50 microRNAs with highest standard deviation. 
The normalized (dCq) values have been used for the analysis. The heat map diagram shows the result of 
the two-way hierarchical clustering of microRNAs and samples. Each row represents one microRNA, and 
each column represents one sample. The microRNA clustering tree is shown on the left. The colour scale 
shown at the bottom illustrates the relative expression level of a microRNA across all samples: red colour 
represents an expression level above mean, green colour represents expression lower than the mean. 
 
 
 
. 
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Table 7 miRNA differentially secreted among undifferentiated and differentiated brown and white 
mouse adipocytes in pairwise analysis  
 UW vs UB UB vs DB UW vs DW DW vs DB 
Tot n 45 123 118 12 
Selected 
miRNAs 
miR-378a-3p miR-378a-3p miR-378a-3p miR-10b 
miR-196a-5p miR-322-5p miR-365-3p miR-196a-5p 
miR-10b miR-365-3p miR-322-55p  
Legend. UW: undifferentiated white adipocytes; UB: undifferentiated brown adipocytes; DB: 
differentiated brown adipocytes; DW: differentiated white adipocytes 
Among these, we selected some of the most significantly differentially secreted miRNAs 
(table 8) to test in other in vitro adipose models both for intracellular and extracellular 
levels. Details of standard deviations (SD), average ΔCqs, fold changes, p-values and 
Benjamini-Hochberg correction (BH adj. p-value) are reported in tables 9-12. MiR-378a-
3p and miR-365-3p levels were significantly higher in media from differentiated brown 
and white adipocytes (DB and DW) compared to the undifferentiated (UB and UW) 
while, miR-322-5p levels went in the opposite direction (tables 10 and 11). MiR-378 was 
previously found to induce differentiation of preadipocytes by increasing lipid droplet 
size and to be specifically involved in brown adipogenesis and metabolism [282, 340, 
341]. Also miR-365 was identified as a key regulator of BAT [342] even though it was 
subsequently found not to be essential for its development [343] and further investigation 
are needed to clarify these conflicting results. Several studies have been conducted on 
miR-322, which has an ortholog in humans referred to as miR-424. This miRNA has been 
found to regulate osteogenesis [344], inflammation [345] and protects against metabolic 
syndrome-induced cardiac dysfunction in mice [346]. As these three miRNAs were 
differentially secreted primarily between undifferentiated and differentiated adipocytes 
and they were identified as regulators of adipogenesis and other processes strictly linked 
to it, they were selected because of their possible involvement in the cross talk between 
cells during the differentiation process. MiR-10b was at the top of the list of miRNAs 
differentially secreted between DB and DW, being very highly expressed in media from 
BAT. Conversely, miR-196a-5p was higher in UW vs UB (table 9), DW vs DB (table 12) 
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and increased in UW vs DW (data not showed). MiR-196a promotes browning of the 
white adipose tissue [302] but to our knowledge no studies have been carried out to 
investigate its secretion. 
Table 8 miRNA differentially secreted between Undifferentiated White and Brown (UW vs UB) 
adipocytes 
miRname SD UW SD UB Average ΔCq UW 
Average 
ΔCq UB 
Fold  
Change P-value 
BH adj.p-
value 
miR-378a-3p 0.16 0.17 -0.120 1.2 -2.4 0.000033 0.0024 
miR-196a-5p 0.26 0.46 0.020 -3.2 9.5 0.000091 0.0036 
miR-10b-5p 1.10 0.25 -4.400 2.5 -1.2e+2 0.000610 0.0083 
Legend. SD UW: standard deviation of undifferentiated white adipocytes; SD UB: standard deviation of 
undifferentiated brown adipocytes; Average ΔCq UW: average of normalised quantification cycle in undifferentiated 
white adipocytes; Average ΔCq UB: average of normalised quantification cycle in undifferentiated brown adipocytes; 
P-value: p-value obtained using pairwise t-test; BH adj.p-value: p-value adjusted using Benjamini-Hochberg 
correction. 
 
Table 9 miRNA differentially secreted between Undifferentiated and Differentiated Brown (UB vs 
DB) adipocytes  
miRname SD UB SD DB Average ΔCq UB 
Average  
ΔCq DB 
Fold 
Change P-value 
BH adj. p-
Value 
miR-378a-3p 0.17 0.20 1.20 7.4 -73 7.8e-9 0.0000016 
miR-322-5p 0.12 0.23 3.90 -0.3 18 0.0000018 0.0000630 
miR-365-3p 0.28 0.11 -0.36 4.1 -23 0.0000093 0.0001700 
Legend. SD UB: standard deviation of undifferentiated brown adipocytes; SD DB: standard deviation of differentiated 
brown adipocytes; Average ΔCq UB: average of normalised quantification cycle in undifferentiated brown adipocytes; 
Average ΔCq DB: average of normalised quantification cycle in differentiated brown adipocytes; P-value: p-value 
obtained using pairwise t-test; BH adj.p-value: p-value adjusted using Benjamini-Hochberg correction. 
 
Table 10 miRNA differentially secreted between Undifferentiated and Differentiated White (UW vs 
DW) adipocytes 
miRname SD UW SD DW Average ΔCq UW 
Average 
ΔCq DW 
Fold 
Change P-value 
BH adj. p-
value 
miR-378a-3p 0.16 0.19 -0.12 7.4 -1.9e-9 1.9e-9 4.2e-7 
miR-365-3p 0.25 0.23 0.30 4.2 -15 4.7e-7 0.00005 
miR-322-5p 0.20 0.57 4.10 -2.1 70 0.0000590 0.00100 
Legend SD UW: standard deviation of undifferentiated white adipocytes; SD DW: standard deviation of differentiated 
white adipocytes; Average ΔCq UW: average of normalised quantification cycle in undifferentiated white adipocytes; 
Average ΔCq DW: average of normalised quantification cycle in differentiated white adipocytes; BH adj.p-value: p-
value adjusted using Benjamini-Hochberg correction.  
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Table 11 miRNA differentially secreted between Differentiated White and Brown (DW vs DB) 
adipocytes 
miRname SD DW SD DB Average ΔCq DW 
Average 
ΔCq DB 
Fold 
Change P-value 
BH 
adj. p-value 
miR-10b-5p 0.42 0.20 -4.40 2.1 -90 0.0000058 0.0013 
miR-196a-5p 0.31 0.42 0.54 -1.9 5.4 0.0001500 0.0056 
Legend. SD DW: standard deviation of differentiated white adipocytes; SD DB: standard deviation of differentiated 
brown adipocytes; Average ΔCq DW: average of normalised quantification cycle in differentiated white adipocytes; 
Average ΔCq DB: average of normalised quantification cycle in differentiated brown adipocytes; BH adj.p-value: p-
value adjusted using Benjamini-Hochberg correction 
   Extracellular miRNA expression in mouse adipose cell lines 
  To validate the results obtained by the miRCURY LNATM Universal RT 
microRNA PCR Mouse&Rat panel I+II we repeated the experiment and analysed the 
expression of the selected miRNAs in unconditioned and conditioned media samples by 
Real Time qPCR as described in paragraphs 4.4 - 4.7. Multiple comparisons two-way 
ANOVA test with cut-off of p-value < 0.05 was performed to analyse the data. 
 None of the selected miRNA was detected in unconditioned media (data not 
shown). MiR-103 was among the miRNAs significantly differentially expressed between 
preadipocytes and differentiated adipocytes even though it did not pass the Benjamini-
Hochberg test in the initial screen. This miRNA was found to negatively regulate insulin 
sensitivity in fat and liver cells [347]. Moreover, circulating miR-103 was identified 
among the miRNAs involved in metabolic disorders [348]. However, these studies were 
based on blood sample analysis and therefore it is not possible to determine the cellular 
component responsible for their secretion. For these reasons, we explored miR-103 levels 
of expression in media from adipocytes. Figure 18 shows that, in accordance with the 
miRNA profiling data (data not shown), miR-103 was significantly overexpressed in 
mature brown adipocytes. MiR-322 secretion, in contrast to previous results (table 10 and 
11), was upregulated in differentiating adipocytes. Except for this miRNA, the data 
obtained in this experiment confirmed the profiling results. Indeed, miR-365 levels 
significantly increased in brown differentiated adipocytes, miR-10b was predominantly 
secreted by mature brown adipocytes, miR-196a by mature white adipocytes and miR-
378 levels increased in differentiated adipocytes.  
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Figure 18 MiRNA expresssion in media samples from mouse undifferentiated and differentiated 
adipose cell lines 
Graphs show miRNA expression in serum-free media from subcutaneous white and interscapular brown 
preadipocytes and mature brown and white adipocytes seeded all at the same cellular density. Expression 
levels were normalised to Unisp6 spiked-in at RNA isolation stage. Bars represent the fold changes means 
of triplicates ± SEM compared to BAT differentiated. ND indicates not detectable. * indicates p≤0.05, ** 
p≤0.01, *** p≤0.001 and **** p≤0.0001 according to multiple comparisons in two-way ANOVA test 
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   CL treatment affects extracellular levels of miRNAs released by differentiated 
mouse adipose cell lines 
 We investigated the effect of ß3-AR activation on miRNA secretion by CL 
treatment. The same number of differentiated adipocytes were seeded into 12-well plates 
and left for 24 hours in serum-free media in the presence of CL (10 µM) or DMSO 
(vehicle) for control wells. After 24 hours, media samples were collected and processed 
for miRNA expression by Real-Time qPCR. Significance was assessed using t-test 
analysis for p-values <0.05. The CL treatment was able to significantly affect the 
secretion of 3 out of 6 miRNAs (figure 19). MiR-322 and miR-196a levels significantly 
increased in BAT media samples after treatment, while, miR-103 was significantly 
reduced. In WAT, the level of secretion of these miRNAs upon CL administration had an 
opposite direction to the one observed in BAT even though this was significant only for 
miR-196a. MiR-10b and miR-365 were only detectable in BAT samples and were not 
particularly affected by CL. 
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Figure 19 CL treatment affects extracellular levels of miRNAs released by differentiated mouse 
adipose cell lines. 
Graphs show miRNA expression in serum-free media from interscapular brown (BAT) and subcutaneous 
white (WAT) mature adipocytes untreated (C) or treated with CL (10µM) for 24 hours. The same number 
of differentiated cells were seeded for each biological triplicate. Expression levels were normalised to 
Unisp6 spiked-in at the RNA isolation stage. Bars represent the fold changes means of the triplicates ± 
SEM compared to BAT or WAT controls (BAT C and WAT C). * indicates p≤0.05 and ** is for p≤0.01, 
according to t-test. 
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   Intracellular miRNA expression in mouse adipose cell lines 
 In this section the intracellular expression of the selected miRNAs was monitored 
in undifferentiated and differentiated white and brown mouse cell lines. Interestingly, the 
intracellular miRNA patterns of expression (figure 20) did not always reflect the ones 
observed for extracellular miRNAs (figure 18). The increase in differentiated brown 
adipocyte intracellular miR-10b compared to preadipocyte levels corresponded to its 
induction in media from the same group of cells and miR-378 intracellular level increased 
with the differentiation in parallel with its extracellular levels. Also, the pattern of miR-
196a intracellular expression was similar to that observed for its secretion, being 
downregulated in differentiated BAT versus preadipocytes and more highly expressed in 
mature WAT compared to mature BAT. In contrast, miR-322 secretion increased in 
differentiated cells while its intracellular level decreased. MiR-365 was almost 
undetectable in media from white adipocytes while its intracellular level was much higher 
in WAT than in BAT besides increasing with differentiation in both cell lines. Finally, 
miR-103 was mostly secreted by mature brown adipocytes even if it was predominantly 
expressed in white adipocytes. Moreover, intracellular upregulation of miR-103 
corresponded to its extracellular downregulation in differentiated WAT. These results 
suggest that miRNA release by adipocytes is not necessarily directly proportional to the 
intracellular expression and therefore it may not simply be a passive process.  
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Figure 20 Intracellular miRNA expression in mouse adipose cell lines. 
Graphs show miRNA expression in differentiated and undifferentiated interscapular brown and 
subcutaneous white adipocyte cell lines. Expression levels were normalised to Unisp6 spiked-in at the 
reverse transcription stage. Bars represent the fold change means of triplicates ± SEM compared to 
differentiated brown adipocytes. ND indicates not detectable. Significance is indicated with * for p≤0.05 
and ** for p≤0.01 according to multiple comparisons in two-way ANOVA analysis. 
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   Effect of ß3-adrenergic activation on intracellular miRNA expression in mouse 
adipose cell lines 
  Differentiated brown and white adipocytes were treated for 6 hours with 
10 µM CL or DMSO for control replicates. Cells were harvested for RNA isolation and 
miRNA expression was analysed by Real-Time q-PCR. The results obtained are reported 
in figure 21. CL significantly induced miR-103 expression in brown adipocytes which 
was about 20-fold higher compared to untreated cells, while in white adipocytes an 
opposite trend of expression was observed. Upon CL treatment miR-10b was strongly 
induced in white adipocytes but only slightly in brown adipocytes. MiR-322 was 
expressed at lower levels in CL treated samples compared to untreated, while, miR-365 
and miR-196a levels increased in both CL-treated brown and white adipocytes. However, 
only miR-365 upregulation in BAT was statistically significant.  
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Figure 21 Effect of CL on intracellular miRNA expression in mouse adipose cell 
lines.  
Differentiated adipocytes were treated for 6 hours with CL (10µM). Graphs show miRNA expression in 
untreated (C) and CL-treated (CL) differentiated interscapular brown and subcutaneous white adipocytes. 
MiRNA levels were normalised to Unisp6 spiked-in at the reverse transcription stage. Bars represent fold 
change means ± SEM of the biological triplicates compared to the controls BAT C or WAT C. Significance 
is indicated with * for p≤0.05 or ** for p≤0.01 according to Student’s t-test. 
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3.3   Mouse primary adipocyte differentiation 
 Mouse primary brown and white cells were differentiated in vitro from the 
purified cells of the SVF isolated from interscapular BAT and subcutaneous WAT. The 
cells efficiently differentiated into adipocytes, as lipid accumulation was apparent in the 
cells imaged prior to RNA isolation (figure 22, panels B and C).  
 
 
Figure 22 UCP1 expression and lipid droplet accumulation in mouse differentiating primary 
adipocytes 
(A) UCP1 mRNA levels in primary preadipocytes and differentiated adipocytes from interscapular brown 
and subcutaneous white were normalised to L19 and expressed as fold changes compared to differentiated 
brown adipocytes. Bars represent means ± SEM of the biological triplicates. ND indicates not detectable. 
Significance is indicated with * for p≤0.05 and ** for p≤0.01 according to multiple comparisons in two-
way ANOVA analysis. Bottom panels show 20x magnification of primary differentiated brown (B) and 
white (C). 
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After reverse transcription into cDNA and Real-Time qPCR amplification, samples were analysed for gene 
expression. Significance was assed using two-way ANOVA with a cut-off of p-value < 0.05. Panel A of 
figure 22 shows UCP1 mRNA expression relative to differentiated brown adipocytes. As predicted, this 
brown marker was overexpressed in differentiated brown adipocytes compared to white adipocytes and 
increased in both cell types with the differentiation.  Subsequently, differentiated primary 
adipocytes were treated for 6 hours with CL (10 µM) and data analysed using t-test. As 
shown in figure 23, UCP1 transcription was enhanced by the ß3-agonist around 8000-
fold in BAT compared to untreated and about 30-fold in WAT. 
 
Figure 23 UCP1 mRNA induction upon CL treatment in differentiated primary adipocytes. 
Graphs show UCP1 mRNA level of expression in interscapular brown adipocytes (left panel) and 
subcutaneous white adipocytes (right panel) untreated (C) and treated with 10 M CL (CL) for 6 hours. 
Expression levels were normalised to L19 and bars represent the fold changes means of the triplicates ± 
SEM compared to the relative controls (C). * indicates p≤0.05, ** p≤0.01 and *** p≤0.001 according to 
Student t-test. 
 
   Extracellular miRNA secreted by primary cells 
  Extracellular levels of the selected miRNAs were analysed in media from mouse 
primary cells. The same number of differentiated or undifferentiated adipocytes was 
seeded into 12-well plates and incubated in serum-free media for 24 hours. Media 
samples were processed as before and analysed for miRNA detection by Real-time 
qPCR. Significance was assessed using multiple comparisons two-way ANOVA 
analysis with cut-off of p-value <0.05 and results are shown in figure 24. MiR-103 was 
not detectable. Expression of all the miRNAs increased in differentiated cells compared 
to preadipocytes except for miR-322 in white adipocytes, which remained unchanged, 
and miR-196a that was not detectable in brown adipocytes. Different from what was 
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observed in mouse cell lines, miR-10b was equally expressed in media from 
differentiated brown and white adipocyte primary cultures. 
 
Figure 24 Extracellular miRNA expression in primary adipocytes. 
Graphs show miRNA expression in serum-free media from undifferentiated and differentiated interscapular 
brown (BAT) and subcutaneous white (WAT) adipocytes. The same number of cells was seeded per each 
well. Expression levels were normalised to Unisp6 spiked-in at the RNA isolation stage. Bars represent the 
fold changes means of triplicates ± SEM compared to BAT differentiated. ND stays for not detectable. * 
indicates p≤0.05, ** p≤0.01 and *** p≤0.001 according to multiple comparisons in two-way ANOVA test. 
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   Effect of ß3-adrenergic activation on miRNA secretion in primary mouse 
adipocytes 
 Undifferentiated and mature primary adipocytes were maintained for 24 hours in 
serum-free media in the presence of CL (10 µM) or DMSO vehicle control. MiRNA 
expression in media samples was evaluated by Real-Time qPCR and data analysed using 
student’s t-test (figure 25). MiR-103 was not detectable once again. The treatment did not 
strongly affect miRNA secretion except for miR-322 and miR-196a. The latter was only 
detectable in white adipocyte samples and significantly decreased upon CL-treatment. 
Upon CL treatment MiR-322 was slightly increased in white adipocytes and significantly 
decreased in brown adipocytes. 
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Figure 25 Effect of ß3-adrenergic activation on miRNA release in differentiated primary adipocytes.  
Graphs show miRNA expression in serum-free media from interscapular brown (BAT) and subcutaneous 
white (WAT) mature adipocytes untreated (C) and treated with 10µM CL for 24 hours. The same number 
of differentiated cells was seeded for each biological triplicate. Expression levels were normalised to 
Unisp6 spiked-in in RNA isolation stage. Bars represent the fold changes means of the triplicates ± 
SEMcompared to BAT or WAT controls (BAT C and WAT C). ** indicates p≤0.01, according to t-test. 
128 
 
 
   Intracellular miRNA expression in primary cells 
 The intracellular miRNA expression in mouse primary cells analysed by Real-
Time qPCR revealed that miR-10b was upregulated in differentiated brown adipocytes 
(figure 26) in accordance with the findings in the mouse cell lines. MiR-378 and miR-
365 were significantly upregulated in differentiated cells compared to pre-adipocytes and 
more highly expressed in white adipocytes, confirming the observations in the cell lines. 
MiR-196a was undetectable in preadipocytes and highly induced following 
differentiation in both white and brown adipocytes. MiR-322 increased in differentiated 
brown adipocytes and was more highly expressed in white adipocyte samples, where it 
was equally expressed between undifferentiated and mature adipocytes. MiR-103 showed 
a similar pattern of expression to that found in the mouse cell lines, being upregulated 
during differentiation and significantly higher in white compared to brown adipocytes. 
Also in this case, the intracellular expression pattern of the miRNAs did not reflect the 
extracellular one, except for miR-365 and miR-378. 
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Figure 26 Intracellular miRNA expresssion in mouse primary adipocytes. 
Graphs show miRNA expression in differentiated and undifferentiated interscapular brown and white 
adipocyte primary cultures. Expression levels were normalised to Unisp6 spiked-in at the reverse 
transcription stage. Bars represent the fold change means of triplicates ± SEM compared to BAT 
differentiated. ND indicates not detectable. Significance is indicated with * for p≤0.05 and ** for p≤0.01, 
*** for p≤0.001 and **** for p≤0.0001 according to multiple comparisons in two-way ANOVA analysis. 
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   Effect of ß3-adrenergic activation on intracellular miRNA expression in primary 
cells 
 Differentiated primary adipocytes were treated for 6 hours with CL and 
intracellular miRNA content was analysed by Real-Time qPCR. Student’s T-test was 
performed and significance assigned for p<0.05. As shown in figure 27, miR-103 was not 
affected by CL treatment, while, all the other miRNAs were induced. Significant fold 
changes of miRNA expression in CL-treated cells compared to controls went from a 
minimum of 1.5 of miR-378 in BAT and a maximum of 10 for miR-196a observed in 
white adipocytes. The latter was not detectable in brown adipocytes. 
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Figure 27 Effect of ß3-adrenergic activation on intracellular miRNA expression in mouse primary 
adipocytes.  
Differentiated adipocytes were treated for 6 hours with CL (10µM). Graphs show miRNA expression in 
untreated (C) and CL-treated (CL) interscapular brown and subcutaneous white primary adipocytes. 
MiRNA levels were normalised to Unisp6 spiked-in at reverse transcription stage. Bars represent fold 
change means ± SEM of the biological triplicates compared to the controls BAT C or WAT C. Significance 
is indicated with * for p≤0.05, ** for p≤0.01 and *** for p≤0.001 according to Student’s T-test. 
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   Explants: mRNA expression  and tissue histology 
 Explants were obtained by dissecting interscapular BAT and subcutaneous WAT 
from 4-6 week old mice. Dissected tissues were washed several times with DMEM to 
remove debris and serum traces. Experiments were run in quadruplicates. Explants were 
maintained in serum-free media for 6 hours to reduce mRNA degradation due to necrosis 
factors production occurring after dissection. Both, tissue and media samples were 
collected and processed for mRNA and/or miRNA expression analysis. The aim of this 
experiment was to investigate intracellular and extracellular miRNA expression in BAT 
and WAT where the adipocytes are integrated in the tissue and therefore in an 
environment resembling the physiological condition occurring in vivo. 
 White adipose tissue starts developing after birth and depending on the age of the 
mouse or the temperature to which the mouse has been exposed, it can present brown-
like feature in terms of morphology and gene expression. The interscapular brown 
adipose depot appears as a dark red butterfly which edges are relatively easily 
distinguishable from the surrounding muscular tissue in young mice. However, with 
growth, the edges start becoming of a paler colour as the beige/white cellular component 
increases.  This area, if present, was removed from the tissues during dissection. In this 
section histology of the dissected tissues, obtained through haematoxylin-eosin stain and 
their mRNA expression of UCP1 are reported in figure 28 Panel B shows the histology 
of BAT, rich in cells containing multilocular lipid droplets. Panel C shows WAT section 
where the major cellular component consists of adipocytes presenting unilocular lipid 
droplets. The analysis of mRNA expression shows that UCP1 was significantly greater 
in BAT than in WAT (panel A) 
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Figure 28 UCP1 mRNA expression and histology of mouse adipose tissues.  
(A) UCP1 mRNA expression in interscapular BAT and subcutaneous WAT explants. Bars represent mean 
±≤  SEM of UCP1 levels of biological quadrulicates normalised to L19 and expressed in fold change 
compared iBAT. Significance was assessed by Student’s t-test analysis and **** indicates p≤0.0001. 
Panels at the bottom show haematoxylin-eosin stain of BAT (B) and WAT (C). 
   MiRNA expression in media from explants 
 MiRNA expression in media samples was normalised for tissue weight (figure 
29). Consistent with previous results in mouse primary cells and cell lines, miR-196a was 
selectively secreted by WAT, mir-322 and miR-378 mostly by BAT. Similar to the 
findings in primary cells, secreted miR-103 was not detectable in media from explants. 
MiR-365, differed from primary cells but in accordance to the data obtained in mouse 
cell lines, was significantly more highly expressed in media from BAT. Surprisingly, 
miR-10b was 100 times higher in media from WAT. Inconsistency between these results 
and the ones observed in mouse primary adipocytes and/or cell lines may be explained 
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by the fact that, in explants, different cellular components alongside with adipocytes are 
present and all of them contribute to miRNA secretion.  
 
 
Figure 29 miRNA expression in media samples from mouse explants.  
Graphs show extracellular miRNA expression in BAT and WAT explants incubated in serum-free media 
for 6 hours. Expression levels in the media were normalised to Unisp6 spiked-in at RNA isolation stage. 
Bars represent the fold changes means of quadruplicates or triplicates divided by the tissues weight ± SEM 
compared to BAT differentiated. ND indicates not detectable. Significance is indicated with * p≤0.05 and 
** for p≤0.01 according to Student’s t-test analysis. 
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   MiRNA expression in explant tissues 
 The analysis of intracellular miRNA expression by Real-time PCR in BAT and 
WAT explants (figure 30) revealed that miR-103 was present in both tissues and more 
highly expressed in WAT. MiR-365 was significantly overexpressed in BAT and miR-
322 showed a trend of expression similar to miR-365. MiR-196a was only detectable in 
WAT and there were no differences in miR-10b and miR-378 expression between BAT 
and WAT. 
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Figure 30 miRNA expression in BAT and WAT explants. 
Graphs show miRNA expression in BAT and WAT explants. MiRNA levels were normalised to L19. Bars 
represent the fold changes means of quadruplicates or triplicates ± SEM compared to BAT explants. ND 
indicates not detectable. Significance is indicated with * p≤0.05 according to Student’s t-test analysis. 
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3.4   Human adipocyte characterization 
 In vitro studies on adipocytes have led to rapidly increase the knowledge on many 
molecular mechanisms underlying the physiological metabolism of the adipose tissue and 
its pathologies. However, while human white adipocytes are largely available, procedures 
to obtain human BAT samples require invasive surgery, making human primary brown 
pre-adipocytes and the relevant cell lines very rare. So far, only few human brown adipose 
cell lines have been created [349-351] and they have been reported to resemble 
characteristics more similar to the beige mouse adipocytes rather than to the brown mouse 
adipocytes [351, 352]. In addition, human brown adipose depots present a more 
heterogeneous cellular population than mouse BAT and selection of the brown 
preadipocyte clones is very difficult. The human adipose cell lines used for this study 
were provided by Prof Fredrik Karpe (University of Oxford). Before performing any 
experiments to investigate miRNA expression or secretion, cells were characterised to 
ensure their reliability as brown and white adipocyte models.  
 
   Oil Red O Staining 
 The human adipocyte cell lines were differentiated and stained with Oil Red O. 
Images were captured at day 0 and 22 of differentiation. On the very first day, after only 
few hours of administration of induction media, cells assumed a flatter and more compact 
shape. Small lipid droplets started to appear at day 4 becoming larger and more numerous 
with the progression of differentiation, until cell edges were no longer distinguishable 
(figure 31, panels C and D). As shown in figure 31, cell size dramatically decreased upon 
increased confluency and progressed differentiation.  
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Figure 31 Oil Red O staining of human brown and white adipocytes.  
Human undifferentiated and differentiated brown and white and brown adipose cell lines were stained 
with Oil Red O and pictures were taken with a 40x magnification. (A) Undifferentiated brown adipocytes, 
(B) undifferentiated white adipocytes, (C) differentiated brown adipocytes, and (D) differentiated white 
adipocytes.  
 
   Gene expression 
 Differentiation of brown and white adipocytes was further assessed by gene 
expression analysis. RNA was isolated from undifferentiated and mature adipocytes and 
processed for Real Time qPCR. As expected, the morphological changes were 
accompanied by induction of FABP4 mRNA in mature adipocytes (figure 32). Cells were 
also tested for marker genes specific of the brown (UCP1, CIDEA, PGC1α, FABP3 and 
SLC27A2) and white (HOXC9) phenotype. Among these, the most relevant brown 
marker gene, UCP1, was strongly upregulated in differentiated brown adipocytes 
compared to all the other groups. Very low levels were detected in mature white 
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adipocytes and no expression was found in white preadipocytes. Similarly, CIDEA and 
PGC1α were only and predominantly expressed in mature brown adipocytes, 
respectively. CPT-1ß and FABP3 significantly increased with differentiation in both 
brown and white adipocytes but were expressed at much higher extent in mature brown 
adipocytes compared to white adipocytes. The white marker gene HOXC9 was 
selectively expressed by white adipocytes and, accordingly to what observed by Carey A. 
at al., it was slightly downregulated in differentiated white adipocytes compared to pre-
adipocytes [353]. 
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Figure 32 Gene expression in human brown and white adipose cell lines. 
mRNA expression of marker genes in interscapular brown and subcutaneous white adipose cell lines before 
and after differentiation normalised to L19. Bars represent fold change means ±SEM of the biological 
triplicates and compared to BAT differentiated. * indicates p≤0.05, ** p≤0.01 *** p≤0.001 and **** 
p≤0.0001  according to multiple comparisons in two-way ANOVA test.  
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   UCP1 mRNA upregulation in human adipocytes upon ß-AR activation  
 To evaluate the ability of the adipocytes to activate UCP1 transcription upon ß-
adrenergic stimulation, differentiated brown and white adipocytes were treated for 5 
hours with 10µM Isoproterenol, a non-selective ß-adrenoreceptor agonist, or DMSO 
(vehicle). Expression of UCP1 was analysed by Real-Time qPCR and data analysed using 
Student’s t-test.  As shown in figure 33, Isoproterenol induced UCP1 upregulation. 
Specifically, UCP1 levels were about 80 times significantly higher in Iso-treated brown 
adipocytes compared to brown control and 5 times increased in Iso-treated white 
adipocytes compared to white control.  
 
Figure 33 UCP1 mRNA induction upon Isoproterenol treatment in human differentiated brown and 
white adipose cell lines.  
Graphs show UCP1 mRNA level of expression in brown (left panel) and white adipose cell lines (right 
panel) untreated (C) and treated with 10µM Isoproterenol (ISO) for 6 hours. Expression levels were 
normalised to L19 and bars represent the fold changes means of the triplicates ± SEM compared to BAT or 
WAT controls (BAT C and WAT C). *** indicates p≤0.001, according to Student’s t-test. 
 
   Mitochondrial content in brown and white adipocytes 
 Brown adipocytes present a higher number of mitochondria than white. Indeed, 
uncoupling respiration takes place in these organelles where UCP1 is located. To evaluate 
the mitochondrial content in human adipocytes, we measured the amount of 
mitochondrial DNA by analysing the relative abundance of the mitochondrial genome 
encoded Cyt-b gene. DNA was isolated and amplified by Real time PCR. Data were then 
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analysed and normalised to genomic DNA levels by PCR of the nuclear encoded RIP140 
gene. CYT-B levels increased with differentiation in both brown and white adipocytes 
(figure 34). Indeed, mitochondria play an important role also in white adipocyte 
metabolism [354]. However, as expected, brown adipocytes presented a significantly 
higher content of mitochondrial DNA compared to white adipocytes.  
   
 
Figure 34 Mitochondrial DNA abundance.  
The Graph shows abundance of the mitochondrial gene CYT-b in brown and white undifferentiated and 
mature adipocytes, normalised to RIP140. Bars represent fold change means ±SEM of the biological 
triplicates or quadruplicates and compared to BAT preadipocytes. * indicates p≤0.05 and ** p≤0.01 
according to multiple comparisons in two-way ANOVA test.  
 
   Oxygen consumption  
 In order to test the functional activity of UCP1, basal OCR of brown and white 
adipocytes was measured by Seahorse technology. Brown and white adipocytes were 
tested simultaneously by seeding the same number of cells (50,000) into each well of a 
24-well seahorse plate. As shown in figure 35, panel A, brown adipocytes presented a 
significant higher consumption of oxygen compared to white adipocytes. Additionally, 
the inducibility of UCP1 upon ß-adrenergic stimulation was assessed by measuring the 
oxygen consumption in brown adipocytes pre-treated with 10 µM Isoproterenol for 40 
minutes or DMSO (vehicle) for controls. Oxygen consumption in treated cells was 
significantly greater than untreated cells suggesting increased cellular respiration, 
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possibly via activation of UCP1 activity under ß-adrenergic stimulation. However to 
confirm this hypothesis, a mitochondrial stress assay should be performed to measure the 
uncoupled respiration. 
 
Figure 35 Oxygen consumption in adipocytes. 
A) Oxygen consumed expressed in pmol/min by white and brown adipocytes at basal conditions. B) 
Oxygen consumption in brown adipocytes pre-treated for 40 minutes with (Iso) or with the vehicle DMSO 
(control).  *** indicates p≤0.0001 according to Student’s t-test. 
 
   Gene expression of miRNA processing machinery during human adipocyte 
differentiation 
 To explore the expression of the genes involved in miRNA maturation in human 
adipocyte cell lines, the mRNA levels of Ago2, Dicer1 and GW182 were monitored 
during adipocyte differentiation in parallel with FABP4. White and brown preadipocytes 
were induced to differentiate and processed for Real Time qPCR analysis at day 0, 3, 10 
and 22. As represented in figure 36, FABP4 in brown adipocytes was strongly 
upregulated at day 3 compared to day 0. Its expression kept increasing until day 22. In 
white adipocytes, FABP4 reached its highest peak of expression at day 10 and decreased 
at day 22, still showing significant overexpression compared to day 0. Interestingly, all 
the miRNA processor genes tested, showed an initial downregulation in both brown and 
white adipocytes, although the changes in mRNA levels at day 3 were significant only 
for Ago2. At day 10 the expression of all the genes increased again, compared to day 3, 
reaching similar levels to the ones observed at day 0, except for Ago2 in white adipocytes, 
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which levels progressively decreased to a fold change of 0.148 ± 0.060 at day 22 
compared to day 0. In brown adipocytes, at day 22, Ago2 was significantly lower 
expressed (fold change: 0.762 ± 0.076) compared to day 0. On the contrary, at day 22, 
Dicer1 and GW182 were upregulated in both cell types compared to day 0, even though 
Dicer1 changes in brown adipocytes were not significant. 
 
 
Figure 36 Regulation of genes involved in miRNA maturation during differentiation of human brown 
and white adipocytes.  
The graphs show mRNA expression of FABP4, Ago2, Dicer1 and GW182 at day 0, 3, 11 and 22 of 
differentiation of brown and white adipocytes. The mRNA levels of each gene were normalised to L19. 
Dots represent average of fold changes of the biological triplicates ± SEM compared to day 0. Significance 
was assessed according to one-way ANOVA, p≤0.05 (*), p≤0.01(**) and p≤0.0001(***). 
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   Extracellular miRNAs secreted by human adipocytes 
 Human undifferentiated and differentiated brown and white adipocytes were 
maintained in serum-free media for 24 hours. To obtain comparable data, the same 
number of cells (5x105) was seeded into each well of a 12-well plate. Media samples were 
collected as previously described. Part of the sample was sent to Exiqon service for 
miRNA PCR panel assay to identify miRNA differentially secreted between brown and 
white adipocytes in humans. The remaining part of the sample was processed for Real 
Time q-PCR analysis to evaluate the expression of the miRNAs previously tested in 
mouse experiments.  
   MiRNA profiling of media samples from human adipocytes 
 The quality control of the data obtained by the miRNA PCR panel assay was 
performed by analysing variation among samples. In the PCA performed on all the 
samples and the top 34 miRNAs with the highest standard deviation, samples from brown 
and white adipocytes grouped in two different areas of the graph based on the largest 
variation defined by PC1 (figure 37) and reflecting the different nature of brown and 
white adipocytes in terms of miRNA secretion. Observing the distribution of the samples 
based on the second largest variation specified by PC2, it is possible to note that, white 
adipocytes clustered very close one to each other. Brown adipocytes spread along the y-
axis, suggesting, even if at low grade, variability among the brown adipocytes group. This 
was not necessarily due to RNA quality, but more likely to the heterogeneous nature of 
brown adipocytes in humans. Reassured of the good quality of the data, we proceeded 
with the statistical analysis to identify miRNAs differentially secreted between brown 
and white adipocytes. 
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Figure 37 PCA plot.  
The principal component analysis performed on all samples, and on the top 34 microRNAs with highest 
standard deviation. The normalized (dCq) values have been used for the analysis. 
 
   Volcano plot 
To identify miRNAs differentially secreted between brown and white adipocytes data 
were analysed using Student’s t-test and Benjamini-Hochberg correction. Log 2 (fold 
change) of brown versus white adipocytes and the –log10 (p value) were plotted on x and 
y axes, respectively to obtain the volcano plot in figure 38. In table 13 the top 11 miRNAs 
differentially expressed between brown and white adipocytes that presented a p value ≤ 
0.05 are reported. Among these, there were miR-378a and miR-365, both overexpressed 
in media from brown adipocytes, in accordance with the results obtained by RT-qPCR. 
The other miRNAs overexpressed in media from brown adipocytes compared to white 
were: miR-335-5p and miR-92a.3p. However, of all the miRNAs identified, only miR-
138-5p passed the Benjamini-Hochberg test, therefore it was included in the list of 
miRNAs to be tested by RT q-PCR in human adipocytes. 
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Figure 38 Volcano plot.  
The graphic shows the relation between the p-values and the ddCq obtained by comparing miRNA 
expression in media from brown versus white adipocytes. 
 
Table 12 miRNA differentially secreted between brown versus white adipocytes 
miRName SD Brown SD White 
Average 
dCq Brown 
Average 
dCq White FC P-value 
Adj.  p 
value 
miR-138-5p 0.25 0.18 0.28 1.80 -2.9 1.2x10-4 0.01 
miR-378a-3p 0.67 0.64 0.21 -2.20 5.2 2.2x10-3 0.09 
miR-15a-5p 0.33 0.64 -3.40 -1.90 -2.9 1.0x10-2 0.22 
miR-34a-5p 0.67 0.41 -2.20 -0.62 -2.9 1.1x10-2 0.22 
miR-320a 0.44 0.26 -0.70 0.28 -2.0 1.3x10-2 0.22 
miR-423-3p 0.71 0.37 -0.22 1.30 -2.9 1.5x10-2 0.22 
miR-23a-3p 0.06 0.27 2.00 2.60 -1.5 2.1x10-2 0.26 
miR-335-5p 0.73 1.5 -1.80 -4.50 6.5 2.5x10-2 0.28 
miR-146a-5p 0.43 0.88 -2.30 -0.71 -3.0 3.1x10-2 0.30 
miR-365a-3p 0.43 0.36 0.82 0.07 1.7 3.8x10-2 0.30 
miR-92a-3p 0.47 0.43 0.95 0.11 1.8 3.8x10-2 0.30 
 
148 
 
   Extracellular miRNAs secreted by human adipocytes, validation by RT qPCR 
analysis 
 Data obtained by RT qPCR were analysed using multiple comparison two-way 
ANOVA (Figure 39). Expression of secreted miR-138, miR-10b miR-365 and miR-378 
increased in differentiated adipocytes versus preadipocytes. MiR-138 and miR-10b were 
overexpressed in media from differentiated white adipocytes compared to brown 
adipocytes. On the contrary, miR-378 and miR-365 were more highly expressed in media 
from differentiated brown adipocytes. Secreted miR-196a and miR-424 levels increased 
in differentiating white adipocytes and decreased in differentiated brown adipocytes 
compared to brown preadipocytes. Both miRNAs were more highly expressed in media 
from differentiated white adipocytes compared to differentiated brown adipocytes. MiR-
103 secretion was downregulated in differentiated adipocytes compared to preadipocytes 
and was slightly higher in differentiated white adipocytes compared to differentiated 
brown. These data confirmed the results observed in the miRNA PCR human Panel. Most 
of the results shown in this analysis were also consistent with that observed for miRNA 
orthologues in mouse experiments. A more detailed comparison among data from human 
and mouse adipocytes is discussed in paragraph 14. 
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Figure 39 MiRNA expresssion in media samples from human undifferentiated and differentiated 
adipocytes.  
Graphs show miRNA expression in serum-free media from subcutaneous white and supraclavicular brown 
preadipocytes and mature adipocytes, seeded all at the same cellular density. Expression levels were 
normalised to Unisp6 spiked-in at RNA isolation stage. Bars represent the fold changes means of triplicates 
± SEM compared to BAT differentiated. ND means non-detectable. * indicates p≤0.05, and ** p≤0.01 
according to multiple comparisons in two-way ANOVA test. 
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    Effect of Isoproterenol treatment on miRNAs secreted by human adipocytes 
 To understand whether miRNA secretion is affected by the cold-regulated 
signalling pathway, we mimicked adrenergic stimulation by administrating Isoproterenol 
to differentiated adipocytes and measured miRNA expression in the conditioned media. 
The same number (5x105) of differentiated brown and white adipocytes were seeded into 
each well of a 12-well plate and incubated for 24 hours in serum-free media in the 
presence of Isoproterenol (10 µM) or DMSO (vehicle) for controls. Media samples were 
collected and processed for RT-qPCR assay and data was analysed using Student’s t-test. 
As shown in figure 40, miR-103 and miR-365 were slightly upregulated in media from 
Iso-treated samples, while, miR-424 levels of expression were reduced. MiR-196a was 
only detectable in media from white adipocytes and its level of expression was 
moderately reduced upon Isoproterenol administration. Extracellular miR-378, mir-138 
and miR-10b were downregulated in brown and upregulated in white adipocytes treated 
with Isoproterenol compared to controls. However, only upregulation of miR-378 in 
white adipocytes treated with Isoproterenol was statistically significant. 
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Figure 40 MiRNAs expression in media samples from differentiated human adipose cell lines upon 
Isoproterenol treatment.  
Graphs show miRNA expression in serum-free media from supraclavicular brown (BAT) and subcutaneous 
white (WAT) mature adipocytes untreated (C) or treated with Isoproterenol (ISO) for 24 hours. The same 
number of differentiated cells were seeded for each biological triplicate. Expression levels were normalised 
to Unisp6 spiked-in at the RNA isolation stage. Bars represent the fold changes means of the triplicates ± 
SEM compared to brown or white controls (BAT C and WAT C). * indicates p≤0.05 according to Student’s 
t-test. 
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   Intracellular miRNA expression in human adipocytes 
 Human undifferentiated and differentiated brown and white adipocytes were 
harvested and analysed for intracellular miRNA expression by RT-qPCR. Significance 
was assessed by performing a two-way ANOVA test. All the miRNAs were upregulated 
in differentiated adipocytes compared to undifferentiated cells and in mature white 
adipocytes compared to differentiated brown adipocytes. Only miR-196a was not 
detectable in brown adipocytes. 
As also observed in mouse experiments, intracellular and extracellular patterns of miRNA 
expression did not always go in parallel. This was particularly evident for miR-103, which 
secretion was downregulated in differentiated cells versus preadipocytes (figure 39), 
while, its intracellular abundance was upregulated in differentiated adipocytes compared 
to pre-adipocytes (figure 41). Extracellular and intracellular levels of miR-424 had a 
similar trend of expression in white adipocytes but opposite in brown adipocytes. 
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Figure 41 Intracellular miRNA expresssion in human dipocytes.  
Graphs show miRNA expression in differentiated and undifferentiated supraclavicular brown and 
subcutaneous white adipocytes. Expression levels were normalised to Unisp6 spiked-in at the reverse 
transcription stage. Bars represent the fold change means of triplicates ± SEM compared to BAT 
differentiated. ND indicates not detectable. Significance is indicated with * for p≤0.05 ** for p≤0.01, *** 
for p≤0.001 and **** for p≤0.0001  according to multiple comparisons in two-way ANOVA analysis. 
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    Effect of Isoproterenol on intracellular miRNA expression in adipocytes after 
Isoproterenol treatment. 
 Differentiated white and brown adipocytes were treated for 5 hours with 
Isoproterenol (10 µM) or DMSO (vehicle) for control wells. RNA was isolated from cells 
and processed for intracellular miRNA expression through RT-qPCR analysis. 
Isoproterenol induced a significant increase of miR-10b and miR-424 expression in 
brown adipocytes and a decrease in white adipocytes (figure 42). The same trend of 
expression was observed for miR-365, miR-138 and miR-378 even though the differences 
in miRNA expression between Iso-treated and control samples were negligible for miR-
138 in brown adipocytes and miR-378 and miR-424 in white adipocytes.  
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Figure 42 Effect of ß-adrenergic activation on intracellular miRNA expression in human adipose cell 
lines.  
Differentiated adipocytes were treated for 6 hours with Isoproterenol (10µM). Graphs show miRNA 
expression in untreated (C) and Iso-treated (ISO) supraclavicular brown and subcutaneous white 
adipocytes. MiRNA levels were normalised to Unisp6 spiked-in at reverse transcription stage. Bars 
represent fold change means ± SEM of the biological triplicates compared to the controls BAT C or WAT 
C. Significance is indicated with * for p≤0.05 according to Student’s t-test. 
156 
 
   Summary and overview 
 In the following tables are summarised the data obtained by RT qPCR analysis of 
the extracellular (tables 14, 16) and intracellular (tables 15, 17) miRNA regulation across 
the different adipose models, both at basal conditions (tables 14 and 15) and upon ß-
adrenergic stimulation (16 and 17). MiR-138 was included in the tables even though it 
was only tested in human adipocytes. Up (­) and (¯) down arrows indicate miRNA 
upregulation and downregulation respectively, in differentiated cells versus 
preadipocytes (Diff vs undiff columns, BAT and WAT sub-columns) or in CL/ISO-
treated cells versus control (CL vs C/ISO vs C, BAT and WAT sub-columns). For Brown 
(B) versus White (W) comparisons in undifferentiated and differentiated cells, B > W 
means that miRNA was overexpressed in brown adipocytes compared to white and vice 
versa. Significance is specified by * for p value ≤ 0.05, 2* for p ≤ 0.01, 3* for p ≤ 0.001 
and 4* for p ≤ 0.0001. If a miRNA was undetectable in both the terms of comparison it is 
indicated as non-detectable (nd), while, if it was undetectable only in one on the two 
terms, it is indicated by the presence of the hash mark (#). Very similar level of expression 
is indicated by the symbol ~, assigned when the difference of the relative expression of 
the two comparative terms was between -0.05 and 0.05.  
 Intracellular quantification of the miRNAs was tested in order to verify whether 
the level of secretion of each miRNA could be a mere consequence of the intracellular 
level of expression. By observing the tables 14 and 15 it is easy to notice that intracellular 
and extracellular pattern of miRNA expression did not always go in parallel, as described 
more in details in the previous sections. This suggests that miRNA secretion is not a 
simply passive process but rather a controlled mechanism. Perhaps cells could use 
secretion to reduce intracellular level of a specific miRNA and simultaneously 
communicate with neighbouring cells. 
  The most consistent results across the adipose models were observed for 
extracellular miR-378a and miR-196a.  
 Intracellular and extracellular miR-378a was consistently upregulated in 
differentiated adipocytes versus preadipocytes. In differentiated cells, its extracellular 
levels of expression were always greater in brown adipocytes compared to white, while, 
intracellular levels were consistently higher in white adipocytes. In explants, both 
intracellular and extracellular miR-378 levels of expression were greater in BAT 
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compared to WAT. CL/ISO treatment increased intracellular miR-378 in all samples 
excluding human and mouse white adipose cell lines, on which it had no effect. Also 
extracellular miR-378 was consistently upregulated by the ß-adrenergic treatment, even 
if, in primary white adipocytes and human brown adipocytes it was slightly 
downregulated. 
 Both intracellular and extracellular miR-196a was consistently overexpressed in 
differentiated white adipocytes/WAT explants compared to differentiated brown 
adipocytes/BAT explants. It was upregulated in differentiated white adipocytes compared 
to preadipocytes, while, when detectable, it was downregulated in differentiated brown 
adipocytes versus undifferentiated. Interestingly, CL/ISO treatment inhibited miR-196a 
secretion in white and increased it in brown adipocytes. Intracellular miR-196a, when 
detectable, was induced by the treatment in all cells, human excluded, in which no 
differences were observed compared to control. 
Extracellular miR-365 was upregulated in differentiated cells versus 
preadipocytes and overexpressed in brown adipocytes/explant compared to white, with 
the exception of primary cells. In contrast, its intracellular level of expression was 
consistently higher in white adipocytes compared to brown adipocytes but not in WAT 
compared to BAT explants. Intracellular and extracellular levels of expression of miR-
365, when detectable, were increased upon ß-adrenergic stimulation, except for secreted 
miR-365 in primary white adipocytes and intracellular miR-365 in white human cell lines. 
In the first case, CL did not have any effect on miR-365 expression. In human white 
adipocytes intracellular miR-365 was slightly lower expressed upon ISO treatment 
compared to control.  
 Regulation of intracellular miR-103 was consistent across the adipose systems but 
not its secretion. Also the results obtained for all the remaining miRNAs were variable 
These were: miR-378a, miR-196a. MiR-138 was included as well as it was the only 
miRNA differentially secreted between human brown and white adipocytes. As 
mentioned before, these miRNAs have been found involved in adipogenesis, but their 
extracellular function is still largely unexplored in the cross talk between the adipose 
tissue and other organs.  
By using miRNATap package (Bioconductor) and setting 2 as minimum source we 
obtained a list of the potential targets of miR-378a-3p, miR-196a-5p and miR-138-5p 
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(table 18). Among the potential miR-378 targets that could be most relevant for adipose 
tissue biology were VEGFA and SULF1 (sulfatase 1) for their involvement in 
angiogenesis and receptor/ligand binding mediated by heparan sulfate proteoglycans 
(HSP) respectively. The most interesting targets of miR-196a-5p were HIF1α which is 
involved in fibrosis of adipose tissue in obesity induced hypoxia, ADAM10 that has an 
important role in the extracellular matrix, TLR4 and NF-kB inhibitor alpha (IKBA) which 
are involved in inflammation and consequent impairment of insulin sensitivity in HFD –
induced obesity. For the same reasons SOCS3, interleukin-6 receptor (IL6R) and 
interleukin-1 receptor antagonist (IL1RA) were selected among the potential targets of 
miR-138-5p. All these targets could be considered for future investigations on the role of 
the selected miRNAs secreted by adipocytes in the cross talk between adipose tissue and 
distal cells.  
Regulation of extracellular miRNAs in mouse and human adipose models 
 
Table 13 Regulation of extracellular miRNAs in mouse and human adipose models 
miRName 
 
Expl Mouse cell lines Mouse primaries Human cell lines 
Brown vs 
white	  
Diff vs undiff Brown vs white Diff vs undiff Brown vs white Diff vs undiff Brown vs white 
BAT	   WAT Undiff Diff BAT WAT Undiff Diff BAT WAT Undiff Diff 
miR-
322/424 B>W* ­
2*	   ­ B>W B>W2* ­3* ~ ~ B>W3* ¯ ­* B>W W>B 
miR-10b W>B2* ­3*	   nd #B>W #B>W4* ­ ­ B>W ~ ­ ­ B>W W>B 
miR-103 nd #­*	   ¯ #W>B B>W2* nd nd nd nd ¯* ¯ B>W W>B 
miR-365 B>W2* #­	   nd nd #B>W #­ #­ # ~ W>B ­ ­ B>W B>W 
mi R-378 B>W* ­2*	   ­ ~ B>W ­* ­ ~ B>W #­ ­ #W>B B>W 
miR-196a #W>B ¯	   ­2* B>W W>B2* nd ­2* #W>B #W>B #¯ ­ W>B #W>B 
miR-138 - -	   - - - - - - - ­ ­2* B>W W>B* 
 
 Table 14 Regulation of intracellular miRNAs in mouse and human adipose models  
miRName 
 
Expl Mouse cell lines Mouse primaries Human cell lines 
Brown 
vs 
white	  
Diff vs undiff	   Brown vs white	   Diff vs undiff	   Brown vs white	   Diff vs undiff	   Brown vs white	  
BAT WAT Undiff Diff BAT WAT Undiff Diff BAT WAT Undiff Diff 
miR-
322/424 B>W* ¯ ¯ B>W B>W #­ ¯ #W>B W>B ­ ­
3* W>B W>B3* 
miR-10b B>W ­2* nd #B>W B>W* ­ ~ W>B ~ ­ ­3* W>B W>B3* 
miR-103 W>B ­ ­ W>B W>B ­ ­ W>B W>B ­* ­4* ~ W>B4* 
miR-365 B>W #­ ­* #W>B W>B2* #­ ­ #W>B W>B ­ ­2* W>B W>B2* 
miR-378 B>W #­ ­ #W>B W>B ­ ­ W>B W>B ­ ­3* ~ W>B* 
miR-196a W>B ¯* ­ W>B W>B nd ­ #W>B #W>B nd ­ #W>B #W>B 
miR-138 - - - - - - - - - ¯ ­ W>B W>B 
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Table 15 Effect of CL/ISO treatment on miRNAs secreted by human and mouse adipocytes 
miRName 
  
Mouse cell lines 
CL vs C 
Mouse primaries 
CL vs C 
Human cell lines 
ISO vs C 
BAT WAT BAT WAT BAT WAT 
miR-322/424    ­* ¯*    ¯2* ­ ¯ ¯ 
miR-10b ¯   nd ­   ¯ ¯ ­ 
miR-103    ¯2* ­ nd nd ­ ­ 
miR-365 ­ nd ­ ~ ­ ­ 
miR-378   ­ ­ ­ ¯ ¯ ­* 
miR-196a   ­2*  ¯2* nd     ¯2* nd ¯ 
miR-138 - - - - ¯ ­ 
 
Table 16 Effect of CL/ISO treatment on intracellular miRNAs in human and mouse adipocytes 
miRName 
  
Mouse cell lines Mouse primaries Human cell lines 
BAT WAT BAT WAT BAT WAT 
miR-322/424 ¯ ¯ ­*    ­2* ­* ¯  
miR-10b ­  #­  ­2*    ­2* ­* ¯ 
miR-103   ­* ¯  ~ ~   ~ ­   
miR-365    ­2* ­ ­  ­* ­ ¯ 
miR-378 ­   ~   ­2*    ­3* ­   ~ 
miR-196a ­ ­ nd    ­2* nd   ~ 
miR-138 - - - -   ­ ¯ 
 
Table 17 Potential targets of selected miRNAs secreted by adipocytes 
miRname Potential target  function of target 
miR-378a-3p VEGFA Angiogenesis SULF1 Receptor/ligand binding via HSP  
miR-196a-5p 
HIF-1α Adipose tissue fibrosis 
ADAM10 ECM remodelling 
TLR4 
Inflammation/insulin resistance 
IKBA 
miR-138-5p 
SOCS3 
IL6R 
IL1RA 
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3.5   Discussion 
 Brown and white preadipocytes present differences in miRNA and gene 
expression and the process of differentiation into mature adipocytes is characterised by a 
further alteration of the transcriptome. We showed for the first time that undifferentiated 
and differentiated brown and white adipocytes present differential profiles of secreted 
miRNAs, supporting the hypothesis that these molecules can mediate the cross talk 
between the adipose tissues and distal cells. Precisely, 45 miRNAs were differentially 
secreted between undifferentiated brown (UB) and undifferentiated white (UW), 118 in 
UW versus differentiated white (DW), 123 in UB versus differentiated brown (DB) and 
12 between DB and DW (table 8). This highlights that there are significant differences 
among the types of adipocytes, especially between undifferentiated and differentiated 
adipocytes, as they presented a high number of differentially secreted miRNAs. Some of 
these miRNAs were selected for validation and further analysis in different adipocyte cell 
models. MiR-322/424-5p, miR-365-5p and miR-378a-3p were selected because they 
were differentially secreted between undifferentiated and differentiated adipocytes, 
while, miR-10b and miR-196a because they were differentially secreted between brown 
and white adipocytes. MiR-103 was added to the list as it was differentially secreted 
between preadipocytes and differentiated adipocytes and previously reported to regulate 
insulin sensitivity [347].  
 The characterization of the adipocyte systems used in this study allowed us to 
conclude that, the systems were good models of brown and white adipocytes and BAT 
and WAT. Indeed, explants showed the classical histology of BAT and WAT. BAT and 
brown adipocytes showed a higher UCP1 expression compared to WAT and white 
adipocytes respectively. Moreover, the cells were able to respond to ß-adrenergic stimuli 
by further raising the levels of UCP1 expression. Additionally, the functional assay 
performed on human adipose cell lines, characterised for the first time, confirmed that the 
brown adipocytes present a higher basal oxygen consumption compared to white 
adipocytes. 
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   Gene expression of miRNA processing machinery during human adipocyte 
differentiation 
 Hypothesising that the switch from undifferentiated to mature status would 
require an increase in miRNA production to promote this process, the expression of Ago2, 
Dicer1 and GW182 genes was analysed in mouse and human adipocytes. Overall, the 
changes in expression of these genes between undifferentiated and mature adipocytes, 
even if statistically significant in some cases, were not as marked as expected. This 
suggests that miRNA production for maintaining the undifferentiated status is as much 
important as for inducing and maintaining maturation. Moreover, if these genes were 
involved in the unique function of miRNA maturation, their level of expression would be 
expected to vary proportionally during differentiation. Conversely, this did not happen 
for all the genes in the different systems. In particular, Ago2 in human WAT significantly 
decreased, while DICER1 and GW182 gradually and significantly increased during 
differentiation. In a previous study on ADMSC, Ago2 was found to translocate in the 
nucleus and bind to specific regions of functional genes such as of selenoprotein N1 
(SEPN1), miR10b, and miR23b, regulating cell survival upon excessive ROS production 
[355]. This supports that fact the genes involved in miRNA biosynthesis and maturation, 
could be involved in other processes not strictly related to miRNA processing. Moreover, 
these additional functions could be different in mouse and humans as the trend in gene 
expression was slightly different between the adipocytes of the two species. 
   miRNAs in different adipose models 
 The analysis in parallel of the intracellular miRNA level allowed us to conclude 
that miRNA secretion is not a passive process but actively regulated, as extracellular and 
intracellular miRNA levels were not proportional. The use of adipose explants in this 
analysis highlighted that the pattern of intracellular and extracellular miRNA expression 
of BAT and WAT can show differences to that of isolated adipocytes, as cell types other 
than adipocytes contribute to miRNA secretion. However, it has to be considered that, in 
explants there is no longer blood circulation. Even though we tried to overcome this 
problem by cutting the tissues in small pieces (~2mm width), miRNAs could be retained 
in the centre of the tissue and only partially released in the media. Additionally, in 
explants, the different cellular components absent in isolated adipocyte cell cultures, are 
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likely to uptake miRNAs from the media contributing to differential concentration of 
circulating miRNAs. 
 The analysis across adipose models allowed as to identify miRNAs that display a 
pattern of expression in media consistent across adipose models, suggesting that their 
function is conserved in different species and therefore very important for the correct 
functioning of adipose tissue. These miRNAs were miR-196a-5p and miR-378a-3p. 
However, this does not imply that the remaining miRNAs tested do not play important 
roles in adipogenesis, adipocyte biology and in the cross talk between the adipose tissue 
and distal cells.  
 The inconsistency of miRNA expression across the different adipose models 
might be due to various reasons besides the intrinsic different nature of the different 
adipose models. Indeed, even though all the experiments were performed under the most 
similar controlled conditions as possible it is not possible to eliminate all the variables 
affecting the systems. Primarily, it has to be borne in mind that the protocols for inducing 
adipocyte differentiation differ in composition and the concentration of the compounds, 
as they are optimised specifically for each cell type. Compounds and their concentrations 
can have a strong impact on miRNA regulation and functioning. For example, it was 
observed that regulation of adipocyte differentiation by miR-378 via phosphodiesterase 
1B (PED1B) was masked by the use of IBMX in the differentiation media [282]. 
Additionally, miRNA expression can be influenced by cellular senescence and related 
molecular events. The same passage number might not correspond to the same grade of 
senescence between human and mouse cell lines. Despite that the cell lines were all used 
at early passages (12-26) their level of senescence is higher than primaries (used 
maximum at passage number 2). An example of an age-related miRNA is miR-10b, the 
expression of which was demonstrated to be upregulated during human foreskin 
fibroblast (HEK) senescence [356]. Therefore, we focussed on miR-196a-5p and miR-
378a-3p for target prediction and consideration of their potential impact on function in 
adipocytes, as their extracellular expression was consistent across the adipose models in 
spite of the variables potentially affecting miRNA expression. 
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   MiR-378a-3p  
 Our results, in accordance with the literature, showed that intracellular miR-378a-
3p was upregulated during adipocyte differentiation (figures 20, 26, 41 and table 15) [270, 
282, 357]. Indeed, miR-378a-3p was found to promote adipogenesis [357]. Interestingly, 
a study documented that ectopic expression of miR-378a-3p, in mice, promotes 
enlargement of interscapular BAT but not of WAT. In vitro experiments revealed that 
miR-378a-3p promotes differentiation of pre-existing brown pre-adipocytes by targeting 
Phosphodiesterase 1B (PDE1B) [282], an enzyme that controls cAMP turnover [358].  
The study pointed out that miR-378a-3p functions are likely to be tissue specific. As in 
our experiments, levels of miR-378a-3p were consistently greater in media from brown 
compared to white adipocytes, it is possible that this miRNA, besides promoting 
differentiation, is involved in the processes regulating BAT vascularization and ECM 
remodelling. Indeed, among its predicted targets there were VEGFA and Sulf1. BAT is a 
highly vascularized tissue and VEGFA involvement in BAT vascularization has been 
documented previously [302]. VEGFA expression is increased in differentiating 
immortalized brown adipocytes and induces cell proliferation of brown preadipocytes. In 
mice, neutralization of VEGFA by intravenous injection of an adenovirus expressing 
sFlt1 (a competitor of VEGFR that prevents VEGF signalling) provoked reduction of 
BAT vascularization density accompanied with tissue fibrosis, inflammation and 
adipocyte apoptosis. VEGFA was found to be regulated by multiple miRNAs amongst 
which there is miR-378a-5p, that originates from the opposite arm of miR-378a-3p. MiR-
378a-5p alone induced downregulation of VEGFA, while, when in combination with 
miR-125, VEGFA expression was increased [359]. Therefore, miR-378a-3p might take 
part in this competition for VEGFA. Additionally, as previously mentioned, miR-378a-
3p could participate to tissue remodelling by targeting Sulf1. This enzyme, by removing 
6-O-sulfate groups from heparan sulfate hampers VEGF binding to the receptor inhibiting 
activation of the signal cascade [264, 360, 361]. Therefore, secreted miR-378a-3p could 
have a paracrine and autocrine function in regulating VEGF signalling, either by 
controlling sulf1 transcription in recipient endothelial cells or by directly targeting 
VEGFA in neighbour cells, enhancing or inhibiting vascularization depending on 
eventual competitors such as miR-378a-5p and miR-125. In a different study miR-378a-
3p was found to prevent liver fibrosis by targeting Glioblastoma protein 3 (Gli3) in 
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activated hepatic stellate cells [362], supporting a role for miR-378a in shaping the 
extracellular matrix (ECM) and suggesting that adipose-derived circulating miR-378a-3p 
has a potential endocrine function. 
   MiR-196a-5p  
 As described in the introduction, miR-196a was found to promote a brown-like 
phenotype in white adipocyte progenitors by targeting the gene HOXC8 [302, 363-
367] which is known to be overexpressed in white versus brown adipocytes [368, 369]. 
The authors speculated that miR-196a is not involved in brown adipogenesis of 
classical brown preadipocytes, as its levels did not vary during brown adipocyte 
differentiation. In accordance with their results, in our experiments, miR-196a 
expression was upregulated in differentiating white adipocytes even in the absence of 
browning stimuli and was not detectable or showed very low expression in 
differentiated brown adipocytes (figure 20, 26, 41 and table 15). This suggests that 
sustained level of miR-196a predispose the white adipocytes to acquire brown 
characteristics upon determined stimuli but, are also required for the activation of the 
white fat program independently of the brown-like features. Upon CL treatment, 
intracellular miR-196a, at least in mouse primary adipocytes, was significantly 
upregulated, suggesting involvement in activation of oxidative program upon ß-
adrenergic stimuli in white adipocytes. Similar results were obtained in vivo and in 
vitro in Mori and colleagues’ study upon acute CL treatment/cold exposure [302]. 
Interestingly, the levels of secretion (table 14) of this miRNA were proportional to the 
intracellular level of expression at basal condition (table15). In contrast, upon ß-
adrenergic stimuli, intracellular miR-196a increased (table 17), while, extracellular 
levels were significantly reduced in white adipocytes (table 16). It is possible that at 
basal condition, miR-196a contributes to maintain the white differentiation status and 
excessive miR-196a is secreted in the extracellular environment to sustain the level of 
differentiation of surrounding adipocytes. Upon ß-adrenergic stimuli, secretion of 
miR-196a might be reduced in order to increase the intracellular levels of the miRNA 
and activate the brown program of already differentiated adipocytes, to provide a 
prompt response to the stimuli. Among the predicted targets of miR-196a there is 
HIF1a which may be important for the correct functioning of BAT. Indeed, BAT of 
transgenic mice expressing a dominant-negative form of HIF1α showed impaired 
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thermogenesis and energy expenditure and decreased angiogenesis [370]. The low levels 
of miR-196a observed in brown adipocytes may prevent HIF1α inhibition in BAT. In 
contrast, as previously described, HIF1α in white adipose tissue fails to trigger 
angiogenesis upon hypoxic stimuli and rather leads to fibrosis. In white adipocytes, 
where it is highly expressed, miR-196a, by inhibiting HIF-1α translation and therefore 
limiting the amount of the protein that can be in the active state during the hypoxic 
stimuli, could prevent fibrosis. Another predicted target of miR-196a is ADAM10. 
This metalloprotease is known to inhibit angiogenesis by modulating Notch signalling 
[136] and was found to be upregulated in obese mice and its silencing ameliorated insulin 
sensitivity [137]. A previous study showed that its deletion in endothelial cells causes 
defects in organ-specific vascular structures [371]. The effect of miR-196a secreted by 
white adipocytes on this enzyme in adipose-derived endothelial cells has not been 
explored and could provide additional information of the role of miR-196a in the white 
adipose tissue. This miRNA conferred resistance to obesity and improvement of glucose 
metabolism in mice [302]. TLR4 was a predicted target of miR-196a and its potential 
suppression induced by miR-196a could be one way through which this miR-196a 
protects against development of insulin resistance in obesity. However, also IKBA, was 
identified as a potential target of miR-196a. Therefore, whether miR-196a has a pro-
inflammatory or anti-inflammatory affect in obesity via repressing IKBA or TLR4 
expression respectively, should be addressed. 
   MiR-138-5p 
 Through the microRNA array performed on media samples from human 
adipocytes, we identified miR-138-5p as the unique miRNA significantly differentially 
secreted between brown and white adipocytes.  This was probably due to the large 
variability observed among the brown adipose sample, which reflects the high 
heterogeneity of the brown human adipocytes The higher the variation and error mean, 
the lower are the possibilities to reach statistical significance when comparing with the 
white adipocytes. As previously discussed, miR-138 might inhibit white adipocytes 
differentiation into brown-like phenotype by targeting EID1. EID1 was found to inhibit 
muscle differentiation [372, 373] while its ablation in ADMSC inhibited preadipocyte 
differentiation [304]. Taking part in the regulation of the cell cycle the effect of EID1 
on cell differentiation could vary depending on the cell type and on the stage of the 
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differentiation program. Therefore, at the early stages of differentiation the anti-
differentiation activity of miR-138 via EID1 inhibition in adipocytes may be 
suppressed by downregulating miR-138 expression. Conversely, at the late stages of 
differentiation, re-increased levels of miR-138 in white adipocytes, in the absence of 
browning stimuli, could help the cells to maintain a low metabolic activity, classic of 
the white adipocytes. This is supported by the results obtained upon administration of 
Isoproterenol (figure 42). Indeed, even though statistical significance was not reached, 
upon ß-adrenergic stimulation miR-138 expression was reduced IN WAT, perhaps, to 
counteract its beige-inhibitory effect, hence permitting the activation of oxidative 
pathways. Isoproterenol had no particularly evident effect on miR-138 expression in 
brown adipocytes, and probably the very low abundance of miR-138 is insufficient to 
inhibit the brown fat program. However, it would be interesting to perform a time 
course to verify how miR-138 is expressed during differentiation of brown and white 
adipocytes. MiR-138 overexpression in hAMSC from obese compared to lean mothers 
could contribute to impair the differentiation of these cells into adipocytes able to 
activate an appropriated oxidative program when required, as often observed in obesity 
[12]. In our study, intracellular and extracellular pattern of miR-138 expression at basal 
condition went in parallel in both brown and white adipocytes, with miR-138 more 
highly expressed in and secreted by white adipocytes compared to brown adipocytes. 
Conversely, upon ß-adrenergic stimulation, intracellular and extracellular levels of 
miR-138 were negatively correlated. However, statistical significance was not reached. 
Interestingly, among the targets predicted for miR-138, there were genes involved in 
the process of inflammation and associated with insulin-resistance such as SOCS3 and 
Interleukin 6 receptor (IL6R). As described in the introduction, these mediators of 
inflammation in obesity impair insulin signalling pathway. Hence, cells that are 
targeted by insulin and express low levels of miR-138 may be more prone to develop 
insulin resistance in an inflammatory environment. Circulating miR-138 was reported 
to be expressed at lower levels in the serum from obese subjects compared to lean [309, 
348], even though intracellular levels of miR-138 are likely to be elevated in adipocytes 
of obese subjects as showed by Nardelli, C., et al., [308]. Moreover, our study showed 
that in physiological conditions extracellular levels of miR-138 secreted by adipocytes 
are proportional to its intracellular levels. Therefore, it is possible that obesity affects 
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the ability of the adipocytes to secrete miR-138 levels sufficient to counteract 
inflammation and insulin resistance in peripheral tissues. Aaccording to this 
hypothesis, lower levels of circulating miR-138 should correspond to more severe 
insulin resistance. Conversely, in the same study, miR-138 was more highly expressed 
in peripheral blood from diabetic obese individuals compared to non-diabetic obese 
subjects. Another predicted target of mR-138 was Interleukin-1 receptor antagonist 
(IL1RA). This gene is translated into a protein that competes with IL-1α and IL-1ß for 
IL-1R and impeding their pro-inflammatory activity. IL-1 was found to inhibit GLUT4 
translocation to the plasma membrane in response to insulin, by indirectly reducing 
IRS expression [374]. In a hypothetical scenario, in obese subjects, where a certain 
grade of inflammation is already present and activated by different factors, a decreased 
expression of circulating miR-138 could sustain inflammation, due to reduced ability 
to inhibit IL-6 signalling pathway. At the same time, low levels of circulating miR-138 
may prevent inhibition of IL-RA resulting in a less severe insulin resistance. 
Nevertheless, further studies are required to clarify different points. Firstly, it would 
be interesting to verify how intracellular and extracellular miR-138 expression varies 
between adipocytes from different fat depots in obesity and physiological conditions. 
Indeed, data obtained from the analysis of serum samples do not allow determination 
of which is the major cell or tissue type secreting the miRNA of interest. Finally, to 
assess whether mR-138 could effectively induce inhibition of the predicted targets and 
determine its effect on the cells that are targeted by insulin and that can potentially 
take up circulating miR-138.   
   Effect of ß-adrenergic stimuli on miRNA secretion 
 Stimulation of ß-adrenergic receptors in adipocytes triggers a cascade that 
induces activation of the beta oxidative program and transcription of several factors that 
contribute to sustain the high metabolic activity of the cell over a prolonged period of 
time. As miRNAs regulate gene expression we sought to verify whether ß-adrenergic 
stimulation affects miRNA expression and secretion. The change of intracellular levels 
of miR-322/424 and miR-103 were very variable across the adipose models upon ß-
adrenergic stimuli, even between mouse primary cells and mouse cell lines. The 
remaining miRNAs, when detectable, were generally induced after ß-adrenergic stimuli 
in all cells except for human white adipocytes where Isoproterenol, either reduced 
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miRNA levels (miR-10b, miR-365 and miR-138) or did not affect miRNA expression 
compared to untreated samples (miR-196a). The significant increased expression of 
miR-10b in white adipocytes upon CL treatment, suggests potential involvement of this 
miRNA in mouse white adipocyte transdifferentiation into brite adipocytes. The fact 
that miR-10b was not induced in human white adipocytes by ß-Adrenergic stimuli, 
suggests that miRNAs involved in the browning of the white adipose process could be 
different between mouse and humans. In general, the great variability of miRNA release 
upon ß-adrenergic stimuli across the different adipose models and even between mouse 
primaries and mouse cell lines, suggests that the changes in extracellular miRNA levels 
observed are not a direct effect of ß-adrenergic receptor activation. Conversely, 
extracellular miR-196a was consistently downregulated in white adipocytes. Previous 
in vivo studies showed that miR-378 and some other miRNAs were not significantly 
affected by acute exposure to cold [282], while miR-196a was increased in BAT and 
WAT of mice treated for 5 hours with CL. All together these data suggest that, in general, 
acute ß-adrenergic stimulation partially affects miRNA intracellular expression, while its 
effect on miRNA secretion could represent the results of secondary factors occurring 
upon the treatment. The only exception in this study is represented by miR-196a for which 
both extracellular and intracellular levels of expression were consistently affected by ß-
adrenergic stimuli. Perhaps, greater effects for all miRNAs could be observed after a more 
prolonged stimulation which in white adipocytes would induce browning and in brown 
adipocytes would facilitate the cellular machinery to maintain high levels of ß-oxidation. 
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4  Chapter 4 – Results                    
MiRNA secretion by adipocytes into 
vesicle and vesicle-free systems 
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4.1   MiRNAs are depleted from conditioned media by ultracentrifugation and are 
detected in the ultracentrifuged pellet  
  MiRNAs have been found in several biological fluids incorporated into 
vesicles [188] and/or associated with vesicle-free systems such as Ago2 protein [375]. 
Ultracentrifugation is a technique widely employed to isolate vesicles from various types 
of fluidic sources [376]. To understand whether miRNAs secreted by adipocytes are 
encapsulated into vesicles and could be depleted from media by ultracentrifugation, 
miRNA content in serum-free conditioned media from differentiated brown adipocytes 
was analysed before and after ultracentrifugation at 120,000xg for 2 hours. The same 
number of differentiated cells was seeded for each biological replicate and kept in serum 
free media for 5 hours. Conditioned media was collected and processed in parallel with 
unconditioned media for miRNA analysis by Real Time qPCR. Figure 43 shows miRNA 
abundance (2-ΔCt values) before and after vesicle depletion from the media. All miRNAs 
investigated were detected at lower levels in the supernatant after vesicle isolation. In 
particular, ultracentrifugation was able to significantly deplete 44.6% of miR-196a, 
41.85% of miR-322 and 19.5% of miR-378 from the media. As expected no miRNAs 
were detectable in unconditioned media. 
 The pellet obtained by the ultracentrifugation was resuspended in 2.5 ml of 
unconditioned media and tested for miRNA content as well. As reported in figure 44 all 
miRNAs were present in the pellet from conditioned media, at relatively high level, while, 
no miRNAs were detectable in the pellet from unconditioned media. Because the pellet 
is obtained by concentrating the vesicles contained in the media, miRNA levels in the two 
types of samples are not directly comparable. However, miRNA presence in the pellet 
and depletion from supernatant suggest that all the microRNAs tested are at least partially 
encapsulated into vesicles and in part associated with vesicle-free systems. 
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Figure 43 MiRNAs are depleted from conditioned media by ultracentrifugation.  
The graphs show miRNA abundance before and after ultracentrifugation of serum free unconditioned and 
conditioned media samples from differentiated brown adipocytes. The same number of cells was seeded 
for each biological replicate. MiRNA levels were normalized to Unisp6 spiked in just prior to RNA 
extraction. Bars express the miRNA mean ± SEM of 2-ΔCt values of the biological triplicates. Student’s t-
test was used to assess significance with cut-off of p-value<0.05(*). ** indicates p<0.01. 
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Figure 44 MiRNAs detected in the pellet of ultracentrifuged media.  
The graphs show 2-ΔCt values (mean of biological triplicates) of miRNAs in pellets obtained from 
unconditioned and conditioned media incubated with brown adipocyte for 5 hours. MiRNA levels were 
normalized to Unisp6 spiked in immediately prior to RNA extraction. 
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   ß3-adrenergic activation affects the level of miRNA depletion in ultracentrifuged 
conditioned media 
 To investigate whether ß3-adrenergic activation has an effect on miRNA secretion 
via incorporation into vesicles or in association with vesicle-free systems, miRNA content 
in serum-free media from differentiated brown adipocytes treated with CL (10 µM) for 5 
hours was analysed before and after ultracentrifugation. The percentage of miRNA 
depletion observed in untreated and CL treated samples are summarized in table 19. The 
first column of the table shows increment (­) or decrement (¯) of total miRNA in media 
from BAT treated with CL compared to untreated from previous experiment (paragraph 
4.1). Consistent with previous results, all the miRNAs were detected in the pellet (figure 
46) and at least partially depleted from the media (figure 45). Little variations in the 
percentage of miRNA depletion were observed between CL-treated and untreated 
samples for miR-196a, miR-322 and miR-103. In contrast, miR-378 depletion from 
19.5% in untreated samples became 42.83% in CL-treated, similar to that observed for 
miR-10b. In untreated brown adipocytes, 48% of miR-365 was depleted after 
centrifugation while its depletion in treated cells was only of 9.9%. These results suggest 
that CL favours miR-378 and miR-10b secretion via incorporation into vesicles while it 
promotes miR-365 release in association with vesicle-free systems.  
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Figure 45 Treatment with CL affects the level of miRNA depletion in ultracentrifuged conditioned 
media  
The graphs show miRNA abundance before and after ultracentrifugation of serum free unconditioned and 
conditioned media samples from differentiated interscapular brown adipocytes treated for 5 hours with CL 
(10µM). The same number of cells were seeded for each biological replicate. MiRNA levels were 
normalized to Unisp6 spiked in immediately prior to RNA extraction. Bars express the miRNA mean ± 
SEM of 2-ΔCt values of the biological triplicates. Student’s t-test was used to assess significance with cut-
off of p-value<0.05(*).  
175 
 
Table 18 Percentage of miRNA depletion after ultracentrifugation of media from differentiated 
brown adipocytes untreated and treated with CL. 
Tot miRNA 
CLvsC 
miRName 
UNTREATED CL TREATED 
% depletion SEM % depletion SEM 
   ­2* miR-196a 44.60 ± 8.70 34.37 ± 48.9 
¯ miR-10b 18.60 ± 38.70 45.74 ± 35.0 
   ¯2* miR-103 36.23 ± 75.39 40.41 ± 25.5 
   ­* miR-322 41.85 ± 8.00 32.95 ± 23.9 
 ­ miR-378 19.50 ± 4.40 42.83 ± 21.4 
 ­ miR-365 48.50 ± 30.00 9.90 ± 25.0 
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Figure 46 MiRNAs detected in the pellet of ultracentrifuged media from CL-treated adipocytes.  
The graphics show 2-ΔCt values (mean of biological triplicates) of miRNAs in pellet obtained from 
unconditioned and conditioned media from brown adipocyte treated with CL for 5 hours (B). MiRNA levels 
were normalized to Unisp6 spiked in just prior RNA extraction 
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   Nanoparticle characterization 
 To investigate the nanoparticles secreted by adipocytes, media samples from 
mouse and human differentiated white and brown adipocyte cell lines were analysed 
through NanoSight technology. This system detects particles suspended in fluids 
determining their concentration and profiling their size distribution. To perform the 
experiment, an equal number of cells was seeded into each T-175 flask and incubated for 
3 days in serum-free media. However, cell density visibly decreased at day 3, probably 
due to long time incubation in serum-free condition. Therefore, cells were counted and 
data normalised to cell count so that the graphs show size distribution (figure 47 and 48 
left panels) and concentration (figure 47 and 48 right panels) of particles/ml secreted by 
1x107 cells. Media samples were collected and processed. As the samples were analysed 
at the University of Cardiff, the first steps of sample preparation (serial centrifugation and 
filtration) were performed prior to freezing at -80 °C, to avoid large particle breakdown 
into smaller particles and therefore false positive results. Media samples were then 
analysed using NanoSight technology. As shown in the right panel of figure 47, non-
conditioned media had a concentration of 1.6 (± 0.8) x108 particles per ml. As the media 
from brown and white adipocytes had a significantly higher concentration of 
nanoparticles per ml, 1.15 (± 0.5) x 1012 and 1.37 (± 0.3) x 1012 respectively, it is possible 
to conclude that nanoparticles in conditioned media originated from adipocytes. The 
analysis revealed that there were no significant differences between white and brown 
adipocytes and that the majority of the nanoparticles had a size of 100 nm. This suggests 
that a large proportion of the vesicles secreted by adipocytes consist of exosomes, which 
are sized 50-200 nm. The different type of vesicles such as microvesicles and exosomes, 
differ not only in size but also in chemical composition. Exosomes are known to express 
on their membrane surface the tetraspanins CD9, CD81 and CD63, which have been 
established as exosomes markers [377, 378]. To characterize the composition of the 
vesicles analysed by nanosight and confirm that adipocytes secrete exosomes, the 
conditioned media from mouse and human adipocytes was ultracentrifuged at 120,000xg 
for 2 hours to isolate vesicles. The supernatant was discarded, the pellet resuspended in 
2.5 ml of PBS and analysed for exosome marker detection through Europium-based 
ELISA-like assay. As reported in figure 47, bottom panel, mouse vesicles were positive 
for CD9, CD81 and CD63 tetraspanins. CD63 was expressed only in BAT. However, no 
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statistical analysis was performed on these data as the replicate number was lower than 
3. 
 
 
Figure 47 Mouse adipocytes secret exosome-like nanoparticles. 
Media samples were collected after 3 days from mouse differentiated brown and white adipocyte cell lines. 
The analysis was performed at the Velindre Centre, University of Cardiff, with the assistance of Dr J. 
Webber. (A) Nanosight analysis of non-conditioned and conditioned media samples from differentiated 
brown and white adipocytes was adjusted for dilutions adopted when loading the samples. Left panel shows 
size distribution of nanoparticles. The curves represent the mean trend lines (period 11) of the 3 biological 
replicates of conditioned media samples for each group. The right panel shows mean concentration of 
nanoparticles and relative SEM. (B) Europium based ELISA-like assay. The graphic shows the mean 
fluorescence intensity for the exosomes markers (CD9, CD81 and CD63) on the surface of the nanoparticles 
isolated from the conditioned media samples normalised to the unconditioned media and non-specific 
signals for primary and secondary antibodies. 
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 Concentration and size profiling of vesicles secreted by human adipocytes, 
through Nanosight analysis, revealed that, also in this case, particle concentration in 
conditioned media was significantly higher than in non-conditioned medium and very 
similar between BAT and WAT, with 2.1 (± 0.2) x1010 and 1.8 (± 0.4) x1010 particles per 
ml respectively (figure 48, right panel). However, a different profile of particle size 
distribution between human BAT and WAT was observed. BAT presented a high 
concentration of particles with a diameter of about 100 nm as shown by the sharp peak of 
the curve in figure 48 top left panel, while WAT is represented by the curve with a 
smoother peak in the range of 100 and 250 nm which reflects a higher heterogeneity in 
the vesicle population.  
 When analysed for the exosome markers expression through the Europium-based 
ELISA-like assay, the isolated vesicles from both human brown and white adipocytes 
were positive for CD9, CD63 and CD81 and showed a similar trend of expression, even 
if the replicates were less than 3 and no statistical analysis were performed (figure 48 
bottom panel).  
 In conclusion, all these results suggest that both mouse and human adipocytes 
secrete nanoparticles and that a large part of these may consist of exosomes. 
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Figure 48 Human adipocytes secret exosome-like nanoparticles.  
Media samples were collected after 3 days from mouse differentiated brown and white adipocyte cell lines. 
The analysis was performed at the Velindre Centre, University of Cardiff, with the assistance of Dr J. 
Webber. (A) Nanosight analysis of non-conditioned and conditioned media samples from differentiated 
brown and white adipocytes. Left panel shows size distribution of nanoparticles. The curves represent the 
mean trend lines (grade 11) of the 3 biological replicates of conditioned media samples for each group. The 
right panel shows mean concentration of nanoparticles and relative SEM. (B) Europium based ELISA-like 
assay. The graph shows the mean fluorescence intensity for the exosomes markers (CD9, CD81 and CD63) 
on the surface of the nanoparticles isolated from the conditioned media samples normalised to the 
unconditioned media and non-specific signals for primary and secondary antibodies. 
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4.2   Discussion 
 Different studies have shown that adipocytes release exosomes and miRNAs 
were found to be incorporated in these vesicles. Thomau T., and colleagues recently 
showed that adipose tissue is the major source of exosomal circulating miRNAs, which 
are capable of gene expression regulation in distal organs [261]. The advantages and 
disadvantages of the different miRNA carriers are still not fully understood. Exosomes 
have attracted the majority of scientists’ attention over the other classes of miRNA 
carriers. Aiming to understand whether different adipose-derived miRNAs are 
preferentially incorporated into vesicles or associated to vesicle-free systems, we found 
out that all extracellular miRNAs tested, were in part incorporated into vesicles and in 
part associated to vesicle-free systems. In detail, our data suggest that adipose-derived 
miR-196a and miR-322 are almost equally distributed between vesicles and vesicle 
free-system, whereas miR-378a-3p is preferentially associated to vesicle-free systems. 
As the remaining miRNAs presented a large variation, it is not possible to establish their 
preferential way of secretion. However, miR-10b showed a similar percentage of 
depletion to miR-378a-3p, while miR-365 and miR-103 a similar trend to miR-196a 
and miR-322. As vesicles may provide a higher level of protection to the incorporated 
miRNAs to travel long distances, and a more specificity of target delivery, we speculate 
that miR-196a and miR-322 have a major chance to function as both endocrine and 
paracrine/autocrine miRNAs, while miR-378 might have a predominant 
paracrine/autocrine function. However, the knowledge on the properties of vesicle-free 
systems in these terms is still too poor to draw conclusions confidently. 
As all miRNAs were secreted both via association to vesicle free systems and 
incorporation into vesicle, we aimed to understand whether ß-adrenergic stimuli favours 
one type of carrier for miRNA release over the other. Our results suggest that CL 
treatment favours incorporation of miR-378 and miR-10b into vesicles as the percentage 
of their depletion after ultracentrifugation was higher than in untreated samples. 
Conversely, a greater percentage of miR-365 was associated to vesicle free systems in 
media from CL treated samples compared to untreated. No particularly evident effects 
were observed for the remaining miRNAs. The preferential way of miRNA secretion 
through one type of carrier over another might implicate the necessity of a miRNA to 
preferentially reach a different cellular target and this aspect should be investigated.  
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   Vesicle characterization 
 As previous studies have reported that adipose tissues secrete exosomes [261, 
379] we characterised the vesicles isolated by ultracentracentrifugation of media samples 
from brown and white adipocytes. We confirmed that a large part of these vesicles 
consisted of exosomes as they had exosome-like size (~200 nm) and were positive for at 
least two of the three exosome markers tested (CD9, CD63, CD81) even though we could 
not perform statistical analysis on the expression of the different tetraspanins between 
brown and white adipocytes. Our results showed that vesicle from brown and white 
adipocytes present similar characteristics even though human white adipocytes secrete a 
more heterogeneous population of vesicles.  
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5  Chapter 5 – Results                       
Gene and miRNA expression in 
human brown and white adipocytes 
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5.1   MicroRNA array, mRNA sequencing and integrative analysis 
 The nature of the brown adipocyte in humans is not as much understood as in 
mice, primarily because of the scarce availability of human brown adipose tissue samples 
and the high heterogeneity of the tissue. Once the human cell lines used in this study were 
characterized, we proceeded to use Next Generation Sequencing technology (mRNA 
sequencing) to explore the differences in gene expression between differentiated brown 
and white adipocytes. In addition, to identify intracellular miRNAs differentially 
expressed between brown and white adipocytes we performed a microRNA array. To 
investigate the potential role in adipogenesis and adipose metabolism of the identified 
differentially expressed miRNAs we performed miRNA target prediction through 
bioinformatics tools and integrated the data from mRNA sequencing and miRNA array 
analyses as described in the following paragraphs. Both types of analysis were performed 
on the same RNA samples and data analysis was carried out with the assistance of Dr 
Mohammad Tauqeer Alam (University of Warwick).  
 First, we examined variation among samples. In figure 49 are reported the PCA 
plots performed on mRNA sequencing (Panel A) and miRNA array (Panel B) data. As 
shown in the graphs, in both cases, where PC1 explains the largest variation, the samples 
clustered similarly so that brown adipocytes grouped on the left side and the white on the 
right side. This is a preliminary indicator of the fact that brown and white adipocytes have 
clearly different gene and miRNA expression profiles, reflecting the different biological 
nature of the samples. PC2 explains the 2.32% and 15% of the variation among samples 
for mRNA sequencing and miRNA array data respectively, which might be due to 
secondary factors such as quality of RNA. In conclusion, the PCAs revealed the high 
quality of the data obtained by the mRNA sequencing and miRNA array analyses, so that 
all samples could be included for statistical and integrative data analysis. 
 
185 
 
 
Figure 49 PCA plots in miRNA array and mRNA sequencing analysis. 
A) PCA plot for brown and white adipocytes on the basis of mRNA sequencing read count data. The PCA 
was performed on all samples and all genes. PC1 explains 94.78% of the variation and PC2 explains 2.32% 
of the variation.  (B) PCA performed on all samples and all miRNAs data. PC1 explains 62% of the 
variations and PC2 explains 15% of the variation. 
   mRNA sequencing 
 mRNA sequencing technology targets all polyadenylated (poly-A) transcripts of 
the transcriptome and allows identification of either known or unknown genes and their 
eventual novel splicing isoforms expressed in the system analysed. For the purpose of 
this study we compared gene expression of known genes between human mature brown 
and white adipocytes. Significance was assessed using Student’s t-test and Benjamini-
Hochberg correction. The graph in figure 50 was obtained by plotting the log2 (fold 
change) (brown versus white) on the abscissa and –log10 (adjusted p value) on the 
ordinate. Genes presenting a log2 (fold change) lower than -1 and higher than +1 with an 
adjusted p value lower or equal to 0.05 were considered significantly differentially 
expressed. This way, we identified 2463 genes upregulated and 1733 genes 
downregulated in brown adipocytes compared to white. 
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Figure 50 Genes differentially expressed between brown and white adipocytes.  
Volcano plot showing the relationship between the p-values and the log2 (fold change) in RNA sequencing 
read count data of brown with reference to white adipocytes. Up means upregulated, dn means 
downregulated. 
   KEGG enrichment in brown and white adipocytes 
 We performed hypergeometric test to explore KEGG enrichment in brown versus 
white adipocytes. We identified 110 pathways (p values ≤ 0.05) associated with 
differentially expressed genes between brown and white adipocytes, of which 71 were 
enriched in brown and 45 in white adipocytes (Figure 51). The top 7 pathways (p value ≤ 
1x10-8) associated with upregulated genes (log2 (fold change) ≥ 1, p value ≤ 0.05) in 
brown adipocytes were: fatty acid degradation, biosynthesis of unsaturated fatty acids, 
propanoate metabolism, citrate cycle, pyruvate metabolism, valine leucine and isoleucine 
degradation and PPAR signalling. All these pathways are known to be involved in the 
main function that distinguishes the brown from the white adipocytes being energy 
consumption. Indeed, BAT degrades fatty acids to use them as the main source of energy 
for heat production [77]. Moreover, polyunsatured fatty acids have been found to activate 
UCP1 more efficiently than saturated fatty acids [380]. This would justify the high 
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expression of genes involved in biosynthesis pathway of unsaturated fatty acids. As 
expected, pathways related to oxidative phosphorylation, insulin signalling and many 
others were also enriched in brown adipocytes. Indeed, BAT is known to regulate glucose 
homeostasis and insulin sensitivity [381]. Some other pathways may seem less obviously 
expected to be differentially enriched between the adipocyte cell types. For example, 
Huntington disease is associated with high energy expenditure and weight loss [382] and 
white adipose tissue of HD mice presents brown-like feature such as a high level of UCP1 
[383] which would explain why the HD pathway was enriched in brown adipocytes. 
Many of the pathways found to be associated with the genes upregulated in white 
adipocytes are involved in cancer and inflammation including the top 4 ones: TNFα 
signalling pathway, proteoglycans in cancer, cytokine-cytokine receptor interaction and 
NOD-like receptors signalling. Indeed, obesity is generally characterized by low-grade 
chronic inflammation in white adipose depots and increases the risk of cancer (reviewed 
in [384] and [385]) as well as the chances to develop T2D [386]. In conclusion, these 
results reflected the biological nature of the brown and white adipocytes and could be 
used in further investigation of the differences between brown and white adipocytes. For 
the purpose of this study, we investigated the potential role of miRNAs in the pathways 
identified in this analysis as described in paragraph 5.4.  
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Figure 51 KEGG enrichment pheatmap.  
The map shows KEGG pathways associated with genes upregulated (green) and downregulated (red) in 
brown versus white adipocytes obtained by hypergeometric test. Ranges of p value for each pathways are 
indicated by the colour scales.  
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   MiRNA array 
 The heat map diagram (figure 52 panel A) shows the result of a two-way 
hierarchical clustering of all miRNAs and samples. The clustering was obtained using the 
complete-linkage method together with the Euclidean distance measure. Rows represent 
the different miRNAs and each column represents a sample. The clustering tree is shown 
on the left. For the relative miRNA expression level of each sample a different colour of 
the red-green scale is assigned. Red represents an expression level below the mean, green 
colour represents expression above the mean. The heat map reports only the top 50 
miRNAs presenting the highest standard deviation, whereas the volcano plot (figure 52 
panel B) reports all miRNAs tested. The thirty-three miRNAs with a log2 (fold change) 
≤ -1, represented by the orange spots on the left side of the volcano plot, are significantly 
(adjusted p value ≤ 0.05) downregulated in brown compared to white adipocytes. The 
twenty green spots on the opposite side in the graphic represent the miRNAs upregulated 
in brown adipocytes relative to white. In tables 20 and 21 the log2 fold change values and 
the adjusted p values (adj.P.Value) are reported for the miRNAs upregulated and 
downregulated in brown adipocytes compared to white respectively. As expected, miR-
196a-5p was among the miRNAs upregulated in white adipocytes. The top 5 miRNAs 
upregulated in brown adipocytes versus white were: miR-143-3p, the members of the 
miR-378 family (e, d and f) and miR-4511. The top 5 miRNA downregulated in brown 
adipocytes were: miR-181a-2-3p, miR-3202, miR-4306, miR-4516 and miR-4644. 
However, all the miRNAs identified as differentially expressed between brown and white 
adipocytes were included in the integrative study between the miRNA array and mRNA 
sequencing.  
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Figure 52 Differential miRNA expression in brown versus white adipocytes.  
A) Heat Map performed on all samples and on the top 50 miRNAs with highest standard deviation using 
the normalized log ratio values for the analysis. B) Volcano plot showing the relation between the logarithm 
of the adjusted p-values and the log2 fold change between brown and white of all the miRNAs. 
 
   Integration of data from miRNA array and mRNA sequencing analyses  
 MiRNAs regulate gene expression either by promoting mRNA target degradation 
or by inhibiting mRNA translation into protein [177]. In the first case, assuming that there 
are no other factors interfering with this process, the increase of a miRNA expression 
should correspond to decreased expression of its mRNA targets. Therefore, if a miRNA 
was found to be upregulated in brown versus white adipocytes, its mRNA targets are 
expected to be lower expressed in brown adipocytes compared to white. Based on this 
principle, we investigated the potential role of miRNAs in the regulation of the pathways 
identified through the mRNA sequencing analysis. First we predicted the potential 
miRNA targets using bioinformatics tools. Next, we verified the relative level of 
expression of these genes, based on the results obtained through the mRNA sequencing 
analysis. For miRNAs downregulated in brown adipocytes, only the predicted targets that 
were upregulated and associated with pathways enriched in brown adipocytes were 
considered and vice versa. In figure 53 the log2 (fold change) of the differentially 
expressed miRNAs is represented by the blue-pink colour scale. The green colour scale 
represents the pathways associated with the genes upregulated in brown versus white 
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adipocytes, while, the orange scale represents the ones associated with the genes 
downregulated in brown adipocytes. Each different shade represents a specific range of p 
value of the pathways as shown in the legend. In the squares are reported the numbers of 
the target genes involved in the pathways with a p value exemplified by the colour of the 
square. In the tables below, are listed the genes upregulated (tables 22-25) and 
downregulated (tables 26-28) in brown versus white and the pathways in which they are 
involved. Tables are arranged per range of p values of the pathways. As a single gene can 
take part in a very high number of pathways, for each gene were reported only the ones 
falling in the lowest p value range. The log 2 (fold change) and p value of the gene are 
annotated in the third and fourth column, respectively. In the first column all the miRNAs 
which were predicted to target the gene are listed. However, data were rearranged in 
tables 20 and 21 to provide an easier visualization of the most relevant pathways in which 
the identified miRNAs are likely to be involved. For each miRNA only the target genes 
associated with the pathways falling in the lowest p value range are reported. As shown 
in figure 53, among all the miRNAs upregulated in brown adipocytes, miR-513a-5p was 
predicted to target the largest number of genes (9) downregulated in brown adipocytes 
and involved in the pathways falling in the lower p value range. Eight of its targets were 
associated with proteoglycans in cancer pathway. In the remaining pathways associated 
with significantly downregulated genes in brown adipocytes it was found to potentially 
target a total of 15 genes. Thirteen more targets were associated with the pathways 
presenting a p value out of the range of significance. MiR-513a-5p, miR-4511 and miR-
4328 showed the highest number of targets involved in the pathways associated with 
downregulated genes in brown adipocytes and presenting a p value in the range of 
significance. Among these, the most significant ones were: cytokine-cytokine receptor 
interaction, proteoglycans in cancer and NOD-like receptor signalling pathways. The 
miRNAs downregulated in brown adipocytes targeting two or more downregulated genes 
involved in the most statistically significant pathways (p value) ≤ 1x10-8) were miR-4698, 
miR-4306 miR-4531, miR-4644, miR-4516 and miR-4306. To our knowledge, none of 
these miRNAs has been documented in the literature as involved in adipocyte biology. 
MiR-29a-3p was predicted to target the highest number of genes suggesting an important 
role in regulating adipogenesis and  
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Figure 53 Integration of miRNA array and mRNA sequencing data.  
The map shows for each miRNA, identified by the miRNA array analysis, the number of predicted targets 
belonging to the pathways associated with the genes differentially expressed between brown and white 
adipocytes. The p value range of the pathways is expressed by the green (for pathways enriched in brown 
adipocytes) and orange (for pathways enriched in white adipocytes) colour scales. Log2 (fold change) range 
of miRNA (brown versus white) is represented by the blue-pink color scale.  
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metabolism in white adipocytes. Here we identified PPARGC1α among its predicted 
targets. Direct regulation of this important brown adipocyte coregulator by miR-29a-3p, 
to our knowledge, has not been demonstrated or documented in the literature.For some 
miRNAs only few or no targets among the ones predicted by the bioinformatics tools and 
eventually involved in the pathways identified, were found to be differentially expressed 
in brown versus white adipocytes. This does not imply that they have a less important or 
no role in adipocyte biology, but it rather suggests that they might regulate gene 
expression without inducing mRNA target degradation. Among them miR-181a-2-3p was 
the most downregulated miRNA in brown compared to white adipocytes. Surprisingly, 
for this miRNA no targets at all were predicted by the algorithms used in this study. 
 
Table 19 miRNAs upregulated in brown vs white adipocytes, their predicted targets 
and enriched pathways 
 
miRNA up miRNA Log2(FC) 
miRNA 
adj.P.Val 
Target 
down Kegg name  
KEGG 
pVal range 
miR-143-3p 1.746 1.46E-08 
PTGS2 TNF signaling pathway 
p ≤1x10-8 
PLAUR Proteoglycans in cancer 
ITPR1 
NOD-like receptor signaling 
pathway 
Proteoglycans in cancer 
miR-378e 1.546 1.46E-08 
IGF1R Proteoglycans in cancer p≤1x10-8 
BMP2 Cytokine-cytokine receptor interaction p≤1x10
-8 
miR-378d 1.543 1.89E-08 
IGF1R Proteoglycans in cancer p≤1x10-8 
BMP2 Cytokine-cytokine receptor interaction p≤1x10
-8 
miR-378f 1.532 1.46E-08 
IGF1R Proteoglycans in cancer p≤1x10-8 
BMP3 Cytokine-cytokine receptor interaction p≤1x10
-8 
miR-4511 1.502 3.82E-08 
CXCL16 Cytokine-cytokine receptor interaction p≤1x10
-8 
TIAM1 
NRAS Proteoglycans in cancer p≤1x10
-8 
OAS3 
XIAP 
NOD-like receptor signaling 
pathway p≤1x10
-8 
miR-378a-3p 1.464 1.46E-08 IGF1R Proteoglycans in cancer p≤1x10-8 
miR-378g 1.448 7.22E-08 ELK1 Proteoglycans in cancer p≤1x10-8 
miR-378c 1.417 1.52E-08 
IGF1R Proteoglycans in cancer p≤1x10-8 
BMP2 Cytokine-cytokine receptor interaction p≤1x10
-8 
miR-4328 1.412 1.48E-07 
WNT5A 
NRAS Proteoglycans in cancer p≤1x10
-8 
PDGFA Cytokine-cytokine receptor interaction p≤1x10
-8 
DAB2IP TNF signaling pathway p≤1x10-8 
miR-378b 1.344 3.82E-08 
IGF1R Proteoglycans in cancer p≤1x10-8 
BMP2 Cytokine-cytokine receptor interaction p≤1x10
-8 
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Continuing table 20 
miRNA up miRNA Log2(FC) 
miRNA 
adj.P.Val 
Target 
down Kegg name  
KEGG 
pVal range 
miR-145-5p 1.302 6.41E-07 
IGF1R 
PXN 
NRAS 
Proteoglycans in cancer p≤1x10-8 
FLT1 Cytokine-cytokine receptor interaction p≤1x10
-8 
miR-378i 1.301 1.13E-07 
IGF1R 
PXN 
NRAS 
Proteoglycans in cancer p≤1x10-8 
BMP3 Cytokine-cytokine receptor interaction p≤1x10
-8 
miR-136-5p 1.213 1.55E-05 ELK1 Proteoglycans in cancer p≤1x10-8 
miR-33b-5p 1.183 1.30E-05 RUNX1T1 Pathways in cancer Transcriptional misregulation in cancer 1x10
-4≤ p ≤1x10-6 
miR-378a-5p 1.174 2.05E-06 NFATC2 
Axon guidance, Hepatitis B, 
HTLV-I infection Osteoclast 
differentiation 
01x10-2≤ p ≤1x10-4 
miR-378h 1.094 7.67E-06 
IGF1R Proteoglycans in cancer p≤1x10-8 
BMP2 Cytokine-cytokine receptor interaction p≤1x10
-8 
miR-30e-5p 1.071 3.32E-06 JARID2 Signaling pathways regulating pluripotency of stem cells 01x10
-4≤ p ≤1x10-6 
miR-513a-5p 1.042 9.80E-07 
CD44 
ITGA2 
HBEGF, 
CAMK2A 
XIAP 
PXN 
NRAS 
Proteoglycans in cancer p≤1x10-8 
PIK3CD TNF signaling pathway, Proteoglycans in cancer p≤1x10-8 
ANTXR2 NOD-like receptor signaling pathway 
miR-642a-5p 1.008 2.92E-07  No targets - - 
Table 20 miRNAs downregulated in brown vs white adipocytes, their predicted targets and enriched 
pathways 
miRName down miRNA Log2(FC) 
miRNA 
adj.P.Val  Target up KEGG name (enriched in brown) KEGG pVal range 
miR-4726-5p -1.001 3.01E-07 
PDE1B Huntington's disease, Renin secretion 
1x10-4≤ p ≤1x10-6 PKIA Tryptophan metabolism 
DAG1 Dilated cardiomyopathy 
PDGFRB Calcium signaling pathway 
miR-4698 -1.013 7.54E-07 
SCD Biosynthesis of unsaturated fatty acids 
p≤1x10-8 
ME1 Pyruvate metabolism 
SORBS1 PPAR signalling pathway 
BCAT2 Valine, leucine and isoleucine degradation 
miR-10a-3p -1.022 1.77E-07 PLCB1 
Aldosterone synthesis and secretion, 
Adrenergic signaling in 
cardiomyocytes Vascular smooth 
muscle contraction 
1x10-6≤ p ≤1x10-8 
miR-221-3p -1.046 5.55E-07 
PPARGC1A Huntington's disease, Glucagone signaling pathway  1x10-4≤ p ≤1x10-6 
MAPK10 cAMP signaling pathway, Huntington disease 
miR-711 -1.096 7.54E-07 COL4A5 Protein digestion and absorption 1x10-4≤ p ≤1x10-6 
miR-3611 -1.098 6.01E-07 BDH1 Butanoate metabolism 1x10-6≤ p ≤1x10-8 
miR-5584-5p -1.100 1.75E-07 ADCY6 
Aldosterone synthesis and secretion, 
Adrenergic signaling in 
cardiomyocytes, Vascular smooth 
muscle contraction 
1x10-6≤ p ≤1x10-8 
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Continuing table 21 
miRName down miRNA Log2(FC) 
miRNA 
adj.P.Val  Target up KEGG name (enriched in brown) KEGG pVal range 
miR-146b-5p -1.101 3.70E-07 BCAT2 Valine, leucine and isoleucine degradation p≤1x10
-8 
miR-1253 -1.114 2.43E-06 HSD17B12 Biosynthesis of unsaturated fatty acids p≤1x10
-8 
miR-483-5p -1.139 2.78E-07 No targets - - 
miR-1261 -1.155 2.04E-04 CALM3 
Aldosterone synthesis and secretion, 
Adrenergic signaling in 
cardiomyocytes, Vascular smooth 
muscle contraction 
1x10-6≤ p ≤1x10-8 
miR-3178 -1.172 4.36E-07 No targets - 1x10-6≤ p ≤1x10-8 
miR-29a-3p -1.184 7.22E-08 LPL PPAR signalling pathway p≤1x10-8 
    miR-146a-5p -1.189 9.15E-08 No targets - - 
miR-3201 -1.199 1.48E-07 No targets - - 
miR-222-5p -1.210 4.06E-07 No targets  - - 
miR-3915 -1.259 3.82E-08 ADIPOQ PPAR signalling pathway p≤1x10-8 
miR-196a-5p -1.299 1.21E-06 CALM3 
Aldosterone synthesis and secretion, 
Adrenergic signaling in 
cardiomyocytes, Vascular smooth 
muscle contraction 
1x10-6≤ p ≤1x10-8 
miR-4531 -1.328 1.70E-07 
FADS2 Biosynthesis of unsaturated fatty acids p≤1x10-8 
ACOX1 Fatty acid degradation, Biosynthesis of unsaturated fatty acids 
miR-204-3p -1.349 1.96E-06 
KCNE3 Protein digestion and absorption 
01x10-4≤ p ≤1x10-6 
RPS6KA1 Oocyte meiosis 
miR-4484 -1.372 5.71E-08 
DAG1 Dilated cardiomyopathy 01x10-4≤ p ≤1x10-6 
miR-4778-5p -1.457 5.33E-08 
miR-222-3p -1.458 7.51E-08 
PPARGC1A Huntington's disease, Glucagone signaling pathway  01x10-4≤ p ≤1x10-6 
MAPK10 cAMP signaling pathway, Huntington disease 
miR-4644 -1.470 6.38E-08 
BCAT2 Valine, leucine and isoleucine degradation p≤1x10-8 
TECR Biosynthesis of unsaturated fatty acids 
miR-4436b-3p -1.479 1.46E-08 
CALM1, 
CALM3 
Aldosterone synthesis and secretion, 
Adrenergic signaling in 
cardiomyocytes, Vascular smooth 
muscle contraction 
1x10-6≤ p ≤1x10-8 
ATP1B1 Adrenergic signaling in cardiomyocytes 1x10
-6≤ p ≤1x10-8 
miR-4516 -1.506 4.71E-08 
ACOX1 Fatty acid degradation, Biosynthesis of unsaturated fatty acids p≤1x10-8 
FADS2 Biosynthesis of unsaturated fatty acids 
miR-4306 -1.574 4.71E-08 
SCD Biosynthesis of unsaturated fatty acids p≤1x10-8 
BCAT2 Valine, leucine and isoleucine degradation 
miR-3202 -1.751 5.33E-08 RXRG PPAR signalling pathway p≤1x10-8 
miR-181a-2-3p -1.806 4.01E-07 No targets - - 
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Table 21 KEGG pathways enriched in brown versus white adipocytes with p value ≤1x10-8 
miRName 
down 
 
Target 
up  Log2(FC)  Adj.pval KEGG name (p value ≤1x10
-8) 
miR-3915 ADIPOQ 4.16 9.20E-139 PPAR signalling pathway 
miR-4306 
miR-4698 SCD 2.68 3.35E-112 Biosynthesis of unsaturated fatty acids 
miR-4698 ME1 2.37 1.29E-62 Pyruvate metabolism 
miR-4516  
miR-4531 FADS2 1.57 9.67E-56 Biosynthesis of unsaturated fatty acids 
miR-4306 
miR-4644 TECR 1.18 4.31E-38 Biosynthesis of unsaturated fatty acids 
miR-1253 HSD17B12 1.21 2.85E-23 Biosynthesis of unsaturated fatty acids 
miR-4516 
miR-4531 ACOX1 1.11 1.25E-21 Fatty acid degradation, Biosynthesis of unsaturated fatty acids 
miR-29a-3p LPL 1.31 1.91E-17 PPAR signalling pathway 
miR-4698 SORBS1 2.48 8.84E-12 PPAR signalling pathway 
miR-3202 RXRG 3.45 1.77E-09 PPAR signalling pathway 
miR-4306 
miR-4644 
miR-146b-5p 
miR-4698 
BCAT2 1.09 2.23E-08 Valine, leucine and isoleucine degradation 
 
Table 22 KEGG pathways enriched in brown versus white adipocytes with p value between 1x10-6 
and 1x10-8 
miRName 
down Target up     KEGG name (p value 1x10
-6≤ p ≤1x10-8) 
miR-4306 
miR-4644 SCARB1 2.38 2.28E-107 Aldosterone synthesis and secretion 
miR-4436b-3p 
miR-29a-3p ATP1B1 2.25 8.43E-59 Adrenergic signaling in cardiomyocytes 
miR-4306 
miR-5584-5p ADCY6 1.54 5.08E-48 
Aldosterone synthesis and secretion, Adrenergic signaling in 
cardiomyocytes, Vascular smooth muscle contraction 
miR-4436-3p MRVI1 5.45 2.34E-42 Vascular smooth muscle contraction 
miR-4436b-3p 
miR-29a-3p 
miR-196a-5p 
miR-1253 
miR-1261 
CALM3 1.32 4.66E-42 Aldosterone synthesis and secretion, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction 
miR-29a-3p 
miR-1253 CAMK1D 2.97 3.12E-35 Aldosterone synthesis and secretion 
miR-4516 
miR-4531 PPP2R5D 1.25 3.26E-34 Adrenergic signaling in cardiomyocytes 
miR-4516 PRKACA 1.32 5.48E-31 Aldosterone synthesis and secretion, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction 
miR-196a-5b PPP1R12B 1.43 3.68E-27 Vascular smooth muscle contraction 
miR-29a-3p 
miR-3611 BDH1 2.01 4.60E-20 Butanoate metabolism 
miR-4516 CACNB2 3.61 3.56E-16 Adrenergic signaling in cardiomyocytes 
miR-10a-3p PLCB1 1.39 3.82E-16 Aldosterone synthesis and secretion, Adrenergic signaling in cardiomyocytes Vascular smooth muscle contraction 
miR-4698 L2HGDH 1.02 1.58E-15 Butanoate metabolism 
miR-29a-3p 
miR-4531 CREB5 1.13 6.07E-15 
Aldosterone synthesis and secretion, Adrenergic signaling in 
cardiomyocytes 
miR-3202 ADCY1 1.52 7.90E-15 Aldosterone synthesis and secretion,  Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction 
miR-3202 BDH2 1.17 2.81E-14 Butanoate metabolism 
miR-4306 
miR-4644 PLA2G2F 5.47 9.13E-14 Vascular smooth muscle contraction 
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Table 23 KEGG pathways enriched in brown versus white adipocytes with p value between 1x10-4 
and 1x10-6 
miRName (hsa-
miR)  Target up  
Log2 
(FC) Adj.pVal  KEGG name (p value  1x10
-4≤ p ≤1x10-6) 
miR-29a-3p COL11A1 3.92 1.29E-247 Protein digestion and absorption 
miR-29a-3p 
miR-222-3p 
miR-5584-5p 
miR-221-3p 
miR-4698 
PPARGC1A 5.87 9.28E-242 Huntington's disease, Glucagone signaling pathway  
miR-4436-3p 
miR-29a-3p 
miR-222-3p 
miR-221-3p 
MAPK10 4.71 4.71E-154 cAMP signaling pathway, Huntington disease 
miR-4726-5p 
miR-4698 PDE1B 2.7 2.70E-151 Huntington's disease, Renin secretion 
miR-4698 AOC3 3.58 4.07E-147 beta-Alanine metabolism 
miR-4306 AR 8.93 4.24E-136 Oocyte meiosis  
miR-4698 FOXO1 2.6 1.06E-126 Glucagon signaling pathway 
miR-29a-3p 
miR-3611 COL4A4 4.17 2.37E-120 Protein digestion and absorption 
miR-1253 CDC25C 2.48 1.09E-71 Synthesis and degradation of ketone bodies 
miR-1253 PDE5A 4.86 2.37E-64 cGMP-PKG signaling pathway 
miR-29a-3p 
miR-196a-5p COL1A2 2.53 1.95E-52 Protein digestion and absorption 
miR-29a-3p OXTR 3.35 1.93E-51 cAMP signaling pathway, Huntington disease 
miR-204-3p KCNE3 3.03 1.66E-50 Protein digestion and absorption 
miR-3611 
miR-4698 DMD 2.19 1.89E-49 Dilated cardiomyopathy 
miR-4726-5p PKIA 1.92 7.70E-49 Tryptophan metabolism 
miR-29a-3p COL5A1 2.16 1.38E-46 Protein digestion and absorption 
miR-4436b-3p CCNE1 2.47 1.10E-44 Synthesis and degradation of ketone bodies 
miR-196a-5p PDGFRA 1.5 8.16E-42 Calcium signaling pathway 
miR-29a-3p GNG2 1.72 1.02E-37 Alcoholism 
miR-29a-3p COL5A3 1.24 2.09E-36 Protein digestion and absorption 
miR-29a-3p TNFRSF1A 1.31 3.17E-36 Alzheimer's disease 
miR-146b-5p PHKB 1.62 1.06E-33 Huntington's disease 
miR-3611 TSHR 4.63 3.21E-32 cAMP signaling pathway 
miR-29a-3p NFATC4 2.23 1.86E-31 cGMP-PKG signaling pathway 
miR-146b-5p MAPT 4.53 2.65E-30 Protein digestion and absorption 
miR-4531 RAC3 2.23 7.89E-29 cAMP signaling pathway 
miR-4436-3p 
miR-10a-3p 
miR-4698 
miR-1261 
MEF2C 2.1 9.61E-28 cGMP-PKG signaling pathway 
miR-29a-3p COL21A1 4.09 7.31E-25 Protein digestion and absorption 
miR-4778-5p 
miR-4484 
miR-29a-3p 
miR-4726-5p 
DAG1 1.03 7.91E-25 Dilated cardiomyopathy 
miR-146b-5p FAXDC2 2.04 1.53E-20 Steroid biosynthesis 
198 
 
Continuing table 24 
miRName (hsa-
miR)  Target up  
Log2 
(FC) Adj.pVal  KEGG name (p value  1x10
-4≤ p ≤1x10-6) 
miR-4306 
miR-29a-3p 
miR-4531 
miR-4698 
miR-196a-5p 
COL1A1 2.5 2.33E-18 Protein digestion and absorption 
miR-4516 DHCR7 1.27 2.82E-18 Steroid biosynthesis 
miR-29a-3p DRD1 6.51 9.59E-18 cAMP signaling pathway 
miR-196a-5p COL24A1 2.68 1.78E-17 Protein digestion and absorption 
miR-29a-3p ELN 3.61 2.25E-16 Protein digestion and absorption 
miR-4778-5p PTCH1 1.98 2.22E-15 cAMP signaling pathway 
miR-29a-3p COL6A3 1.1 2.57E-14 Protein digestion and absorption 
miR-4726 ITPKC 1.01 5.79E-13 Calcium signaling pathway 
miR-1253 PTGER4 1.98 7.24E-13 Renin secretion 
miR-204-3p RPS6KA1 1 1.55E-12 Oocyte meiosis 
miR-29a-3p COL4A3 2.97 3.57E-11 Protein digestion and absorption 
miR-3915 
miR-4698 SNAP25 3.16 1.13E-08 Insulin secretion 
miR-4698 SOX9 1.14 1.48E-06 cAMP signaling pathway 
miR-29a-3p 
miR-4531 
miR-711 
COL4A5 1.46 1.94E-05 Protein digestion and absorption 
miR-3202 
miR-29a-3p 
miR-4726-5p 
PDGFRB 1.03 5.73E-04 Calcium signaling pathway 
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Table 24 KEGG pathways enriched in brown versus white adipocytes with p value between 1x10-2 
and 1x10-4 
miRName 
down Target up 
Gene 
Log2(FC) 
Gene 
Adj.pval KEGG name (p value 1x10
-2≤ p ≤1x10-4) 
miR-4698 LEPR 3.97 1.59E-259 AMPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Adipocytokine signaling pathway 
miR-711 DAAM2 4.97 3.04E-257 Wnt signaling pathway 
miR-4698 PRKAR2B 3.6 6.14E-237 Histidine metabolism 
miR-146b-5p SESN3 3.65 9.71E-208 p53 signaling pathway 
miR-3202 SFRP1 5.83 3.24E-137 Wnt signaling pathway 
miR-29a-3p CNR1 6.17 3.41E-120 Axon guidance 
miR-4436b-3p MLXIPL 2.27 7.07E-109 Insulin resistance, Non-alcoholic fatty liver disease (NAFLD) 
miR-4484 
miR-222-3p 
miR-4698 
AXIN2 4.76 2.88E-99 p53 signaling pathway, Inflammatory mediator regulation of TRP channels 
miR-1261 MITF 4.47 1.02E-92 Pathways in cancer 
miR-4306 
miR-222-3p 
miR-221-3p 
SLC4A4 2.95 9.32E-86 Proximal tubule bicarbonate reclamation, Bile secretion 
miR-4531 TBC1D4 2.2 6.82E-72 Insulin resistance 
miR-29a-3p GSTA4 2.57 8.99E-72 Glutathione metabolism 
miR-222-3p 
miR-221-3p 
miR-196a-5p 
CDKN1B 1.96 2.53E-69 Cell cycle, Inflammatory mediator regulation of TRP channels, AGE-RAGE signaling pathway in diabetic complications 
miR-4698 ENPP1 2.3 4.61E-68 Starch and sucrose metabolism 
miR-196a-5p GYG2 3.14 4.74E-68 Starch and sucrose metabolism 
miR-29a-3p GPAM 2.5 6.15E-67 Glycerolipid metabolism 
miR-3915 
miR-3202 
miR-4698 
PPARGC1
B 2.88 2.79E-51 Insulin resistance 
miR-3202 PLXNA4 2.91 2.33E-48 Pathways in cancer 
miR-3915 G6PD 1.57 2.43E-46 Glutathione metabolism 
miR-3202 
miR-4726-5p SSH2 1.5 5.54E-43 Axon guidance 
miR-4778-5p 
miR-4698 ABCA12 3.12 7.69E-43 ABC transporters 
miR-4306 
miR-4644 
miR-29a-3p 
miR-4531 
CCND2 2.09 2.30E-40 Focal adhesion, Cell cycle, p53 signaling, Wnt signaling pathway 
miR-4306 
miR-146b-5p FLOT2 1.54 1.01E-33 Insulin signaling pathway 
miR-29a-3p LEP 2.27 4.72E-32 AMPK signaling pathway, Thyroid hormone synthesis, Adipocytokine signaling pathway 
miR-3611 TCF7L1 1.96 1.75E-29 Wnt signaling pathway, Inflammatory mediator regulation of TRP channels  
miR-29a-3p ASIC1 2.57 4.43E-28 Inflammatory mediator regulation of TRP channels 
miR-4306 
miR-4644 ABCG4 4.7 9.38E-27 ABC transporters 
miR-4698 PCYOX1 1.24 5.83E-26 Terpenoid backbone biosynthesis 
miR-29a-3p DPYSL2 1.16 4.10E-24 Pathways in cancer 
miR-4698 JAK2 1.41 5.92E-24 Adipocytokine signaling pathway AGE-RAGE signaling pathway in diabetic complications 
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Continuing table 25 
miRName 
down Target up 
Gene 
Log2(FC) 
Gene 
Adj.pval KEGG name (p value 1x10
-2≤ p ≤1x10-4) 
miR-4306 
miR-3202 
miR-4644 
miR-4726-5p 
EFNB1 1.28 1.17E-21 Axon guidance 
miR-4436-3p 
miR-29a-3p VCL 1.23 2.08E-21 Focal adhesion 
miR-5584-5p MAGI3 1.78 8.83E-20 Rap1 signaling pathway 
miR-4698 TBL1XR1 1.11 8.16E-19 Wnt signaling pathway 
miR-146b-5p 
miR-204-3p SEMA3G 1.14 1.61E-18 Axon guidance 
miR-29a-3p DAAM1 1.04 1.20E-17 Wnt signaling pathway 
miR-4778-5p 
miR-4698 FZD5 1.21 6.32E-16 
Wnt signaling pathway, Inflammatory mediator regulation of 
TRP channels  
miR-4436b-3p SEMA4F 1.29 7.67E-16 Pathways in cancer 
miR-29a-3p TUBB2A 1.21 2.93E-15 Gap junction 
miR-29a-3p TUBB2B 2.18 6.13E-15 Gap junction 
miR-204-3p COLGALT
2 
2.7 1.06E-12 Lysine degradation 
miR-29a-3p DNM3 2.53 2.55E-11 Endocrine and other factor-regulated calcium reabsorption 
miR-4698 ABCB10 1.1 9.33E-11 ABC transporters 
miR-3915 NKD2 4.53 5.80E-10 Wnt signaling pathway 
miR-3202 PFKFB4 1.23 6.60E-10 AMPK signaling pathway 
miR-4436b-3p 
miR-4726-5p TRAF1 1.19 7.77E-10 Inflammatory mediator regulation of TRP channels 
miR-29a-3p CTNNBIP1 1.17 1.43E-09 Wnt signaling pathway 
miR-196a-5p RASGRP1 2.39 6.49E-09 Inflammatory mediator regulation of TRP channels 
miR-3202 
miR-4726-5p EFNA3 1.65 1.37E-08 Axon guidance, Rap1 signaling pathway 
miR-29a-3p 
miR-146b-5p 
miR-3611 
RARB 2.62 1.27E-07 Pathways in cancer 
miR-4436b-3p SEMA4G 1.71 2.11E-06 Axon guidance 
miR-146b-5p WNT3 1.25 4.15E-06 Wnt signaling pathway, Pathways in cancer 
miR-4698 TGFA 1.43 4.37E-05 Inflammatory mediator regulation of TRP channels 
miR-1261 FZD3 1.5 6.38E-05 p53 signaling pathway, Inflammatory mediator regulation of TRP channels, Pathway in cancer 
miR-4484 FGFR3 1.96 2.12E-04 Inflammatory mediator regulation of TRP channels, Axon guidance 
miR-222-3p 
miR-221-3p CDKN1C 1.47 3.87E-04 Cell cycle 
miR-4726-5p RGS14 1.29 1.04E-03 Axon guidance 
miR-29a-3p RND1 1.28 9.80E-03 Pathways in cancer 
miR-3202 EFNB3 1.13 2.42E-02 Axon guidance 
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Table 25 KEGG pathways enriched in white vs brown adipocytes with p value ≤1x10-8 
miRName up Target down 
Gene 
Log2(FC)  
Gene 
Adj.pval KEGG name (p value ≤1x10
-8) 
miR-143-3p PTGS2 -6.35 0.00E+00 TNF signaling pathway 
miR-513a-5p CD44 -2.83 8.34E-268 Proteoglycans in cancer 
miR-513a-5p ITGA2 -4.25 6.09E-224 Proteoglycans in cancer 
miR-378e 
miR-378f 
miR-378c 
miR-378d 
miR-378b 
miR-378i 
miR-378h 
BMP2 -5.41 8.28E-202 Cytokine-cytokine receptor interaction 
miR-4328 WNT5A -3.8 4.09E-158 Proteoglycans in cancer 
miR-4328 PDGFA -3.59 8.92E-75 Cytokine-cytokine receptor interaction 
miR-143-3p PLAUR -2.39 6.03E-68 Proteoglycans in cancer 
miR-513a-5p ANTXR2 -1.27 8.39E-41 NOD-like receptor signaling pathway 
miR-513a-5p 
miR-145-5p PXN -1.07 7.96E-28 Proteoglycans in cancer 
miR-513a-5p HBEGF -1.49 6.72E-27 Proteoglycans in cancer 
miR-143-3p ITPR1 -1.1 2.07E-25 NOD-like receptor signaling pathway and proteoglycans in cancer 
miR-4511 CXCL16 -2.13 5.05E-24 Cytokine-cytokine receptor interaction 
miR-513a-5p 
miR-4328 
miR-4511 
miR-145-5p 
NRAS -1.08 9.42E-24 Proteoglycans in cancer 
miR-513a-5p 
miR-4511 XIAP -1.09 8.25E-22 NOD-like receptor signaling pathway 
miR-378a-3p 
miR-378e 
miR-378f 
miR-378c 
miR-378d 
miR-378b 
miR-378i 
miR-378h 
miR-145-5p 
IGF1R -1.06 6.73E-21 Proteoglycans in cancer 
miR-136-5p 
miR-378g ELK1 -1 4.43E-16 Proteoglycans in cancer 
miR-4328 
miR-145-5p FLT1 -2.39 1.46E-10 Cytokine-cytokine receptor interaction 
miR-4328 DAB2IP -1.05 2.88E-10 TNF signaling pathway 
miR-513a-5p PIK3CD -1.29 1.62E-09 TNF signaling pathway, Proteoglycans in cancer 
miR-513a-5p CAMK2A -3.92 3.97E-09 Proteoglycans in cancer 
miR-4511 TIAM1 -1.01 3.16E-05 Proteoglycans in cancer 
miR-4511 OAS3 -1.18 1.40E-04 NOD-like receptor signaling pathway 
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Table 26 KEGG pathways enriched in white vs brown adipocytes with p value between 1x10-4 and 
1x10-6 
miRName up Target down 
Gene 
Log2(FC) 
Gene 
Adj.pval KEGG name (p value 1x10
-4≤ p ≤1x10-6) 
miR-4511 HRH1 -3.4 1.64E-106 Inflammatory mediator regulation of TRP channels 
miR-4511 TBX3 -2.4 3.19E-97 Signaling pathways regulating pluripotency of stem cells 
miR-4328 FGF7 -2.9 1.86E-90 Pathways in cancer 
miR-4511 FGF5 -3.5 3.12E-88 Pathways in cancer 
miR-513a-5p  RUNX1 -1.7 1.43E-72 Pathways in cancer, transcriptional misregulation in cancer 
30e.5p JARID2 -2.2 1.76E-49 Signaling pathways regulating pluripotency of stem cells 
miR-378g SKIL -1.9 3.28E-41 Signaling pathways regulating pluripotency of stem cells 
miR-145-5p SMAD3 -1.5 1.14E-34 
Pathways in cancer, AGE-RAGE signaling pathway in diabetic 
complications, signaling pathways regulating pluripotency of 
stem cells and TGF-beta signaling pathway 
miR-143-3p FGF1 -1.5 2.46E-23 Pathways in cancer 
miR-378e 
miR-378f 
miR-378c 
miR-378d 
miR-378b 
miR-378i 
miR-378h 
REST -1 3.47E-17 Signaling pathways regulating pluripotency of stem cells 
miR-4328 PTGER2 -1.3 8.09E-14 Inflammatory mediator regulation of TRP channels, pathways in cancer 
miR-513a-5p HOXA10 -1 4.79E-13 Transcriptional misregulation in cancer 
miR-513a-5p PRKCH -1.2 5.04E-08 Inflammatory mediator regulation of TRP channels 
miR-513a-5p 
miR-4328 
miR-378g 
miR-33b-5p 
RUNX1T
1 -1.3 1.89E-07 Pathways in cancer, transcriptional misregulation in cancer 
 
 
 
 
 
 
 
 
 
203 
 
Table 27 KEGG pathways enriched in white vs brown adipocytes with p value between 1x10-2 and 
1x10-4 
miRName up Target down 
Gene 
Log2(FC)  
Gene 
Adj.pval KEGG name (p value 1x10
-2≤ p ≤1x10-4) 
miR-513a-5p 
miR-4328 
miR-33b-5p 
SEMA7
A -3.2 8.82E-127 Axon guidance 
miR-513a-5p 
miR-143-3p GFPT2 -1.6 1.40E-71 Amino sugar and nucleotide sugar metabolism 
miR-4328 SEMA3A -3.83 1.22E-64 Axon guidance 
miR-513a-5p 
miR-4328 GRB10 -1.65 1.19E-62 mTOR signaling pathway 
miR-4328 EGR2 -4.34 7.49E-49 Hepatitis B HTLV-I infection 
miR-513a-5p RAPGEF3 -3.97 1.02E-48 Rap1 signaling pathway, salmonella infection 
miR-513a-5p 
miR-143-3p 
miR-4511  
ABL2 -2.28 2.91E-44 Ras signaling pathway 
miR-145-5p SIRPA -1.56 4.41E-41 Osteoclast differentiation 
miR-33b-5p 
miR-145-5p RASA1 -1.56 5.60E-39 Axon guidance, MAPK signaling pathway  
miR-378a.5p NFATC2 -4.29 3.42E-31 Axon guidance Hepatitis B HTLV-I infection, osteoclast differentiation 
miR-513a-5p WDR43 -1.09 4.15E-29 Ribosome biogenesis in eukaryotes 
miR-378g NOTCH2 -1.15 5.08E-29 Dorso-ventral axis formation 
miR-143-3p RAB7A -1.02 4.83E-28 Rap1 signaling pathway, salmonella infection ,tuberculosis 
miR-513a-5p ADORA2B -1.46 1.10E-27 Rap1 signaling pathway 
miR-513a-5p 
miR-4328 
miR-143-3p 
LIMK1 -1.29 8.72E-26 Axon guidance 
miR-513a-5p RICTOR -1.11 4.95E-23 mTOR signaling pathway 
miR-145-5p RASA2 -1.55 1.61E-21 MAPK signaling pathway  
miR-513a-5p  SESN2 -1.1 1.11E-14 mTOR signaling pathway 
miR-513a-5p FOSB -3.69 1.15E-14 Osteoclast differentiation 
miR-145-5p CPEB1 -2.29 2.35E-13 Amoebiasis 
miR-4511 EPHA5 -4.99 2.79E-09 Axon guidance 
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5.2   Discussion 
 As the nature of human brown adipocytes is still poorly understood, we performed 
mRNA sequencing and miRNA array analysis on human brown and white adipocytes to 
explore their differential gene and miRNA expression and KEGG enrichment. This 
allowed us to identify 2463 genes and 20 miRNAs upregulated in brown versus white 
adipocytes and 1733 genes and 29 miRNAs upregulated in white versus brown 
adipocytes. The KEGG enrichment analysis reflected the nature of brown adipocytes 
highlighting the pathways that are involved in the development and functioning of the 
two types of cells. Integrating the data from miRNA array and mRNA sequencing 
analysis we identified miRNAs that potentially control the KEGG pathways differentially 
enriched between brown and white adipocytes by targeting the associated genes. In this 
section the miRNAs targeting genes of particular interest or with the highest number of 
predicted target associated to the top differentially expressed pathways will be discussed.  
   miRNAs downregulated in brown adipocytes potentially involved in the top 
pathways enriched in brown adipocytes 
 The top pathways enriched in brown versus white adipocytes were: fatty acid 
degradation, biosynthesis of unsaturated fatty acids, propanoate metabolism, citrate cycle, 
pyruvate metabolism, valine leucine and isoleucine degradation and PPAR signalling. In 
total 10 miRNAs downregulated in brown versus white adipocytes (miR-4516, miR-
4531, miR-4306, miR-4698, miR-4644, miR-146b.5p, miR-3915, miR-1253, miR-29a-
3p and miR-3202) were predicted to control some of the genes associated to these 
pathways. 
 Of these miRNAs, miR-4698 was predicted to target a total of twenty four genes 
associated to the pathways enriched in brown adipocytes with a significant p value, four 
of which were among the top ones. Among these genes there was (SCD). This enzyme, 
as previously described, participates in de novo lipogenesis, the second main source of 
fatty acid of brown adipocytes [77]. This gene was also predicted to be targeted by miR-
4306. Another two important enzymes involved in fatty acid degradation are acyl- CoA 
oxidase 1 (ACOX1) and fatty acid desaturase 2 (FADS2). Both were predicted to be 
targeted by miR-4516 and miR-4531. Therefore, the downregulation of these miRNAs in 
brown adipocytes may be very important to allow the high oxidative activity typical of 
BAT. 
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 MiR-29a-3p was predicted to target the highest number of genes associated with 
the significant pathways enriched in brown adipocytes. Accordingly to the literature, 
miR-29 was predicted to target LPL [387], the enzyme responsible for FAs uptake from 
the blood stream, the main source of energy of brown adipocytes. Even if LPL is 
important in white adipocytes as well, its expression is known to be increased during high 
metabolic activity, which would justify its higher expression in brown versus white 
adipocytes. Interestingly, among the targets of miR-29a-3p there was also PGC1α. MiR-
29a-3p might play an important role by repressing a large number of genes involved in 
brown adipogenesis and metabolism in order to promote the white phenotype.   
 Finally, we identified miR-3915 as a potential repressor of ADIPOQ, the gene 
encoding adiponectin. This adipokine, presenting an anti-inflammatory function, and 
promoting lipid oxidation protects against obesity and associated insulin resistance [70-
72]. As levels of circulating adiponectin are reduced in obese subjects [73] it would be 
interesting to investigate whether the expression of this miRNA is altered in adipose 
tissue of obese subjects.  
   MiRNAs upregulated in brown versus white adipocytes potentially involved in 
suppression of the genes associated the top pathways enriched in white adipocytes 
 The top pathways enriched in white adipocytes associated to the downregulated 
genes in brown adipocytes were: TNFα signalling pathway, proteoglycans in cancer, 
cytokine-cytokine receptor interaction and NOD-like receptors signalling. We identified 
six miRNAs (miR-143-3p, miR-4328, miR-513a-3p, miR-145 and miR-4511) plus the 
members of the miR-378 family, to potentially control these pathways by targeting some 
of the associated genes.  
  MiR-513a-3p was predicted to target the highest number of genes (9) involved in 
these pathways. Interestingly, it was found to potentially target both CD44 and ITGA2, 
which encodes integrin-α2 subunit. CD44 and integrins are involved in cell motility [122, 
388]. CD44 was reported to play a role in gonadal WAT remodelling as a subpopulation 
of adipose-precursors expressing PDGFRα and CD44 started proliferating after being 
attracted by recruited macrophages overexpressing osteopontin [389]. As both CD44 and 
integrins were found to be involved in insulin resistance [125, 128] miR-513a-3p may 
play an important role in regulating these genes in obesity. Another predicted target of 
miR-513a-3p potentially involved in obesity is XIAP (X-linked inhibitor of apoptosis). 
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XIAP was found upregulated in squirrel adipose tissue during hibernation, when the 
respiratory rate is dramatically reduced, to prevent hypoxia-induced apoptosis [390]. This 
gene was predicted to be also targeted by miR-4511. Another interesting potential target 
of miR-513a-3p HB-EGF (Heparin-binding EGF-like growth factor) which was found to 
be involved in cellular plasticity and to promote brown-like phenotype in mouse 
fibroblasts [391]. 
 Also miR-4511 presented a high number of potential targets (5) associated to the 
pathways enriched in white adipocytes. Among its predicted targets, besides XIAP, there 
is Chemokine (C-X-C motif) ligand 16 (CXCL16). This membrane-bound chemokine, in 
the soluble form, attracts immune cells expressing Chemokine (C-X-C Motif) Receptor 
6 (CXCR6) such as natural killer cells, CD8T and Th1-polarized T cells [392, 393]. 
CXCL16 was also found to have antimicrobial action against Staphylococcus aureus and 
Escherichia coli [394] therefore, its activation could be related to toll-like receptors upon 
LPS stimulation and play a role in the HFD-induced inflammation.  
 Finally, miR-4328 could be another miRNA with important functions in obesity. 
Indeed, among its predicted targets there were Wnt5α and PDGFA. Wnt5α is a non-
canonical Wnt protein as it triggers β-catenin–independent signalling activation. 
Importantly, it was found to promote adipose tissue inflammation and insulin resistance 
in obesity [395]. PDGFA was found to promote adipose stem cell self-renewal via 
PI3K/AKT2 (phosphoinositide 3-kinase/protein kinase B) in dermal WAT [396]. PDGFA 
is increased in subcutaneous WAT of obese compared to lean and may be involved in 
obesity-induced fibrosis by activating the pro-fibrotic pathway mediated by PDGFRα in 
CD9high PDGFRα+ progenitors [397]. 
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6  Chapter 6 – General Discussion 
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6.1   Discussion 
 The incidence of obesity and associated metabolic disorders constantly increases 
worldwide [398-400] and challenges the health care systems.  BAT, with its ability to 
burn energy and counteract obesity has become a candidate target for the development of 
new treatments against metabolic disorders. An increasing number of studies aim to 
investigate the complex network among the metabolic organs in order to understand the 
mechanisms underlying energy homeostasis balance. MiRNAs are potent regulator of 
gene expression and, as previously discussed, many of them have been identified as 
modulators of adipogenesis and adipose metabolism, some miRNAs are known to 
promote or inhibit differentiation, some others to enhance the development of a specific 
adipose phenotype. Their potential ability to induce brown adipogenesis or white 
transdifferentiation into brite adipocytes has attracted scientific interest and novel adipose 
miRNAs are constantly identified. However, there are sometimes discrepancies among 
studies, mainly due to the utilization of different types of adipose models, but also because 
the effect of one miRNA can vary depending on the stage of the differentiation. Cell 
maturation requires an alteration of the transcriptome. MiRNAs are known to regulate 
these changes, but recent studies have shown that genes in turn regulate miRNA function 
[227-229]. Moreover, several miRNAs have been identified as inhibitors of adipogenesis 
even though they can be upregulated during differentiation. This is the case of let-7 and 
miR-488 in 3T3-L1 cells [310, 401]. This indicates that differentiation is not simply a 
process where all the players act towards one single direction, but is rather a complex 
mechanism where the balance of contrasting forces is shifted towards maturation, as this 
last never relies on one single factor. Therefore, the function of a miRNA taken in 
isolation might be considered as anti-adipogenic, but contextualized into a system where 
the balance is shifted towards differentiation by other factors, it may be relevant for the 
definition of one adipose phenotype over another, such as brown, beige and white. This 
could be true for miR-138-5p, which, as previously discussed, could either inhibit 
differentiation or promote the white phenotype by suppressing brown gene expression, 
depending on the stage of differentiation. The hypothesis that the environment defines 
the final function of a given miRNA and hence its tissue specificity is further supported 
by the case of miR-378a-3p, which promotes BAT but not WAT expansion [282], even 
though it is overexpressed in both brown and white adipocytes during differentiation. 
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Similarly, miR-196a-5p promotes the beige phenotype in white adipocytes by targeting 
HOXC8 but had no evident effect in BAT [302]. Additionally, miRNAs could be 
upregulated in order to be secreted into the extracellular environment and explicate their 
function in distal cells. For example, Let-7 inhibits adipogenesis by downregulating high-
mobility group AT-hook 2 (HMGA) [401]. This miRNA is also known to promote 
angiogenesis [402, 403], therefore, despite its anti-adipogenic function it might be 
upregulated during differentiation in order to be secreted and stimulate angiogenesis to 
support tissue expansion.  
 Another source of discrepancies among results from different studies is 
represented by the inconsistency of miRNA nomenclature and by the fact that the arm 
from which the miRNA of interest generates is not always specified [281]. Even though 
lead and passenger miRNA strands, when almost equally expressed, generally take part 
in similar processes, they can have opposite functions, therefore it is important to specify 
the strand of interest. One example is represented by miR-378a-3p and mir-378-5p, 
which, as previously mentioned, were found to have opposing effects on LDHA 
regulation [280]. Moreover, miRNAs with very similar sequences can target the same 
genes. Once again, miR-378 provides a good example. The members of miR-378 family, 
as also demonstrated in our results, are predicted to share many gene targets. In 
experiments where the effect of a miRNA is studied by its forced expression or deletion, 
the other members of the miRNA family should be taken into consideration, as they could 
be responsible for compensatory action.  Additionally, having very similar but not equal 
sequences, their affinity for the same target might be different and it would be interesting 
to explore their combinatorial effect. This could help in predicting the effect of a secreted 
miRNA taken up by a different cell, where the expression of the members of the miRNA 
family might be different from the donor cell. The mechanism of function of miRNAs, as 
revealed by an increasing number of studies, is very complex and intricate. Many factors 
can interfere with miRNA effects. This can mask miRNA actions or lead to false results 
when performing experiments. The development of always more sophisticated 
bioinformatics algorithms and databases provides a potent tool for predicting miRNA 
functions. In particular, miRegulome (http://bnet.egr.vcu.edu/miRegulome), an online 
miRNA data and analysis repository, incorporates miRNA dynamics, upstream and 
downstream targets and the regulatory effect of chemicals on these targets [404]. 
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Therefore, before approaching experimental miRNA studies, the usage of this type of 
tool, would be strongly recommended.   
 The importance of miRNAs in the cross-talk between adipose tissue and distal 
cells is further supported by the fact that in obesity levels of circulating miRNAs are 
altered compared to lean subjects. However, the majority of the studies on extracellular 
miRNA secreted by adipocytes mainly focused on mouse models or on analysis of blood 
samples, which does not allow to determinate which cellular component contributes to 
miRNA secretion. In this study, we identified miRNAs differentially secreted specifically 
by undifferentiated and differentiated brown and white adipocytes. Among these miR-
322-5p, miR-10b, miR-103, miR-365-5p, miR-378a-3p and miR-196a-5p were selected 
and considered for further analysis. Even though only extracellular miR-378a-3p and 
miR-196a-5p showed consistent results across the adipose models, all these miRNAs 
could play an important role in cell-to-cell communication. Still poorly explored in 
adipogenesis, they have been reported to be involved in processes such as angiogenesis, 
insulin resistance inflammation and their secretion by adipocytes might be of relevant 
contribution in obesity and associated disorders. For instance, miR-365, in a study on 
HEK293 and HeLa cells inhibited IL-6 expression. Moreover, the miR-365 promoter 
presents consensus sites for NF-kB. This last in cooperation with Sp1 was found to highly 
upregulate miR-365 [405]. Our data show that miR-365 is more highly secreted by 
BAT/brown adipocytes in most of the adipose models and it would be interesting to 
investigate whether BAT-secreted miR-365 has any effect on inflammation and insulin 
resistance in obesity via regulating IL-6.  
 MiR-10b besides promoting angiogenesis [406, 407], and cell migration in several 
types of cancer [407-411], and was found to be induced by and to suppress IL-17 by 
targeting MAP3K7 [412]. IL-17 is required to maintain Th-17 immune cells functional 
activity against altered microbiota flora in the intestine upon HFD and IL-17 absence was 
reported to promote obesity [413]. To our knowledge, no studies have demonstrated the 
effect of miR-10b on IL-17 and consequently on Th-17 in adipose tissue and obesity. 
According to our results and previous studies, miR-103 is upregulated in adipocytes 
during differentiation in physiological conditions (table 15) but downregulated in obesity 
[414, 415]. TNFα was found to inhibit miR-103 expression [414]. RaeAnna et al., showed 
that miR-103 suppresses angiogenesis in a tumor environment by inhibiting non-
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canonical DNA repair enzymes, three prime exonucleases (TREX) 1 and 2 in endothelial 
cells [416]. Whether miR-103 also inhibits angiogenesis in adipose tissue has not been 
proven yet. If this was the case, downregulation of miR-103 during inflammatory status 
in obesity might be a strategy adopted by the cells to prevent inhibition of angiogenesis 
and reduce the grade of obesity-induced hypoxia. 
 MiR-424 was found to be induced by hypoxic stimuli in endothelial cells and to 
prevent HIF-1α degradation by inhibiting expression of Cullin-2 [417], important in the 
ubiquitin ligase system [418]. MiR-424 was also reported to promote differentiation of 
the monocytes that infiltrate in atherosclerotic plaque sites by inhibiting miR-9, a 
repressor of differentiation [419]. Therefore, miR-424 could play an important role in 
sustaining inflammation and HIF-1α-induced fibrosis in obesity. As previously discussed 
miR-196a-5p, miR-378a-3p and miR-138-5p were predicted to target genes involved in 
inflammation fibrosis and angiogenesis, therefore all the aforementioned miRNAs may 
be implicated in obesity and associated dysfunctions. Some of them are predicted to share 
some gene targets and their effect could be different depending on the acceptor cell. For 
example, targeting HIF1α in BAT could result in impaired angiogenesis, while in WAT 
it could prevent adipose tissue fibrosis. PPARɣ expression in endothelial cells has an 
antiproliferative effect, hence it inhibits angiogenesis. Conversely, its expression in 
adipocytes induces expression of the pro-angiogenic factor VEGFA [114]. Therefore, a 
miRNA targeting PPARɣ has the potential to induce or inhibit angiogenesis, depending 
on the host cell. Most of the targets that we predicted in this study for miR-378a-3p, miR-
196a-5p and miR-138-5p are expressed in different cell types, either in cellular 
components of the adipose tissue adipocytes included, or of other different organs. Our 
analysis also demonstrated that miRNAs are secreted both via incorporation into vesicles 
and in association to vesicle free system. The preference of one type of carrier over the 
other could implicate specificity of acceptor cell for miRNA delivery and this aspect 
together with the endocrine, autocrine and paracrine potential miRNA functions should 
be further investigated. As previously discussed, the properties of vesicle free system are 
still largely unknown. Moreover, so far the most explored vesicular miRNA carriers are 
exosomes, but a large variety of vesicles exist and they could be relevant as well in 
conferring specificity of miRNA delivery.  
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 The mRNA sequencing and miRNA array analyses provided a large amount of 
information. In this study we have only discussed some of the novel miRNAs identified 
as potentially involved in brown and white adipogenesis/metabolism. We mainly 
focussed on the miRNAs that were predicted to target genes associated to the 
differentially enriched pathways between brown and white adipocytes falling in the most 
significant p value. However, we provided the full list of miRNAs targeting the genes 
associated to all the pathways identified and these can be used for future analysis as well. 
One of the limits of this analysis consists in the fact that it does not consider miRNAs 
targeting genes which level of expression remains unvaried or is only slightly reduced 
even though their translation into protein is inhibited [420, 421]. Therefore, each miRNA 
can target many other genes, besides the ones reported by us. Through the mRNA 
sequencing analysis, we also identified isoforms of genes that are differentially expressed 
between brown and white adipocytes, besides identifying novel genes. These will be 
considered in future work to verify whether the different isoforms of a gene can compete 
for miRNA interaction. Moreover, our findings could be integrated with total 
transcriptome analyses performed on human adipocytes by other groups, in order to 
further improve the knowledge on the nature of human adipocytes. 
6.2   Next experimental steps 
This study has provided many results that could be used as a starting point for 
future experiments that aim to improve the knowledge on miRNA function in adipocyte 
biology and their role in the cell-to-cell communication among adipocytes and the distal 
organs involved in maintaining the energy homeostasis balance. Here we list the next 
immediate steps in continuation of this work, that can constitute a possible initial 
approach. 
Experimental validation of miRNA target identification 
 There exist different strategies to validate a predicted target of a determined 
miRNA, which have been reviewed in different publications [422-424]. The most direct 
way to check the actual activity of a miRNA on its predicted mRNA target would be to 
control the downstream production of the translated protein. In this study we particularly 
focussed on miR-196a-5p, miR-378a-3p and miR-138-5p for their potential role in cell 
to communication. As discussed in paragraphs these secreted miRNAs could have both 
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an autocrine and paracrine role, therefore, the effect of the miRNAs will be investigated 
in both adipocytes and endothelial cells blood vessels from adipose tissue. Specifically, 
in separate experiments, miR-196a will be exogenously expressed through miRNA 
transfection and knocked down using antisense miRNA (antagomiR) in adipocytes and 
endothelial cells. The protein and mRNA expression of TLR4, IKBA, HIF-1α and 
ADAM10 will be then analysed and compared to controls. If these genes are under the 
control of miR-196a their protein expression will be decreased after exogenous miRNA 
expression and increased after miRNA knock down. Measuring both mRNA and protein 
changes in these experiments will provide further information on the mechanism through 
which the miRNA inhibits gene expression. Indeed changes in the protein expression of 
the miRNA target and unvaried mRNA expression upon miRNA knock down or 
transfection would suggest that the miRNA induces gene silencing without mRNA 
degradation, providing further elucidation on miRNA mechanism of action. The same 
experiment will be performed for miR-138 and miR-378 with their respective targets 
(table 18) in both endothelial cells and adipocytes. With regard to the intracellular 
miRNAs identified in this study, as differentially expressed between brown and white 
adipocytes, we focussed on miR-513a-3p, miR-4511, miR-4328 miR-4698, miR-4516, 
miR-4531, miR-29a-3p and miR-3915 as they are novel miRNAs with potential function 
in adipocytes or because we identified targets that were not predicted before for these 
miRNAs, as discussed in paragraphs 5.1.4 and 5.2. For these miRNAs, the results 
obtained by the microRNA array analysis will be first validated through q-RT PCR to 
confirm their differential expression between human brown and white adipocytes. 
Afterwards, their predicted targets considered in this study, (paragraph 5.2) will be 
experimentally validated in adipocytes, as explained above.   
 
Investigation on feedback regulation 
 In the cases where the miRNA target regulation is experimentally confirmed, the 
experiments will be repeated in the opposite direction. Therefore, to investigate whether 
the expression of a predicted target gene at both protein and mRNA level can induce or 
inhibit miRNA expression, in separate experiments, the target will be transfected into the 
target cell (adipocyte and/or endothelial cell) to force its expression or knocked down 
214 
 
using short interference RNAs. Alteration of miRNA expression will reveal the existence 
of positive/negative feedback regulation. 
 
MiRNA transfer into recipient cells  
 To investigate whether the adipose miR-196a, miR-378 and miR-138 can be 
transferred into the hypothesised recipient cells, distal adipocytes and endothelial cells, 
and to test autocrine and paracrine action respectively, the function of the miRNA 
processor machine will be compromised in the acceptor cells by depleting or knocking 
down DICER in two different ways as explained below. This would induce the blockage 
of endogenous mature miRNA production, at least, of those miRNA which maturation 
relies on DICER activity. Subsequently, the cells will be incubated with conditioned 
media from adipocytes. Intracellular content of the miRNAs of interest and expression of 
their targets will be measured through qRT-PCR in both cells exposed to conditioned 
media and non-exposed cells. The target protein expression will be analysed by western 
blot. To assess adipose miRNA uptake in adipocytes the BAT DicerF/F Cre-LBD and 
subcutaneous WAT DicerF/F Cre-LBD cell lines will be employed. In the DNA of these 
cells, Dicer gene is flanked by loxP (lox) sites. These sequences are recognized by Cre 
recombinase enzyme which is fused to the ligand binding domain of the estrogen receptor 
(LBD ER). Only upon tamoxifen administration, Cre recombinase protein, previously 
confined in the cytoplasm, translocates to the nucleus where it catalyses recombination 
of the target DNA sequence flanked by lox in the same orientation [425]. In this way it 
will be possible to deplete Dicer only when required. Dicer ablation would be permanent 
and the cells could be exposed to conditioned media for a longer period of time, allowing 
the clearance of the cell from the pre-existing DICER protein. Moreover, it will be 
possible to explore the function of the miRNA uptaken miRNAs at different points of the 
differentiation process, that in total takes around 10 days. Alternatively, if such a cell 
system is not available, such as in our case for endothelial cells, transient DICER knock 
down will be obtained using siRNAs and the protein DICER product will be monitored. 
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Effect of multiple miRNA interaction on target genes 
 Through the use of the Cre recombinase models, the interaction of multiple 
miRNAs predicted to target the same gene will be evaluated. In particular, after depleting 
dicer, via tamoxifen administration, the cells will be co-transfected with different 
combinations of miRNAs and the expression of the target will be assed via RT qPCR and 
western blot. This will allow us to identify the presence of miRNA competitors. The 
choice of the miRNAs will be based on the data obtained through the integration of 
microRNA array-mRNA seq and the results that will be provided from the experiments 
described before. 
 
Active release of miRNAs  
 Inducible vesicle secretion is dependent on intracellular Ca2+ [237]. Intracellular 
Ca2+ concentration is regulated by purinergic receptors in response to extracellular ATP 
[238]. Brown adipocytes response to ATP through multiple P2 receptors. Brown 
adipocytes have been found to be positive for 9 purinergic receptor mRNAs (P2Y2, 
P2Y6, P2Y12, P2X1, P2X2, P2X1, P2X2, P2X3, P2X4, P2X5 and P2X7) [426]. After 
testing the presence of these receptors in both brown and white adipocytes, the 
involvement of these purinergic receptor in the process of miRNA-vesicle secretion will 
be investigated. P2 receptor expression will be inhibited using single or a combination of 
specific short interference RNA (siRNA) for receptor silencing. Afterwards, the 
expression of the miRNAs that will give us the best results in the experiments previously 
described for testing miRNA transfer into recipient cells, will be measured. both in the 
medium and in the ultracentrifugation pellet. This experiment will be performed in the 
presence and absence of Isoproterenol/CL, to investigate whether the ability of ß-
adrenergic stimulation to directly affect miR-196a-5p observed in this study, involves 
these receptors.  
 
 
6.3   Conclusion and future prospective 
 This study allowed us to conclude that undifferentiated and differentiated brown 
adipocytes present differential profiles of secreted miRNAs. The analysis of the 
intracellular and extracellular expression of the selected miRNAs in different adipose 
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models revealed that miRNA secretion is not a passive process but rather actively 
controlled. The use of different adipose models also revealed that the expression of 
intracellular and extracellular miRNAs in adipose tissue does not reflect the patterns of 
miRNA expression of the corresponding adipocytes. Moreover, among the miRNAs 
selected, miR-10b, miR-322/424, miR-103, miR-365, miR-378a-3p and miR-196a, only 
the last two showed a consistent pattern of extracellular expression across adipose 
models, suggesting that they play important roles in adipose cross-talk to be conserved 
across species. As mouse and human adipocytes displayed differences in miRNA 
expression, a miRNA PCR array was performed on media samples from human 
adipocytes and miR-138-5p was identified as the most differentially secreted miRNA 
between human brown and white adipocytes. By predicting miRNA targets through 
bioinformatics tools and correlating our results with scientific studies in the literature we 
hypothesised the potential functions of miR-378a, miR-196a and miR-138-5p. In 
particular, different types of evidence led us to think that miR-378a-3p is potentially 
involved in BAT angiogenesis and ECM remodelling by targeting VEGFA and Sulf1. 
MiR-196a-5p may play an important role in inflammation, ECM remodelling and adipose 
tissue fibrosis in obesity as it is predicted to target ADAM10, HIF1α, TLR4 and IKBA. 
Finally, miR-138-5p, the unique miRNA identified as significantly differentially secreted 
miRNAs between human brown and white adipocytes, could be involved in inflammation 
and the associated insulin resistance in obesity. The analysis of miRNA depletion from 
media by ultracentrifugation revealed that all the miRNAs tested are secreted both via 
incorporation into vesicles and in association with vesicle free systems. As miR-378a-3p 
and miR-10b-5p were mostly associated with vesicle free systems while the other 
miRNAs showed equal distribution between the types of carriers we speculate that 
vesicle-free systems are important miRNA carriers as much as vesicles and their 
characteristics should be further explored. We found out that ß-adrenergic stimulation can 
affect miRNA expression and secretion, probably due to secondary events triggered by 
the stimuli, while, miR-196a-5p secretion could be under its direct control. The ß-
adrenergic agonist CL affects the modality by which miRNAs are secreted even though 
it can favour one carrier over another one depending on the miRNAs. Finally, through 
the microRNA array and mRNA sequencing analysis, we identified 2463 genes and 20 
miRNAs upregulated in brown versus white adipocytes and 1733 genes and 29 miRNAs 
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upregulated in white versus brown adipocytes. This analysis allowed us to identify poorly 
studied or novel miRNAs that potentially control the most significant pathways 
differentially enriched between brown and white adipocytes. Among the significantly 
downregulated miRNAs in brown versus white adipocytes we highlighted miR-513a-3p, 
miR-4511 and miR-4328. While, among the significantly upregulated miRNAs in brown 
versus white we highlighted miR-4698, miR-4516, miR-4531, miR-29a-3p and miR-
3915.  
 In conclusion, these results provide new insight and further work is warranted to 
more precisely define miRNA roles in adipocytes and cells that take up adipocyte-
secreted miRNAs. Experimental tests will be needed to prove that miRNAs and their 
predicted target can actually interact. Further investigation of the mRNAs highlighted in 
this study should be done in consideration of the language dictated by the MRE sequence 
miRNA interactions between miRNAs and potential competitors. Alternative 
mechanisms for miRNA production should be investigated, as well as the potential 
additional functions of the genes involved in miRNA biosynthesis/maturation. As the 
adipose models in this study were representative of healthy adipocytes, further analysis 
should be performed in models of obesity to investigate if, the expression of the miRNAs 
identified in this study, is different between adipocytes from obese and lean 
subjects/mice. More attention should be directed towards the different miRNA carriers 
and their characteristics, as knowledge is still lacking on the modality by which miRNAs 
are taken up. All together our data provided encouraging results for the importance of 
further investigating miRNAs for future development of treatments against metabolic 
disorders. 
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